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ABSTRACT 
A randomised, placebo-controlled double-blind crossover design was 
employed in assessing the effects of piracetam treatment on the 
fuhctional capacities of absti~ent chronic altoholics. 
i 
A sample of 63 subjects, selected for reliability (to counteract an 
anticipated high drop-out rate) and for a minimum period of abstinence 
from problem drinking of three months was drawn from the William Slater 
Hospital, Rondebosch and commenced the trial. The trial consisted of 
two 8-week periods, with daily dosages of 4,8gm of piracetam or placebo. 
Subjects were assessed on a psychometric battery yielding a total of 
31 scores at baseline, crossover (8 weeks) and trial termination 
(16 weeks). The final sample size was 48 after drop-outs and non-
compliance had been taken into account. Scoring of test data for these 
subjects was completed before breaking protocols. Results were analysed 
by means, of two way analysis of variance with repeated measures on 
the trials variable. 
Only two of the 31 analyses yielded significant differences between 
piracetam and the placebo. These yielded opposed results, and as this 
' 
number of significant results could be expected due to chance alone, it 
was concluded that they were probably chance result~ a~d that no 
differences existed between the effects of piracetam and placebo on 
the functional capacities of chronic alcoholics. 
(ij-j)' 
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1. CHRONIC ALCOHOLISM 
1.1 TRENDS IN THE STUDY OF ALCOHOLISM 
To date a large portion of the studies on chronic alcoholism have 
concentrated on personality and demographic variables and drinking 
typologies. However, excessive long-term alcohol consumption has also 
been regularly associated with neurological and neuropsychological 
complications. Withdrawal of alcohol frequently results in states of 
epilepsy, delirium tremens and hallucinosis, while interactions of 
alcohol and vitamin deficiencies are considered to cause Wernicke's 
encephalopathy, Korsakoff's psychosis, polyneuropathy (including 
peripheral neuropathy) and pellagra (Ron, 1977). Several of these 
conditions can be fatal. Lesser complications include ataxia, 
nystagmus and tremor (Rix, 1983). 
Early studies of the chronic effects of alcohol on the brain concentrated 
around the Wernicke-Korsakoff psycho-syndrome, very probably due to its 
clearly defined symptomatology. A factor con.tributing to the 1 imited 
interest shown in this field was undoubtedly the seeming intactness 
of the majority of chronic alcoholics when measured on indices of 
overall intellectual functioning (eg - FitzHugh et al., 1960; Grant 
et al., 1979; Ron, 1982), while diagnosed brain damaged populations 
were regularly reported as exhibiting marked deficits on performance 
sub-tests of the more commonly used intelligence tests (FitzHugh et al., 
1960, 1965; Anastasi, 1968). 
Memory impairments have been the most commonly reported deficits ln 
chronic alcoholics who do not exhibit signs of the Wernicke-Korsakoff 
psycho-syndrome, the earliest of these reports dating back to the 
nineteenth century. With the advent of-neuropsychological test batteries 
in the last thirty years specifically designed to assess subtle changes 
in functional capacities, more evidence of functional impairment has 
2 
been uncovered. Further, neuropathological and neuroradiological 
studies, the latter made possible by recent technical advances, have 
provided a steadily mounting body of information indicative of morpho-
logical abnormalities in the brains of chronic alcoholics. 
With these advances interest was at first shown In changes in the 
c~rebellum. Nystagmus, ataxia and tremor are frequent consequences of 
cerebellar damage (Rix, 1983). However, such was the extent and 
variety of the impairments found in chronic alcoholics that cerebellar 
damage could not account for more than a portion of this (Lynch, 1960). 
Lishman (1981) now feels that the bulk of emphasis of study has shifted 
to the cerebrum. As yet the less clinically marked morphological and 
functional abnormalities of chronic alcoholism are only imperfectly 
understood. 
1.2 THE EFFECTS OF ALCOHOLISM ON THE BRAIN 
1.2.1 The Contribution of Studies in Neuropathol-0gy · 
Courville (cited in Ron, 1977) studied the effects of alcohol on the 
central nervous system~ He found a high degree of cerebral atrophy 
which was often widespread, but was more marked in the frontal lobes. 
Ventricular enlargement was also observed, but this was not as emphasised 
by Courville. At a microscopic level Courville found cell loss and other 
abnormalities. 
He concluded that dietary deficiencies could not be responsible for the 
atrophy observed and attributed this to alcohol toxicity. Although 
Courville did not supply data to support his contention, he asserted 
that alcohol abuse was the commonest cause of cerebral atrophy between 
the ages of 40 and 60 years. This implies an argument of increasing 
vulnerability to alcohol toxicity as a function of age, a contention 
which has received considerable support in recent years~ 
Eleven well-nourished alcoholics were studied by Lynch (1960) who 
compared their brains to those of five matched controls. Lynch found 
3 
differences between the two groups in that the alcoholics exhibited a 
greater degree of diffuse cortical atrophy, although he did not single 
out the frontal lobes as did Courville. Cortical cell loss was 
estimated at between 20% and 40% in the alcoholics, taking the conditions 
of the controls' brains as baseline values. 
Lynch also found numerous small lesions in the alcoholics' thalamus, 
and found their livers both fatty and cirrhotic. Courville had 
mentioned that much of the cell loss observed had been avascular. 
Lynch concluded that this implicated the capillary microcirculation 
which might be severely impeded by repeated fatty emboli originating 
in the liver condition of the alcoholic group. This contention was 
supported by the findings of Acker et al .(1982) who found significant 
positive correlations between degrees of liver and brain damage, and 
by Kroll etal. (1980) who found liver damage consistently related to 
moderate cortical atrophy. However, Lynch considered this to be only 
·one of several possible mechanisms and suggested that toxic and anoxic 
factors, as well as imbalances of metabolites and vitamins, should also 
be considered. 
·Harper (1982) studied brain weights of 101 chronic alcoholics, relative 
to other alcoholics all taken from a routine unselected series of 
autopsies. These were of interest in that only 21 of the 101 had been 
diagnosed as experiencing episodes of Wernicke's encephalopathy while 
alive, although all showed evidence of Wernicke-type lessions in the 
mammillary bodies and the tissues surrounding the third ventricle, in 
conjunction with frontal lobe cortical atrophy. 
Harper found that brain weights of both the 101 alcoholics exhibiting 
signs of Wernicke's encephalopathy and other alcoholics in the series 
were significantly smaller than the brain weights of non-alcoholics. 
He argued that, as alcoholics without signs of Wernicke's encephalopathy 
lost approximately the same amount of brain weight, malnutrition which 
is usually cited as being involved in the aetiology of Wernicke 1 s 
encephalopathy, could not be responsible for the observed brain 1esions 
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in the undiagnosed cases, and that these lesions were possibly the 
result of repeated sub-clinical episodes during life. Lishman (1981) 
took up the argument, proposing that with the now increased consumption 
of vitamins, alcohol abuse which previously would have resulted in 
clear cases of Wernickers encephalopathy, now results In a sub-clinical 
form of the same disease, characterised by circumscribed cerebral 
lesions which go unnoticed individually, but which develop stepwise 
towards structural damage of increasing size. This might present the 
external appearance of a dementing process. 
The common feature of all· the above studies is the finding of loss of 
cerebral cells through atrophy, particularly in the frontal lobes. 
There is evidence of sub-cortical damage sustained through alcohol abuse, 
but this ~ppears to occur only in some cases. Harper and Plumberg (1982) 
in a related study to Harper 1 s (1982) study, concluded that ventricular 
enlargement, a measure used to assess atrophy of a central nature, is 
an inaccurate marker of cerebral atrophy. From this body of evidence 
the only safe conclusion to be drawn is that chronic alcoholism results 
in cerebral atrophy, especially in the frontal lobes. There is also a 
suggestion of damage to arousal regulating areas such as the thalamus and 
the mammillary bodies, although functional reduction in arousal should 
not necessarily be taken as prodf of such damage because arousal is a 
joint function of both the cortex and subcortex (M~loney & Ward, 1976; 
Lezak, 1976).. 
1 .2 .2 The ·contrrbutioh of Neuroradrological ·Studies 
The greatest contribution to the Increased understanding of morpho-
logical changes associated with chronic alcohol abuse comes from 
studies utilising the Pneumoencephalogram (PEG) and Computerised 
Axial Tomography (CAT). Whereas prior to their advent the only study 
directly investigating these changes was neuropathological, it is 
now possible to investigate these changes in living subjects.· 
The PEG was the first of these instruments to be developed and 
involves injecting air Into the subarachnoid sp~ces. ··Its application 
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causes considerable discomfort ot patients and thus it has 
not been used on non-clinical (ie - normal) populations (Ron, 1977). 
Consequently, only other clinical populations can be used as controls. 
The CAT scan is a modern and non-invasive procedure which Is safe 
and eminently suitable for both research and clinical purposes. 
As a diagnostic instrument it has superseded the PEG nowadays in 
routine practice. 
1.2.2.1 Pneumoencephalographic Studies: 
Tumarkin et al. (cited In Ron, 1977) used the PEG on a group 
of seven US servicemen referred for assessment because of 
declining work performance associated with alcohol abuse. 
This was a very young group relative to most alcoholism research, 
with a mean age of 32 years and a mean reported drinking 
htstory of 11 years. Des~ite their youth all subjects were 
found to exhibit cortical atrophy, and four also had ve.ntricular 
enlargements. As Tumarkin et al. had excluded all other 
probable aetlologles beforehand, the only interpretation 
possible was that the observed changes were due to alcohol 
abuse. 
In a controlled study using schizophrenics as controls, Haug 
(cited in Ron, 1977) assessed chronic alcoholics between two 
and four weeks after the disappearance of delirium tremens 
following withdrawal of alcohol. Of the alcoholic subjects 
74% exhibited cerebral.atrophy, compared to only 8% of the 
schizophrenic sample, a statistically significant difference. 
A positive correlation was found between length of drinking 
history and presence and severity of cerebral atrophy. 
Brewer and Perrett (cited in Ron, 1977) assessed a group of 
33 subjects described as 'alcoholics' and 'heavy social 
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drinkers' with a mean age of 50 years. The authors excluded 
persons over 60 years of age and any cases where brain damage 
might be ascribed to other aetiologies, and several days were 
allowed to elapse so as to avoid contamination due to acute 
effects of alcohol. Cortical atrophy was found in 30 subjects, 
in 28 of whom frontal atrophy was present and of these, 
19 exhibited additional atrophy in the parietal lobes. 
The above studies may be criticised on several grounds, the 
most notable of which is the method of scoring the PEG. This 
is usually a rating and can thus be substantially contaminated. 
The absence of.control groups in two studies also makes the 
conclusions drawn appear weaker. Nevertheless, Ron (1977) in 
her review concluded, on the basis of many more studies, 
that findings repeatedly reflected cortical and subcortical 
atrophy, the former frequently involving the frontal lobes~ 
1. 2. 2. 2 Computerised Axial Tomographic Studies: 
Fox et al. (1976) compared the scans of 12 alcoholic subjects 
to 60 scans reported to be normal. Ages of the alcoholic 
subjects ranged from 34 years to 64 years, so in the absence 
of a reported mean age, it may be concluded that these subjects 
probably represented a 'middle aged' alcoholic population. 
As a result, neurological abnormalities should be expected to 
be more common than in younger subjects, due to normal 
degenerative processes. 
The alcoholic group represented a selected series, chosen for 
scanning because of symptoms of neurological disease. Taken 
in conjunction with the previous point, this argues for caution 
in generalising from this study. The findings, however, 
statistically differentiate between the groups, marked vent-
ricular enlargement being observed in 8 .alcoholic subjects, 
but in only one control subject. 
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The findings of this study should be regarded as merely 
suggestive of ventricular enlargement due to the effects of 
alcohol abuse, possibly combined with Idiosyncratic factors. 
Interestingly, Fox et al. also found liver damage in all 
alcoholic subjects. This study holds no further direct 
implications for cortical atrophy, however, as scans containing 
such evidence were excluded from this study. 
Studying CAT scans of 60 hospitalised alcoholics constituting 
an unselected group, Von Gall et al. (1978) found moderate to 
severe atrophy in 75% of alcoholic subjects, while only 4 
alcoholics were totally free of atrophic signs. Cortical 
atrophy was more common than subcortical atrophy, although 
there were more 'severe' cases of the latter, in the ratio 
of 3:2. All alcoholics admitting to a drinking hist6ry of more 
than 20 years were found in the 'moderate atrophy' and 'severe 
atrophy' classifications, none falling into the 'mild atrophy' 
classification. Cortical atrophy was found most frequently 
in the frontal lobes, with decreasing incidence, in order, in 
the temporal and parietal lobes. Comparing indices of sub-
cortical atrophy (le - ventricular enlargement) to those of 
a group of headache sufferers, it was found that these indices 
were more highly related to age In the alcoholic group, arguing 
for an increasing vulnerability of subcortical areas to alcohol 
with advancing age. 
Cala et al. (1978) found cerebral atrophy in 19 of their 26 
alcoholic subjects (mean age 39,3 years) and found cerebellar 
atrophy in 16 of the 19 cerebrally atrophied alcoholics. 
In all, 22 alcoholics exhibited cerebral or cerebellar atrophy, 
or both. Subjects displaying mild cortical atrophy displayed 
this alone, while more advanced cortical atrophy was associated 
with ventricular dilation. Cortical atrophy was diffuse and 
symmetrical across the hemispheres, but was prominent in the 
frontal lobes. Significant correlations were found between 
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degrees of cerebral atrophy and both age and length of drinking 
history, but these were of minor predictive value. 
In a later study utilising a control group of normal volunteers, 
Cala and Mastaglia (1980) distinguished between alcoholics and 
heavy social drinkers. They found only 5% of the 240 alcoholics 
scanned had normal CAT scans, compared to 33% of heavy social 
drinkers. The control group did not contain the same age range 
as the oth~r two groups and normaiive data could only be 
obtained to the age of 40 years. Nonetheless, the grades of 
atrophy at comparable ages demonstrated clear differences 
between normal controls and heavy ~ocial drinkers and alcoholics. 
All groups showed increasing atrophy with age, but controls 
differed in the extent of these age-related changes, these 
being much smaller than those observed in the other two groups, 
which differed between themselves. Alcoholics demonstrated 
the highest mean grades of atrophy at all but one age bracket. 
Subjects with histories implicating possible head injuries 
from other sources had been excluded to leave alcohol as the 
only known variable operative. Cortical atrophy was found to 
be widespread and symmetrical In nature in alcoholics and heavy 
social drinkers, but again was severest in the frontal lobes. 
The authors pointed out that the alcoholic sample constituted 
a selected sample and that this must temper their findings, 
but were still forced to conclude that there is a progressive 
premature shrinkage of the brain in alcoholics. They also 
noted that heavy social drinkers exhibited significant brain 
damage without noticeable symptoms. 
Similar findings came from Cal a et al. (1980) who found 
pathological degrees of atrophy in alcoholics relativ~ to 
healthy controls. Alcoholic subjects exhibited global atrophy 
more often, particular mention, though, b~ing made of the 
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frontal lobes. The vast majority of alcoholics suffering 
cortical atrophy also had ventricular enlargement. There were 
already marked differences between groups in the age range 
from 20 to 29 years, and age was significantly related to 
the presence of cortical atrophy in the male, but not the 
female subjects of either group. Length of drinking history 
was also found to correlate with cortical atrophy. 
In none of the above three studies is it clear as to how 
abstinent the alcoholic subjects were at the times of assess-
ment. 
Lusins and Zimberg (1980) found ~significant difference 
between sub-groups of their a 1coho1 i c sa-mp 1 e exhibiting or 
failing to exhibit normal CAr scans as a function of length 
of drinking history. Age and age. of onset of drinking did 
not relate to CAT scan results. The predominent finding was 
of cerebral atrophy, although a large minority of subjects 
exhibited normal scans. Lusins and Zimberg differed from 
prior studies in using precise linear measurements to define 
their categories of atrophy, as opposed to rating. As the 
human brain varies greatly in size and shape, this objective 
approach, not being related to overall features, can in any 
individual either over-estimate or under~estimate atrophy. 
Rating, conversely, is related to overall features,' but relies 
on subjective clinical judgment. These differences can possibly 
result in varying findings. 
Blind rating of CAT scans of alcoholics and matched medical 
controls was used by Krol 1 et al. (1980).. The alcoholic group 
was examined f6r occult brain damage and subjects with medical, 
neurological or nutritionally suspect histories were excluded. 
All subjects were under 50 years of age. Results indicated 
mild to moderate cortical atrophy in 11 of the 16 alcoholic 
subjects. This result implies that alcoholic~, whether they 
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outwardly exhibit symptoms of neurological abnormalities or 
not, do. in fact, appear to possess such abnormalities. 
Methodologically the blind rating procedure elimin~tes the 
possible influence of sunjective bias in ratings. 
Assessments of the occurrence and patterns bf development of 
atrophy in the normal population were made by Bergman et al. 
(1980). Using official state agencies the authors drew a 
stratified random sample from the population at large. They 
found that ventric~lar enlargement increases in incidence 
with age to an incidence of 23% in the age bracket from 
60 to 65 years (the oldest group in the study) •. Although they 
found several significant correlations between incidence and 
the extent of the various forms of atrophy, these were small 
and worthless for explanatory purposes. 
Eighteen subjects in this sample, loosely described as 
'problem drinkers,• were then compared to the rest of the 
sample. The incidence of central atrophy, ie - ventricular 
enlargement, was 33% in the 'problem drinker' group compared 
to 10% in other subjects. Problem drinkers also differed in 
the incidence of cortical atrophy, about 40% of their number 
being so classified compared to 14% of other subjects. These 
findings were supported by the results of a further study 
comparing alcoholic subjects to normal controls (Bergman et 
al., 1980). The conclusions went further insofar as the degree 
of ventricular englargement as a function of age was accelerated 
in the alcoholic group. 
Wilkinson and Carlen (1980) compared neurologically impaired 
and neurologically unimpaired alcoholics to normal controls. 
Ventricular wid~ning and sulcal widening (ie - cerebral atrophy) 
differentiated alcoholics from controls, and severity of 
cerebral atrophy correlated with age in the rieurologically 
impaired alcoholics, but not in unimpaired alcoholics: 
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The impaired group Included cases of Wernicke's encephalopathy 
and Korsakoff 's psychosis and it was these cases which exhibited 
the severest abnormalities. 
Zelozowiki et al. (1981) took CAT scans of 25 alcoholics who 
constituted a series of hospital admissions from which all cases 
exhibiting neurological symptoms of brain damage or any history 
suggestive of such a possibi.lity were excluded. This sample 
was predominently male.with a mean age of 36,8 years and a mean 
history of alcohol abuse of 11 ,4 years. ~canning took place 
between 2 and 6 weeks after cessation of drinking, thus 
eliminating the possibility of contamination from acute in-
toxication. The authors examined ventricular enlargement 
relative to the two dimensional area of the brain on the CAT , 
scan slice, a method which is less influenced by subjective 
bias and by the variability of brain size. Scores indicated 
definite brain damage in 8 subjects, while 23 subjects yielded 
scores one standard deviation or more above the mean score for 
the normal population on this index. No assessment of cortical 
atrophy was attempted. However, another study on a young 
alcoholic sample (30 years mean age) by Lee et al. (1982) found 
cerebral atrophy in half of the subjects. These subjects were 
also abstinent and, once again, selection had eliminated all 
cases where other aetiologies could have caused brain damage. 
A further young alcoholic group of 30 subjects with drinking 
histories of 10 years were scanned in the first three days of 
a detoxification programme (Graff-Radford et al., 1982). 
Eliminating other aetiologies the authors repeated the findings 
of frequent occurrence of cortical atrophy (18 subjects) and 
slightly less frequent ventricular enlargement, measured as a 
ratio of areas (11 subjects). Graff-Radford et al. concluded 
that, in the light of their own and previous results, it could 
be concluded that alcoholics developed brain damage at a 
relatively early age, but also found that length of drinking 
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history and cortical measures only related systematically in 
. older alcoholics. 
Possibly the strongest study to date was that of Ron (1982) who 
compared 100 alcoholics (mean age 43,5 years) to 50 controls, 
mostly life-long abstainers. Ron's alcoholic sample appeared 
neurologically normal and was scanned after the effects of 
detoxification had subsided, on average, 34 days after the last 
drink. At initial scanning the alcoholic subjects were inpatients. 
Ron found that all CAT indices separated alcoholics and controls 
and that these differences were accentuated by advancing age. 
All but cerebellar atrophy were postively and significantly 
correlated with age in the alcoholic group, but age of onset of 
drinking and duration of drinking history did not correlate with 
these indices. 
What emerges from the above studies is that, even in 'younger' 
alcoholics, pathological degrees of cortical atrophy and, to 
a lesser extent, ventricular enlargement are repeatedly 
reported. Cortical atrophy is most frequently cerebral in 
nature and tends preferentially to involve the frontal lobes, 
although the temporal and parietal lobes are also affected. 
The atrophy is diffuse and symmetrical, showing no lateral 
preferences. 
Although the studies by Ron (1982), Lusins and Zimberg (1980) and 
Zelozowiki et al. (1981) used data gathered after the acute 
effects of intoxication should have subsided, other studies 
might reflect these acute effects rather than more 'long term' 
effects. Several studies have reported the possibility of 
a limited degree of reversibility of brain damage. 
1.2.3 The Reversibility of Brain Damage in Chronic Alcoholism 
Carlen et al. (1978) repeatedly administered CAT scans to eight alcoholics 
(mean age of 48,75 years, mean drinking hist6ry of 18,6 years). Repeat 
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scans, rated independently by two judges, revealed partial reversal 
of atrophy in four cases, aJl of whom remained absttnent between scans. 
Of those unimproved, two had continued drinking while the remaining 
two had ceased pos~-detoxif ication functional improvement before the 
intial CAT scan. It was found that cortical atrophy had reversed more 
than ventricular enlargement. 
The authors concluded that the differences observed were too great and 
too sustained to be attributable solely to alcohol withdrawal syndrome 
resolution, the effects of which are biochemical, but should rather be 
attributable to structural changes. They cited animal research 
indicating inhibitory effects of alcohol on brain protein synthesis, 
which increases after cessation of alcohol consumption, and suggested a 
link between this and cerebral blood flow, reportedly reduced in 
alcoholics (Berglund & lngvar, ]976). 
Carlen et al. concluded that re-hydration of brain tissue could also not 
account for their findings, as this usually occurs shortly after with-
drawal. Consequently, they proposed the argument that alcohol has· toxic 
effects on brain neurons, killing some and incapacitating others through 
its action o~ supporting tissues. The cessation of alcohol comsumption 
is then seen as permitting regrowth of lost dendrites and re-arborization 
of incapacitated neurons, as well as restitution of supporting tissues. 
In view of the limited degree of reversibility observed, Carlen et al. 
questioned the use of the word •atrophy.• with its implication of 
irreversible death of cells, in alcoholic studies. 
In a similar study, Carlen and Wilkinson (1980) divided re-scanned 
alcoholics into 1abstinent, 1 reduced drinking' and 'unchanged drinking• 
groups. No statistical differences on atrophy indices wer~ found, 
though a statistical trend indicated increasing atrophy scores with 
greater amounts of alcohol consumed. The failure to attain significance 
here could be attributable to the sm~ll sample size~ ~sed. 
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Ron et al. (1980) established cortical atrophy and ventricular en-
largement in a large group of 100 alcoholics (43,5 years mean age; 
17,3 years mean drinking history) relative to 41 control subjects 
(40 years.mean age). On average the alcoholics were 34 days abstinent~ 
When re-scanned a year later, abstinent alcoholics showed a decreased 
degree of ventricular enlargement, still greater than that of controls, 
although cortical indices were not reduced in all subjects. 
Ron (1982) followed up on her original scans of 100 alcoholics, re-
scanning 56 at intervals ranging between 30 and 152 weeks. At the time 
of follow-up scanning only 16 subjects were considered abstinent. No 
signific~nt inter-scan differences were found on any Indices used, 
although trends were observed in the abstinent sub-group towards both 
less severe cortical atrophy and ventricular enlargement. 
Blind ratings. of the pairs of scans for each subject allowed categorisation 
as either improved, unchanged or worse. These categories differed 
significantly as a function of days of abstinence before re-scanning 
(p (,001)). Comparison of abstinent and drinking groups at re-scanning 
yielded no significant differences, although trends towards less severe 
atrophy were evident on two indices of cortical atrophy, in favour of 
the abstinent group. 
It appears from these'studies that a limited degree of reversibility of 
brain damage occurs in the alcoholic brain if abstinence is maintained. 
This reversibility is only partially due to resolution' of the withdrawal 
syndrome and, possibly, it also reflects inproved cerebral blood flow and 
protein synthesis. The latter results in increased brain mass which, on 
the basis of animal data, might indicate the increasing formation of 
dendrites and arborisations. 
The important finding is that the extent of reversibility is so small that 
it cannot,. assessed by 'objective' m~ans, attain statistic~l significance 
and even after a year of abstinence, leaves the alcoholic markedly 
deficient relative to controls. It can, thus, be concluded that 
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alcoholics suffer lasting degrees of brain damage which abstinence can 
no more than partially remedy and that relative to the normal population 
they will probably, for the rest of their lives, present a clinical 
picture of accelerated cortical and ventricular deterioration for their 
age. 
1.3 THE FUNCTIONAL IMPLICATIONS OF PEG & CAT RESEARCH FINDINGS 
The frontal lobes are regarded as the seat of 'associative' mental 
functions (McGhie, 1969). According to Lezak (1976) general problems 
associated with frontal lobe damage are mental slowing (apathy and 
decreased spontaniety)~ difficulties in making shifts of mental set 
(perseveration), deficient self-awareness and concreteness, with little 
sustained goal directed behaviour. Cognitive deficits are most associated 
with the upper and/or outer sides of the frontal lobes adjacent to the 
parietal and temporal lobes, both of which have also frequently been 
reported as atrophied in neuroradiological studies of alcoholics. 
More specifically, diffuse brain damage adversely affects memory, 
attention and concentration, impairs higher and more tomplex levels of 
thought and results in general response slowing. It is suspected that 
memory impairment might be a function of impaired concentration 
(Lezak, 1976). 
Ventricular enlargement is the result of central atrophy, ie - the loss 
of subcortical cells, with resulting skrinkage of remaining white matter, 
reflected as widened ventricles. Both Lynch (1960) and Harper (1982) 
reported lesions in the tissues surrounding the ventricles. The 
thalamus and mammillary bodies were also implicated and it appears 
likely that other areas such as the hypothalamus an~ hippocampus might 
also be involved. It should be noted that the hypothalamus is believed 
to serve memory functions (Smythies, 1966). The thalamus regulates 
cortical arousal and is responsible for selective attention in conjunction 
with the frontal lobes (Maloney & Ward, 1976) and the hippocampus inter-
connects with both these bodies (Pribram, 1971). As it is argued that 
cerebral organisation is best descrlbed as ·~ complex of integrations 
' 
' 
. ' 
I. 
I 
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rather than specific and independant localisations of function" 
(Sarason & Sarason, 1980), it is likely that damage in any connected 
part of the brain might impair a function principally, though not 
exclusively, associated with another area~ Thus the effects of diffuse 
cortical and central atrophy on attention, in particular, might arguably 
be great. Consequently, a wide range of functions for which the 
smallest amounts of attention are required may be impaired. Lezak (1976) 
goes further to claim that damage to the thalamus iriterferes with the 
integration of cortical centres which could impair all complex central 
processes. 
1 . 4 PYSCHOLOG I CAL DEFICITS ASSOCIATED WITH ·CHRONIC ALCOHOLISM 
Reviewing the literature of the previous 25 years, Kleinknecht and 
Goldstein (1972) concluded that there was little agreement on which 
functions were most affected by prolonged alcohol abuse. The authors 
combined the deficits previously reported into two broad areas of 
abstract reasoning and problem solving and speed and complex psychomotor 
abilities. Within these two areas were subsumed deficits in abstract thought, 
numerical aptitude, manipulative problem solving, memory for spatial 
relations, discriminative ability, attention, psychomotor speed, finger 
and manual dexterity and motor co-ordination. 
The authors notes, in addition, the observation made by Kish and 
Cheyne (1969) in one of the reviewed papers that the functional deficits 
exhibited by alcoholics in their thirties resembled those of normal 
subjects in their fifties. Kish and Cheyne proposed that the effects 
of alcohol abuse could be described as akin to premature ageing. 
Lezak (1976) lists as typical of chronic alcoholics deficits in memory, 
cognitive set maintenance, persistence, visual search procedures, 
. . . 
motor inhibition, organisation of perceptual-motor responses, synthesis 
. . .. 
of visual elements, temporal and spatial orientation and perseveration. 
These deficits are very specific, however, and in general they are 
referred to in terms of attentional disturbances, .decreased conceptual 
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abilities, disorders of memory and meaningful use of language and 
intellectual deterioration (Anastasi, 1968). Learning difficulties 
have been noted, but are usually treated under the general heading of 
•memory deficits.• 
Usually, IQ scores do not reflect impairments in alcoholics (Ron, 1982), 
although it is frequently reported that performance tests in particular 
are subject to the effects of alcohol abuse. It would be expected that 
this would result in decreased full scale IQ, as well as a marked 
difference between verbal IQ and performance IQ, but this seldom occurs. 
However, when sub-tests are grouped the deficits are reduced, unless 
they occur on all sub-tests, as the remaining normal values raise the 
mean scores. 
1.4.1 Recent Studies of Functional Impairment in Chronic Al~oholics 
FitzHugh et al. (1960) compared a group of 17 detoxified chronic alcoholics 
to groups of brain-damaged and non-brain-damaged subjects matched on age, 
race, education and handedness. All subjects were hospitalised men, 
excepi one subject in the latter group. 
Scores on the Wechsler-Bellevue lnte11 igence Scale for full scale IQ, 
verbal IQ and performance IQ (FSIQ, VIQ and PIQ respectively) indicated 
significant differences between the brain-damaged group and the other 
two groups, but no differences were found between the alcoholic and non-
brain-damaged groups. However, on measures taken from the Halstead-
Rei tan Neuropsychological Battery, significant differences were found 
between alcoholics and non-brain-damaged subjects on the lmpairement 
Index, Category Test and Tactual Performance Test scored for time. 
Only one sub-test statistically differentiated between alcoholics and 
brain-damaged subjects. The results, besides indicating significant 
deficits in abstract thought processes, concept formation and adaptive 
capabilities, cast doubt on the use of standard intelligence tests for 
diagnostic purposes in ,alcoholic populations. 
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In an attempted replication of the above study, FitzHugh et al. (1965) 
used groups of 35 male subjects, matched for age and education, 
representing the alcoholic, brain-damaged and normal populations. The 
groups were, on average, four years younger than in the previous study. 
The same pattern of results emerged,.with no differences observed between 
alcoholics and normal subjects on FSIQ, VIQ and PIQ, although normal 
subjects did prove significantly superior on Block Design. Alcoholics 
scored in the normal range for all Wechsler-Bellevue indices, on or above 
mean values, while the brain-damaged group consistently scored below 
mean values. On Halstead-Reitan tests, however, the alcoholics proved 
significantly inferior to. normal subjects on seven of the ten subtests 
while, in turn, the alcoholics' performance was significantly superior 
to that of the brain-damaged subjects on seven sub-tests. Comparisons 
between normal subjects and brain-damaged subjects were significant in 
a 11 cases. 
Effectively the increased number of sub-tests differentiating alcoholics 
from normal subjects was a statistical phenomenon caused by the doubling 
of sample sizes in the replication. In the original study (1969) 
those tests which later achieved significance had all approached 
significance. 
Dividing the samples at the age of 40 years into younger and older sub-
groups, FitzHugh et al. further found that older subjects performed better 
on measures reflecting past experience and accumulated information while 
younger subjects were better at tests of adaptive abilities. Younger 
subjects in all groups were better on Wechsler Bellevue performance 
sub-tests and Halstead-Reitan sub-tests. In addition, comparison of 
Halstead-Reitan sub-test data trends within each diagnostic category 
indicated that differences between younger and older alcoholics were 
not as marked as in the normal group, and it was suggested that the data 
fitted an argument of premature ageing effects in the alcoholic group. 
Talland (1963) investigated several types of reaction timing procedur~s 
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on currently abstinent alcoholics and control subjects matched for age 
and sex. The mean age of the alcoholic group was 42,2 years and all were 
in good health, none being colour-blind nor showing any signs of motor 
or neurological disorders. Results showed alcoholics slower on all forms 
of reaction time measurement. In his experiments Talland showed that 
alcoholics could not utilise alerting cues preceding stimulus onset as 
could controls, but that on the contrary, this slowed them down further. 
This, he argued, implicated central processes, not peripheral processes 
nor motor disorders. 
Short and long term alcoholics were matched on age, education and 
drinking history by Jones (1971) and their performances compared on 
the Ravens Progressives .Matrices and Shipley-Hartford tests, the former 
a predominently visual-spatial test of intelligence and the latter a 
test of verbal intelligence. This study was interesting in that 
duration of 1drinking 1 history was not taken as a possible independent 
variable; but was used as another matching variable, while the term of 
1alcoholic 1 drinking was separately determined. The influence of the 
period of 1alcoholic 1 drinking, as distinct from the total length of 
drinkin~ history on intellettual functions was assessed. Each pairing 
differed by at least five years on the 1alcoholic 1 drinking variable. 
It was found, compared to an age and education matched hospitalised 
control group that alcoholics were significantly poorer in visual-
spatial intel 1 igence, but not in verbal intel 1 igence. When the alcoholic 
sub-groups were compared, significant differences were found on both 
visual-spatial and verbal intelligence measures in favour of the short 
term alcoholic sub-group. Jones went on to correlate the two measures 
and found significant relationships between visual spatial and verbal 
intelligence in the control and short term alcoholic groups, but not in 
the long term alcoholic group. He concluded that with longer histories 
of 'alcoholic' drinking there arises a differential hemispheric sensitivity 
leading to dissoci~tion of the intellectual functions involv~d. This, 
however, implies strict localisation of functions, which the majority of 
researchers reject because functions are subserved ·by association areas 
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quite remote from them. 
However, the study has another merit, in that it offers a warning against 
the blind use of measures of verbal intelligence or vocabulary as 
approximations of premorbid intelligence, as these do not appear always 
to remain as impervious to alcohol abuse as was believed. It would 
be well to treat these findings only as suggestive, however, as samples 
were small and it appears likely that information on which the judgments 
9f both duration of drinking history and durations of 1alcoholic 1 
drinking were made might be inaccurate. This follows from reported 
consumption-minimising by alcoholics, which might extend beyond current 
drinking behaviour (Knox, 1980). In any event, the discernment of the 
point at which drinking becomes problematic must of its very nature be 
subjective and liable to large degrees of error. 
Jones and Parsons (1971) compared groups of 40 abstinent alcoholics, 
hospitalised controls and brain-damaged subjects on.the Category Test 
(part of the Halstead Reitan Battery), three sensory-motor tests and a 
measure of global intellectual functioning. Subjects were matched on 
age and education. 
Major emphasis was given to the Category Test in an attempt to repeat the 
findings of FitzHugh et al. (1960, 1965), as the abstracting deficits 
reflected by high scores on this imply frontal lobe damage. Results 
indicated that the alcoholic and brain-damaged groups did not differ 
from each other, but both significantly differed from the control group. 
Significant differences were found between young and old subjects in 
the alcoholic and brain-damaged groups, but not in the control group, 
although in all cases the older subjects performed worse. Among younger 
. . 
subjects, controls and alcoholics did not differ significantly, but the 
brain-damaged group differed significantly from both. In older subjects, 
on the other hand, alcoholics did not differ significantly from brain-
damaged s_ubjects, but did differ significantly from controls. ·on the 
. . 
sensory motor tests, both group ·and age factors yielded significant 
. . 
results, but no differences ~ere foun~ b~tween alcoholics ~nd controls~ 
.2.1 
although the controls performed better.· Younger alcoholics performed 
better than older alcoholic~, ~s expected. 
Fina 11 y, the a lcoho 1 i c 'group was· sp 1 it into two groups matched for 
age and education, representing long and short term problem drinking, 
histories, and it was found that the long term group made significantly 
more errors on the Category Test. 
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This study successfully re.pl icated FitzHugh et al.'s (1960, 1965) 
results, and it was concluded that alcoholics probably suffer a mild form 
of brain-damage to the prefrcintal area of. the· frontal lobes, or related 
sub-cortical structures, or.both. It was also~shown'that with ageing, 
the rate of error productioh accelerates in alcoholics relative to other 
groups and that the error score v~ries as a function of durati6n of. 
problem drinking. The alcoholic group also showed ihcreased vulnerabll'lty 
with age in sensory-motor abil itles; which w~s not the case in other 
groups .• 
The Wisconsin Card S~~ting Test (WCST) re~utedly Is a test of abstracting 
ability and concept formation (Parker, 1980). Pendleton and Heaton 
(1982) compared it to the t~tegory Test, finding the WCST more sensitive 
to frontal lesions, although the Category Teit was more accur~te 
diagnosing d I ff use atrophy and a superior glob-a 1 index of brain damage, 
irrespective of nature or location. Tarter and Pars6ns (1971) 
compared alcoholic subjects to controls using WCST and found that 
alcoholics made more etrors ~nd took more trials to reach criterion. 
Contrary to expectations, the difficulty experienced 'by alcoholics was 
n6t due to p~rseveratfon, but to diffic~lty ~aintaining a pattern of 
search. It was a~gued on statistical grounds that frequent sequences of 
. .. 
five correct responses before ah error had·a thance probability of 
p (,001, and therefore proved the set had been acqui~ed~ .yet tould not 
be maintained to criterion. The alcoholics simply could not ho.Id the 
set as well as controls. 
I 
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This argues for lapses in concentration and distractability. Tarter 
and Parsons argued that this was consistent with sub-cortical damage, 
probably to the reticular formation. However, Maloney and Ward {1976) 
emphasised that selective attention is a joint function of both the 
thalamus and the cortex, so the conclusion can not be limited to 
central atrophy alone. 
Tarter {1973) replicated the above study, dividing the alcoholic group 
~nee more in term? of duration of problem drinking. He found controls 
and short term alcoholics statistically indistinguishable, but long term 
alcoholics dif~ered significantly on total trials, total errors and 
number of perseverative ertors. He argued that the major cause of errors 
was a deficit in 'set persistence,' rather than a distinct perseverative 
tendency. Both alcoholic groups were deficient in this regard, the 
long term alcoholic group more so, although this group also had a 
greater tendency to repeat errors, ie - to perseverate. Tarter concluded 
that the results indicated frontal lobe atrophy. 
Cutting (1978) found differences between alcoholics and controls on non-
verbal memory and verbal fluency, but none on verbal concept formation and 
ve rba 1 1 earning. 
1 ight drinkers. 
Heavy drinkers were significantly more impaired than 
Cutting suggested that non-verbal memory is a right 
temporal lobe function, not a frontal lobe function, drawing attention 
to the fact 'that the 1 iterature largely ignores the neuropathological 
and neuroradiological findings of diffuse symmetrical atrophy only 
preferentially, but not exclusively, involving the front-al lobes. 
However, it is still possible to account for non-verbal memory impairment 
in terms of frontal lobe atrophy Impairing 'association' areas located 
there {McGhie, 1969), The fact ~hat the function is markedly impaired 
does, however, argue more in favour of temporal lobe atrophy. 
An ~ttempt to derive a discriminant function capable of identifying 
alcoholics was made by O'leary et al. (1979) using orthopaedic patients 
and hospital staff as controls. All subjects were lower middle class 
males and groups did not differ on age and education. Persons with 
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diagnosed thought disorders, psychiatric symptomatology or history of 
drug abuse were excluded. 
The alcoholics were tested on the Wechsler Bellevue and the Halstead 
Reitan battery between the 9th and 14th days of their inpatient programme, 
thus eliminating effects of alcohol withdrawal. The 20 sub-tests involved 
were statistically analysed for differences between groups. 
The authors found that, contrary to expectations, of the 8 sub-tests 
which yielded significant differences, only two were Halstead Reitan 
scales. The Block Design sub-test was the best discriminator and it was 
found in developing a muliple regression prediction equation that none 
of the other scales could add significantly to that obtained from 
Block Design scores. This implies considerable overlap between the 
scales which yielded significant differences, Block Design being the 
best overall index of the combined deficient functions. O'Leary et al. 
concluded that their data indicated alcoholics to be deficient in 
abstract problem solving, visual-spatial co-ordination and perceptual-
motor skills. These are all represented in Block Design performance. 
Overall, verbal tests on the Wechsler Bellevue did not discriminate 
as well as the performance tests. 
Scores on the WAIS Block Design and Similarities sub-tests featured 
prominently in a discriminant function derived by Miller and Orr (1980) 
to differentiate between alcoholic and brain-damaged subjects. Howeve~, 
in another function differentiating between alcoholics and psychiatric 
controls (who of the three groups should most represent the normal 
population) WAIS sub-test scores were totally unrepresented, only 
Halstead Reitan scores contributing meaningfully. In the former case, 
the logical deduction is that abstracting ability and capacity for 
conceptual thought, the common features between performance~ 1 on the 
Block Design and Similarities sub-tests, distinguish between alcoholics 
.and brain-damaged subjects. In the latter case, the difference between 
this equation and that derived by 01 Leary et al. (1979) in terms of 
the number of variables involved and the nature of such variables, 
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conceivably derives from the differing groups from which subjects 
representing the normal population were drawn: hospital staff and 
orthopaedic patients in 01 Leary et al.'s study~ and psychiatric patients 
in this one. These differences might involve abstract problem 
solving and the integrative central component of perceptual-motor 
performance. 
The authors did, however, find significant deficits in alcoholics on 
WAIS performance sub-tests, relative to psychiatric subjects. ·In 
addition, they interpreted their data as consistent with advancing 
global impairment, as distinct from a developmental seque~ce, assocrated 
with length of drinking history, in alcoholics. Their data thus 
supported the 1 premature ageing' hypothesis cited previously. 
Ryan (1980) studied memory and learning in alcoholic and control 
subjects. Using a variety of methodologies Ryan finally concluded that 
it could not be proved that alcoholics suffered durable memory and learning 
deficits, but problem•solving remained deficient for at least several 
months after detoxification. 
Controls were superior in delayed recall, alcoholic subjects not even 
being able to use mnemonic techniques spontaneously. When instructed 
to use such techniques, however, the difference was greatly reduced, 
alcoholics performance alone responding. Similarly, the use of prompts 
in certain tasks showed that 'forgetting' was largely the result of 
poor retrieval operations, not defective encoding or storage, on the 
part of alcoholics. Ryan suggested that memory be regarded as a creative 
ski 11 heav i 1 y dependent on prob 1 em so 1 vi ng ab i 1 it i es·' poor memory being 
principally the result of deficient problem solving skills. 
A large scale study by Ron (1980) used 100 alcoholic subjects and 
50 controls. On average the alcoholics had been abstinent for 34 days 
and all subjects were screened for possible brain damage of non-alcoholic 
origin. When age and. premorbid IQ were controlled it was found that 
alcoholic subjects were significantly cognitively impaired compared 
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to controls. Dividing the groups into high and low IQ sub-groups it 
was found that differences were accentuated between the higher 
IQ. sub-groups. Ron proposed a 'floor effect 1 active in low 
IQ alcoholics, arguing that these subjects have a smaller 'alcohol-· 
vulnerable' component of cognitive abilities and, hence, could not show 
as large a set of impairments relative to IQ matched controls. 
Memory impairments persisted beyond acute withdrawal, this suggesting 
either very long recovery periods or irreversible damage. ·Ron supported 
Tarter and Parson (1971) and Tarter (1973) in their findings of alcoholics 
making frequent perseverative errors and experiencing difficulty in 
maintaining a cognitive set. 
Specifically, alcoholics and controls differed on an overall measure 
of verbal IQ, verbal and performance WAIS sub-~ests, aspects of 
immediate and delayed recall, and cognitive set maintenance. Considering 
the higher premorbid IQ subjects alone, al 1 comparisons except for the 
verbal IQ test became significant. In considering lower premorbid IQ 
subjects, only tests of delayed and immediate recall of logical memory 
showed significant differences. 
t.4.2 Reversibility ·Of Functional Deficits after Alcohol Withdrawal 
Psychometric assessment of alcoholics in acute withdrawal is almost 
certainly invalid as an indication of their normal levels of functioning 
(Lezak, 1976). In this phase both physical and psychological equilibrium 
are disturbed and, consequently, poorer scores can be expected. 
Individuals appear to vary greatly in their reactions to alcohol 
withdrawal, some experiencing delirium tremens and alcoholic hallucinosis, 
while others appear to escape unscathed. Although the argument from 
CAT studies that reversibility of atrophy must reflect morphological 
rather than biochemical changes appears sound, it is not clear at what 
point biochemical parameters re-stabliae. Several studies have 
investigated logitudinally the effects of withdrawal and abstinence 
over varying periods and these offer some clues as to the point after 
which deficits ~ight be regarded as stable. 
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Page and Linden (1974) tested five groups of alcoholics after detoxi-
fication on the WAIS, Trail Making Test and Benton Visual Retention 
Test. One group was tested one week after withdrawal and others after 
two, four, six· and eight weeks· respectively. This design was used to 
counteract learning effects. 
Most improvement was found between scores at week one and week two, 
the graph of improvement thereafter becoming almost asymptotic, but with 
clear deficits relative to standard norms still evident after eight weeks. 
Functions observed to improve between weeks one and two included abstract 
reasoning, visual motor co-ordination, spatial ability and short term 
memory. However, Page and Linden only tentatively accepted these 
improvements, arguing that assessments at week one might in fact have 
been abnormally depressed by lingering effects of withdrawal, and that 
the resultant functional improvement might be spurious. The authors 
cautioned against assessment too soon after detoxification. Their 
findings received support from a similar longitudinal study by Page and 
Schaub (1977) where post-withdrawal improvements did not continue beyond 
week three, although still abstinent alcoholics were re-asse~sed after 
six months. 
r 
However, improvement.was observed over a one year period of abstinence 
by Long and Mclachlan (1974) who re-tested a group of seventeen alcoholics. 
Many scales of the Halstead Reitan battery showed gains, including the 
Category Test. ?ignificant improvements were found in WAIS performance, 
but not verbal sub-tests. The authors concluded that with abstinence 
there are improvements in cognitive~ perceptual and motor abilities, 
but that some abilities were still impaired after a year and possibly 
needed longer periods to recover, if they were not permanently impaired. 
However, if one considers the likely contribution of learning effects 
being responsible for a large portion of the observed gains, the claims 
of this study might be reduced. Certainly, performance tests are known 
to be highly susceptible to practice effects. 
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Limited evidence of the differential effects of abstinence and continued 
alcohol consumption was obtained by Mclachlan and Levinson (1974), who 
re-tested large groups of abstinent and drinking alcoholics after one 
year, using the Block Design sub-test of the WAIS. Analysis showed that 
abstinent alcoholics scored significantly higher at the re-test than 
drinking alcoholics, and that the abstinent group improved significantly 
over the intervening year, while drinking alcoholics did not. 
Clarke and Haughton (1975) assessed heavy drinkers two, six and ten weeks 
after withdrawal on the WAIS Similarities, Vocabulary, Block Design and 
Object Assembly sub-tests, as well as a visual reproduction test. 
A control group was tested twice, with a four week interval. Heavy 
drinkers performed worse on all measures except Vocabulary, at all 
assessments. 
Most improvement occurred between the first and second assessments, 
but the trend continued to the third assessment. This was taken as 
indicating that functional recovery is still continuing after ten weeks 
of abstinence. Grant et al. (1979) compared a recently detoxified 
three week abstinent alcoholic group to an eighteen month abstinent 
alcoholic group, using the WAIS and the Halstead Reitan battery. The 
authors found no differences between the groups according to the 
proportions of each rated as impaired, and concluded that alcoholics 
after three weeks abstinence can become 'essentially normal neuro-
psychologically. 1 
However, a one year folJow-up study related to that of Grant et al. 
(Adams, et al., 1980) recorded different gains in the three groups, 
with more significant gains achieved by the control group~ The longer 
abstinent group recorded fewer signific~nt gains than the control group, 
but far more than recorded in the less abstinent group. The authors 
proposed that at the time of the previous study a sub~clinical form of 
deficit, impairing incident~l learning, went unnoticed and this gave 
rise to the failure by this group to record practice effects. However, 
the data on subject abstinence during the 1nterveMing period are very 
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sketchy and it might well be that the poorer performari~e Of the '~ess 
abstinent• group· reflect~ undlsc16sed drlnkirig behavr~~r·whlch 
differentiates this group from the 6thers.· :A further criticism of the 
original itudy (Grant et al.~-1~79) Is that It was subject to selection 
bias. in that:only available, r~~dy-formed groups were assessed. ·It 
' . 
has "been shown (Clarke &.Haughton, 1975) that subjects who drop out of 
longitudinal studies tend to have h~d poorer sco.res at initial assessment. 
This tendency thus enhances the mean score of the group.at later 
assessments, leading .to more 'normal 1 scores. 
Guthrie and Elliot (1980) reported~ significant r~ductiori in the number 
of psychometric indices on Which their alcoholic group· exhibited 
deficiency after six months, if they remained abstinentw ·performance 
of those subjects who continued drinking between assessments was even 
more impaired at re-assessment. 
A·study by Schau et al. (1980) found ~lCohol.ics functionally impaired a't 
both Initial testing and at re-test In~, on average, 14 months 
:later, relative to a control group. ·Initial testing was coriducted 
9 to 14 days after alcohol withdrawal. Particular improvements were 
. . . .. 
observed on WAIS performance sub~tests. A factor of re~evaMce to other 
studies was the estimation of the strength or practie.e effects, which: 
were shown to be very weak In alcoholics. 
Eckhardt et al. (1980) assessed two groups of alcoholic~, abstinent 
for either 2 to 6 days, or 14 to 31 d·ay~, on a· battery of 24 tests, 
including WAIS sub-tests, the Halstead Reitan battery and the Wisc6nsiri 
Card Sorting Test. The subjects were.all males in thei~ mid-thirties 
. . ' 
and the groups were ·matched for ~ge and educatioh. The less abstinent 
group was rated impaired on 13 of the 24. tests, while the more abstinent 
group was rated impaired on 11 of the same 13 tests, but on none of the 
·others. ·For the latter group impairments were _mostly found on Halstead 
Reitan indices. Scores ·tended to be marginally superior in the more 
abstinent g~oup~ but statistical analysis failed· to reveal any ove~all 
differences between the group~, using age·and educatioh'as 6o~variates. 
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The above studies conflict in theJr conclusions. Page and Linden 
(1974), Page and Schaub (1977) and Grant et al. (1979) recorded no 
improvements beyond the third week of abstinence. The rest of the 
studies recorded continuing improvements up to as much as thirty months. 
It is, however, arguable that in the event of practice effects being 
controlled in certain of Ehe latter group of studies, the conclusi~ns 
drawn might have been different; However, the size of control groups 
in certain of these. studies (eg - Clarke & Haughton, 1975: Schau et 
. . . 
al., 1980) strongly indicates that practice effects cannot fully account 
for observed gains, and that functional recovery continues considerably 
beyond three weeks, though~t a much slower rate. Consequently, caution 
must be exercised in interpreting tests scores obtained ~hortly after 
the res6lution of the alcohol withdrawal syndrome, as these scores may 
seriously underestimate the future functional capabilities of those 
assessed. In this regard it is of relevance that Le~ak (1976) advise~ 
that for any form of assessment of brain damage, testing should take 
place between three and six months after the trauma, to ensure validity 
of the test results. 
1.5 A SUMMARY OF IMPAIRMENTS IN CHRONIC ALCOHOLICS REPORTED IN 
NEUROPATHOLOGICAL, NEURORADIOLOGICAL & NEUROPSYCHOLOGICAL STUD I ES · - .. .. - . . . . 
The findings of neuropathological studies on alcoholic brains, two of 
which used normal controls, are unanimous in finding greater degree1s of 
diffuse cerebral atrophy in the brains of chronic alcoholics.· Two of 
these studies (Courville, 1955: Lynch, 196-0) specifically indicate 
preferential involvement of the frontal lobes, and in the two studies 
mention is made of co-existent sub-cortical atrophy, but in all studies 
the primary emphasis is laid on advanced cerebral (cortical) atrophy in 
alcoholic brains. Lynch (1960) estimated cell loss in alcoholics, 
relative to matched controls, at between 20% and 40% and Harper found 
.brain weights of alcoholics considerably less than those of non-alcoholits. 
Studies utilising pneumeoncephalograms and computerised axial tomography 
are more abundant than neuropathologlcal studles, but great uniformity 
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is evident in their conclusions. Repeatedly results show very large 
proportions of the alcoholic samples studied suffer mild to mode~ate 
cerebral atrophy while some, more rarely, also record more limited 
incidence of severe cerebral. atrophy. Ron (1982), 'however, found that 
in only a small minority of alcoholic cases were the degrees of cortical 
atrophy and ventricular enlargement comparable to those found in 
dementia cases and most findings are in agreement with her claim. 
In all cases cerebral atrophy is reported as diffuse and symmetrical, 
many studies emphasising greater damage to the frontal lobes, while the 
temporal and parietal lobes suffer less involvement. A small incidence 
of cerebellar atrophy is also frequently found. 
Sub-cortial atrophy, in the form of ventricular enlargement, is frequently 
reported, but in general fewer subjects suffer this than cerebral atrophy. 
When ventricular enlargement does occur this is usually in conjunction 
with cor'tical atrophy, rather than in isolation. Although several of 
the above studies did not include control groups and thus involve some 
subjectivity in ratings of presence and degrees of atrophy, m~ny othe~ 
studies do include non-alcoholic control groups and no great differences 
are discernable between the findings qf these studies. 
Studies which evaluate the effects of abstinence report a limited degree 
of recovery of brain mass. No statistically significant differences 
were found by either Carlen and Wilkinson (1980) or Ron (1982), though 
both· reported statistical trends indicative of increaslng brain mass 
with abstinence. It appears likely that these statistical trends, if 
not entirely spurious, would only attain statistical significance if 
very large samples were to be used. This appears to imply that even 
over the long period of Ron's (1982) study, recovery due to abstinence 
in extremely limited in extent and that alcoholics ~ave little chance 
of fully regaining 'normal' brain mass. 
l 
Psychometric studies have us~d a wlde variety of test materials, many 
of which are not directly comparable. It frequently emerges that on 
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standard measures of intellectual capacities, alcoholics score well 
within the normal ranges and are indlstiri~uishable from the general 
population (FitzHugh et al .• , 1960; 1965). ·As the evidence from neuro-
pathological and neuroradiological studies indicates that alcoholics 
·are a brain-damaged population, this might be regarded as unexpected 
as on standard IQ tests identified brain-damaged groups are easily 
identifiable by a marked deficit in performance IQ relative.to their 
obtained verbal IQ scores. 
However, numerous studies have shown that tests particularly sensitive 
to the organic state of the brain, especially the Halstead Reitan and 
Luria Nebraskaneuropsychological batteries, do discriminate between 
alcoholics and non-alcoholics. It has been argued that the limited 
deficits observed on standard tests of intellectucal ability are 
ascribable to their measuring crystallised intelligence, which is 
relatively impervious to the toxic effects of alcohol, whil~ ~biological' 
or adaptive intelligence is detrimentally affected (Chelune, 1982). 
Repeated' findings of deficits in alcoholics on the Halstead Reitan 
Category Test, the Wisconsin Card Sorting Test and the WAIS Block Design 
Test indicate impairments in the non-verbal concept formation, abstract. 
thought and complex psychomotor ability in alcoholics. Particular 
attention has been directed at the failure of alcoholics to persist 
with a set, which appears to indicate a high degree of distractability. 
General performance on neuropsychological batteries indicates poorer 
adaptive capacities with respect to novel problems, compared to that of 
the non-alcoholic population. 
In addition, memory deficits are frequently reported and, less frequently, 
deficits In visual-spatial abilities. Although scores on WAIS and 
Wechsler Bellevue scales tend to remain within normal limits, scores 
on most scales are found to reflect slight non-significant deficits 
compared to normal subjects. 
Attempts have been made to relate psychological deficits in alcoholics 
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to drinking related variables. No consistent results have emerged and 
the most regularly related variable is age. There are growing indications 
that with. increasing age, irresp•ctlve of the total amount of alcohol 
. . 
consumed in the past, the brain becomes increasingly vulnerable to the 
toxic effects of alcohol. 
Indications· are that with abstinence, psychological. performance of 
alcoholics improves slightly, but this appears to be a protracted process 
and total recovery appears unl ike'ly. Overal 1, the three sets of studies 
cited above reflect morphological and functional abnorma.litles in 
alcoholics. With abstinence a limited degree of recovery of brain mass 
and of functional capacities appears possible, but in both instances 
alcoholics are left with long term deficits which are unlikely to be 
totally eliminated. 
A 1 though the evidence of deficits both .morpho 1 og I ca 1 and !unc;t i ona 1 ·1 s 
disputa&le, the relationship between the two is not clear. Carlsson 
et al. (1979) related many indices of cortical·atrophy and ventricular 
enlargement to psychometric performance.· Though several significant. 
correlations were found, the highest of these yielded a co-efficient of 
0,46 which is of little practical significance. Wilkinson and Carlen 
(1980) found small significant correlations of most WAIS sub-tests to 
sulcal enlargement, a measure of cerebral cortical atrophy, while 
Zelozowiki et al. (1981) found numerous correlations of psychometric 
indices to ventricular enlargement, though none exceeded a value of 0,50. 
Graff-Radford et al. (1982) found. modest, but significant, correlati~ns 
of both cortical and sub-cortical indices of atrophy to psychometric 
performance. On the other hand, both Lee et al. (1982) and Ron (1982) 
found no correlations between these sets of measures.· 
The above findings are inconsistent in·.that.relationshipsare found only 
. . . 
in some cases, despite large sample size·s, which tend to yield si~r-
, , ' . . . 
nificant results. Some findings indicate cerebral atrophy re.lates to 
psychdmetric performance, while others indica~e that ventricular e~)arge­
ment correlates with psychometric performance.·· In a minodty of cases 
·-·~-----·~--- ·---------·--··-------·-~---~-------.-~ ·-
f 
/ 
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some indices -0f both cerebral and ,central atrophy have been correlated 
to psychometric performance. 
The one common feature among these findings is that where a significant 
correlation co-efficient is obtained, its value is modest~ and any 
regression equations utilising these co-efficients are consequently of 
little practical significance as predictions based on these are subject 
to large degrees ~f er~or. Thus it is very dangerous to attempt to 
, 
interpret scores from either set of indlces in terms of the other. 
However, despite the obs~U.Jfe relationship between the morphological and 
functional aspects of impairment in alcoholics due to the toxic effects 
of alcohol, the evidence of the existence of long term impairments on 
both types of assessment is overwhelming. 
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2. PIRACETAM 
2. 1 THE PHARMACOLOGICAL ACT I ON ·OF P l·RACETAM 
Piracetam is a cy~lic derivative of gamma-amino-butyric acid (GABA), 
an important mediator in brain cell bio-energetic processes. As GABA does· 
hot cross the blood-brain barrier, its levels cannot be manipulated 
directly. Piracetam has been shown to cross the blood-brain barrier 
(Calliauw & Marchau, 1975), however, and appears to take on some of 
the functions of GABA while not influencing GABA levels in the brain. 
The total mechanism of action of piracetam is complex and as yet 
imperfectly understood. 
The main effect of piracetam is in increasing the turnover of adenosine 
triphosphate (ATP), a substance known for its role in the storage of 
energy in brain cells. This energy is used, resulting in increased 
.synthesis of macromolecules, including ribonucleic acid (RNA). In so 
doing, overall cell metabolism is increased and this, in conjunction 
with an enhancing effect on blood erythrocyte deformability, leads to 
a gross improvement in microcirculation in cases where microcirculation 
is inadequate (Garay & Costa, 1979; Herrschaft, 1979; Nalbandian, 1979), 
Animal studies have revealed that piracetam has no sedative, tran-
quil 1 ising or stimulatory effects~ nor does lt affect the cardiovascular, 
' . . ,, 
respiratory or gastro-intestinal functions (Guirgea, 1973). Piracetam 
does not accumulate, although a small amount of renal reabsorbtion has 
been recorded and it is excreted unmetabolised (Gobert & Baltes, 1977). 
It has no known side effects, nor has it been known to interact with 
other medications. 
In humans piracetam can be detected in all organs, but has Its longest 
half-1 ife in the brain, this being •pproxim~t~ly 7 hours ~n~ 4~ minut~s, 
compared with a blood half-lif~ of about 5 hour~ ~nd 18 ~inut~s 
(Calliau .. & Marchau, 1975), Peak blood levels In man are attain~d about 
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forty minutes after administration and in fasting humans excretion is 
almost complete after thirty houts. 
2.2 THE ·EFFECTS OF -PIRACETAM IN ANIMAL STUDIES 
Guirgea (1973) reviewed much of the literature concerning the effects 
of piracetam on animals. Piracetam was shown to protect the brain from 
experimentally induced hypoxia, to facilitate learning and memory 
functions, and to offset treatments destgned to interfere with learning 
and memory. Piracetam reduced the loss of acquired l'earning substantially, 
but more so when administered prior to learning, rather than after 
amnesic treatment (electroconvulsive shock). 
Because of the beneficial effects demonstrated, Guirgea argued that 
piracetam must be active in the central nervous syst~m. Citing EEG 
evidence which indicated influence restricted to cortical associative 
areas, Guirgea concluded that piracetam acts at the telencephalic level 
of the forebrain and has no direct effects on the limbic or reticular 
formations, the thalamus or peripheral functions. 
Burnotte et al. (1973) studied the effects of piracetam in ageing rats, 
in whom the process involving RNA synthesis was in decline. The authors 
found evidence of enhanced brain cell efficiency and increased presence 
of substances critical to protein synthesis than in untreated animals. 
Consequently it was concluded that piracetam improves the processes of 
protein synthesis and, as long term memory depends on protein synthesis in 
brain cells, that this held possible implications for.memory and learning 
functions. Bonifac.i et al. (1982) obt~ined similar findings. Additional 
support for the argument for facllltation of brain RNA and protein 
synthesis was obtained from a study on spinal fixation time (UCB, 1980). 
Piracetam was shown to shorten the time taken to encode learning at the 
spinal level. This action is common to drugs which enhance RNA and 
protein production in the brain. 
In further studies reported (UCB, 1980) piracetam.was found to Ttihibit 
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central nystagmus provoked in rabbits by electrical stimulation of the 
lateral geniculate body. As it is possible to facilitate nystag~us by 
induclng cortical spr~ading depression through the application of 
potassium chloride to the cortex, it was argued that the cortex exercises 
a form of control which 1 imits the extent of nystagmus under normal 
conditions. The improved inhibition observed under the influence of 
piracetam argued, since its action was known from previous studies to 
be solely cortical, for enhanced cortical control of sub-cortical 
brain structures (Guirgea & Salama, 1977). 
Combined with the findings from other studies which indicate improved 
interhemispheric communication via the corpus callosum (UCB, 1980), it 
appears from animal studies that the action of piracetam at the level of 
the cell is one of increased turnover of cerebral energy, resulting in 
improved metabolism and increased functional capacity, and protection 
against toxic, anoxic and hypoxic effects, while at a functional level 
this appears as overall enhancement of learning, resistance to impairing 
agents, improved integration of the cerebral hemispheres and increased 
control exercised by the cortex on sub-cortical functions (Guirgea & 
Salama, 1977). The above features suggest that piracetam could be 
usefully applied to human subjects. 
2.3 ·PIRACETAM IN HUMAN CLINICAL TRIALS 
2.3.1 Studies outside ·the Area of Chronic Alcoholism 
Lagergren and Levander (1974) examined the action of piracetam on 
perceptual a~d psychomotor functions under conditions of experimentally 
induced hypoxia, using twelve subjects equipped with artifical pace-
makers. The authors found that while on placebo, subjects were severely 
functionally impaired by a reduction of heart rate from a normal value of 
70 beats per minute to one of 45 beats per minute, although subjects were 
not able to detect the differences in heart rate. Under piracetam these 
impairments were all reduced, though not all reductions were statistically 
significant. The authors concluded that their findings were consistent 
with either a protective effect or a cortical arousing effect, ~ounter-
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acting the expected decrement in vigilance associated with iriduced 
hypoxia. 
In a similar study, also involving subjects fitted with pacemakers,' 
. . 
lsaksson et al. (1975) foun~, within a double-blind methodoldgy 
involving piracetam and a placebo, that the effects of piracetam were 
evident on the EEG even at ncirmal heart rates. ·The authors had expected 
that the effects of piracetam would only become evident in the induced 
hypoxia condition. 
The effects observed in this study were small and were not detectable 
by visual inspection, but were detected ·by on-line com~uter analysi~.· · 
The differences were, however, statistically significant, reflecting a 
. . .. . 
decrease in slow EEG activity due to piracetam. The ·authors concluded 
that the effect of piracetam was not lim1ted to protection against 
hypoxia and that the alternative possibility mentioned ·by Lagergren 
' .. · . . 
and Levander (1974), namely, that piracetam had a iortical arousing effect, 
received support from these findings. 
Dimond (1975) investigated the effects of piracetam on verbal learning 
in 16 student subjects, using a placebo controlled double-blind 
procedure. No differences were apparent after one week 6f treatment, 
but significant improvements in favour of piracetam were found after 
two weeks. Trends indicating improved delayed recall in the piracetam 
group were also reported. 
Dimond (1975) also assessed these subjects' performance on a dichotic 
1 istening task and reported an improvement of approximately 15% under 
piracetam treatment, but this result did not achie~e statistical sig-
nificance. Further examination, however, revealed .that most of the 
improvement was due to improved recall of items fed to the left ear 
which meant that, for recall to occur, this· information had to be 
transferred from the right cerebral hemisphere to the left, via the 
corpus· callosum. The improved recall of these ii~ms ~hen:piracetam was 
given was consistent with the findings of animal .studies reported by 
38 
Gui rgea (1973) which reflected improved interhemispher,ic transfer of 
information. 
Using a double-blind design, Wedl and Suchenwirth (1977) compared the 
effects of piracetam and placebo on a group of 24 st~dents. Ove~ a 
five day period, the authors found positlve effects due to piracetam on 
mental tone, alertness and learning. 
Demay and Bande (1980) used a low pressure tank to examine the effects 
of piracetam and placebo on visual attention and concentration under 
conditions of induced hypoxia. The subjects were 12 normal volunteers 
and a double-blind procedure was employed. ·It was found that under hypoxic 
conditions speed of test completion was not differentially affected by 
piracetam compared to placebo, but the proportion of errors decreased 
with piracetam. The effects of piracetam were more marked in the longer 
periods of hypoxia and the authors concluded that piracetam protected 
mental efficiency under hypoxic conditions. 
The above findings were all derived from cerebrally normal subjects 
and reflect the findings of animal studies. It should be noted that both 
Dimond (1975) and Lagergren and Levander (1974) found that subjects 
could not distinguish between piracetam and placebo treatments, ~hus 
ruling out the possibility of contamination of results through perceived 
demand effects. 
The effects of piracetam were also evaluated in several .non-alcoholic 
clini~al populations. Patients undergoing surg~ry Involving general 
anaesthesia were studied to extend the animal findings that piracetam 
. ,..., 
protects the brain against the effects of hypoxia. Richardson~and 
Bereen (1977), Rivas Vidal (1979) and Samayoa de Leon (1979) al 1 
reported bcnoflclnl effects attributed to plracetam, in terms of raised 
post-operative levels of consciousness, shortened recovery times and 
faster elimination of the toxic effects of anaesthesia. ·oosages in 
these studies were· 1arge and appear to indicate that pi racetam has no 
detectable toxic effects in dosages up to 10 gra~s per day (Richardson & 
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Bereen, 1977). Beneficial effects on post-operative levels of 
consciousness, but not on survival rates,·were also reported in a study 
of head injury patients (Cal 1 iau & Marchau, 1975). · Schvartsman (1979) 
found that piracetam shortened periods of coma resulting from overdoses 
of psychotropic drugs. 
Volavka et al. (1979) found that piracetam increased overall EEG 
frequencies in a group of children with learnin~ disbrders. As these 
children usually exhibit EEG slowing, the authors contended that 
piracetam appeared to remediate this problem, and probably increased 
. . 
alertness and decreased fatiguabil ity. Interestingly, the authors 
described the piracetam-induced EEG changes as similar to those 
obtained after administration of amphetamines. As amphetamines are 
psychostimulants, this isolated finding appears to run counter to 
earlier reports (Call iau & Marchau, 1975) that piracetam has ~o 
stimulant properties. 
Similar findings to those of Volavka et al. (1979) were obtained by 
' 
Bente (1977) in a study of eleven elderly subjects. Bente observed 
reduced slow frequencies in the delta and theta bands, a slight increase 
in beta frequencies and a marked increase in alpha frequencies under 
piracetam treatment and concluded that these changes reflected 
improvements upon previous levels of vigilance regulatory functions. 
Mindus et al. (1977) examincid the effects of piracetam on perce~tual 
motor ability in an ageing but unimpaired sample. The authors found, 
using a double-blind placebo controlled design, that piracetam proved 
superior to placebo on most tests. Self-ratings of improvement, while 
indicative of improvement, did not attain significance, however,. 
possibly indicating that the changes were too small or too subtle for 
the subjects to detect. The authors conclud~d that piracetam enhanced 
mental alertness and cortical functions. 
Ageing persons frequently suffer disturbances of the cerebral .blood 
. . . 
supply, resulting in ischemic (undersupplied) areas and hyperemic 
' 
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(oversupplied) areas. lt has been found that manipulation of venous 
blood supply does not remedy these imbalances. However, Heinitz '(1975), 
using a brain scintigram technique~ found that piracetam acted to 
restore balanced cerebral blood flow, but the improvement disappeared 
after the withdrawal of piracetam treatment. 
Heinitz found the improved cerebral blood flow ·related.to positive 
changes in alertness, attentiveness, memory and speech. 'He argued that 
age-related decreased GABA production resulted in dysf~nction of 
inhibitory neurons due to energy shortages in these neurons, and that 
the result of this was increased overall excitability of the central 
nervous system. Heinitz claimed this excessive excitability expressed 
itself as great distractabil ity, which could be diminlsh~d by piracetam. 
Herrschaft (1979) recorded similar findings on regional cerebral blood 
flow, adding that piracetam showed its activity in the grey matter only, 
that is, only in the cortex. 
The dominant emphasis in piracetam studies appears to have fallen on 
piracetam•s efficiency in the treatment of the psycho-orgaMic syndromes 
of ageing (Suchenwirth, 1979). Reviewing the literature of German 
studies on piracetam in these syndromes, Suchenwirth concluded that the 
most frequently reported improvements were in vigilance, lucidity, drive, 
mood, concentration, memory, orientation and aphasia. Caro Mendevil 
(1979) also cited findings of improved psychmotor functions, but both he 
and Chouinard et al. (1979) gave prominence to findings 6f improv~d 
alertness or awareness while, in general, they and Castellanos et al. 
(1979) supported Suchenwirth's conclusions. However, Skandia (1982),.in 
a study using more objective measures, found improvements 6n the WAIS 
Object Assembly and Similarities sub-tests, but not on the Block Design, 
Digit Symbol, Digit Span or Information sub-tests. The failure to 
record significant improvements on the Block Design and Digit Symbol 
sub-tests, in particular, was unexpected, as these tests have frequently 
been reported as most sensitive to any form of brain impairment. 
Skondia's findings are, therefore, somewhat equivocal. Piracetam has 
also been found useful in the tre,atment of depression (Kabe.s· et al.,· 1979). 
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2;3;2 Piracetam Research ·ln Alcoholism. 
2.3.2.1 Acute Withdrawal Syndrome: 
Several studies have evaluated pireacetam's efficacy in the 
treatment of various aspects of alcoholism. Studies of the 
acute withdrawal syndrome relate in nature to studies of the 
efficacy of piracetam in post-anaesthetic recovery and treatment 
of overdosage cases involving psychotropic drugs. 
Knott and Beard (unpublished paper) conducted a placebo-
control led randomised double-blind trial utilising both rating 
scales and standardised tests. Results indicated no differences 
on perceptual motor tests, but significant differences in 
assessment of symptom severity after 2 and 3 days. ·In particular, 
beneficial effects on vigour and fatigue items and items related 
to confuslonal states were noted in piracetam treated subjects. 
These results were replicated by Petty (unpublished paper), 
except that he did not attempt assessment of perceptual motor 
' . ' 
functions. Ulbricht (1976) concluded that piracetam was a 
useful adjunct to standard treatment of withdrawal syndrome, 
finding that it controlled states of deli~ium and pre-delirium 
in all cases except those involving alcoholic epilepsy. 
Marks (1977) presented findings thatrpiracetam did not generally 
differ from chlorpromazine, another medicationused in the 
treatment of withdrawal states, both showing beneficial effects.· 
However, the results showed piracetam caused less ataxia and 
drowsiness and more social interest. Findi~gs of less lethargy 
and more sociable behaviour were also reported by Almeida 
Vargas (1979). 
2.3.2.2 Chronic Alcoholism: 
Binder (1974) conducted a placebo controlled blind clinical 
trial involving 50 ~ale alcoholic inpatieht~ ~ho were regarded 
. ( . . 
as having completedwithdrawal·and who were not taking psychtropic 
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medications. The groups· were matched for age, education and 
duration of alcoholism~ A battery of psychomotor tests and 
self-rating scaleswas applied at the commencement of the study 
. . 
and after six weeks. 'Binder recorded improvements over the 
period of the trial in both groups, but the piracetam treated 
group showed superior improvement. Results indicated that 
piracetam did not enhance performance on 'stimulus ·response' 
. ' . ,. 
type tasks, but i nf1 uenced the extent, speed and quality of 
constructive performance. Binder concluded that piracetam 
improved concentration and co-ordination of higher mental 
functions, reflecting enhanced functional potential of the cortex. 
Subjectively, subjects rated themselves as more inclined to 
work, and more peaceful. 
A placebo controlled double-blind·crossover design .was used by 
Binder and Ooddabela (1976) to study the effects of-piracetam on 
40 detoxified alcoholic subjects over a period of 14 to 18 
weeks. Subjects were assessed on a battery of psychometric 
tests and the authors found improvements in associative and 
discriminative aspects of learning and in concentration. ·Further 
analysis of their data led the authors to conclude that the 
observed significant results reflected general, non- specific 
enhancement ~f functions due to treatment with pir~cet~m. · 
They considered this a result o! 11more regular, stronger and 
continuous cortical activiation. 11 · 
43 
. 3 •. :TAE-AIM-OF THIS~STUOY 
Neuropathological and neuroradiological studies cited above have 
repeatedly shown alcoholic subjects to exhibit advanced cortical 
atrophy and ventricular enlargement for their ages. This has been shown 
to revert partially towards normal values when abstinence from alcohol 
is maintained, but the available evidence indicates that total recovery 
is unlikely or, at least, extremely protracted.· Similarly, neuro-
psychological studies have regularly indicated functional impairments 
in alcoholic populations, which only partially recede with abstinence. 
The precise nature of the link between morphological and functional 
abnormalities in this population is not clear. However, correlations 
between morphological and functional impairment indices, while not 
large and while not being of great predictive value, nevertheless 
frequently attain statistical significance. · tt thus· appears 1 ikely that 
in some as yet unclear fashion, morphological abnormalities do underly 
the function deficit~ recorded in the alcoholic population. 
Clearly, the collective contributions of cortical atrophy and sub~cortical 
(central) atrophy, as reflected by ventricular en 1 argements towards these 
observed functional deficits, are not yet known. However, the 1 iterature 
has shown that cortical atrophy is found more frequently than central 
atrophy, and certain studies have recorded central atrophy predominently 
or exclusively in the presence of cortical atrophy. Central atrophy 
is only reported consistently in older alcoholic populations and appears 
to makes its appearance at a later stage than cortical atrophy. ·eoth 
forms of atrophy advance with ageing, but the advance ts accelerated 
by alcohol abuse. 
Consequently, it appears that the functional deficits ~xhiblted by young 
alcoholics are more likely to reflect cortical atrophy that central 
atrophy. There is no reason to expect that cortical atrophy should not 
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continue, with advancing age, to contribute to functional impa1rments, 
although later central atrophy might well lead to additional impairments 
or to strengthening of impairing mechanisms.· 
There is, then, reason tb expect that a drug which is claimed to enhance 
the level of functioning of cortical neurons and cells might pa~tially 
remedy the functional deficits associated with cortical atrophy. ·In 
the brain the action of piracetam is predominently in the gr~y cortical 
matter. Piracetam increases the production and turnover of adenosine 
triphosphate(ATP), a substance which stores energy for use in brain cells. 
As all membrane phenomena and nervous conduction, as well as the synthesis 
of nucleic acids and proteins depend on a regular sup~ly of ATP, piracetam 
optimises cellular and neuronal functions. This has been shown to have 
protective aspects, where stored ATP may enable cells to survive acute 
intoxications and hypoxia and a 'cortical arousal 1 effect which goes 
beyond mere protective functions. 
As aspects of attention and concentration fall under the joint action of 
both cortical and sub-cortical areas of the cerebrum~ it is ~ossible 
that vigilence, attention and concentration might be improved by purely 
cortical treatment. The findings of numerous studies support the view 
that piracetam does not directly affect specific functions, but that the 
improvements noted reflect improved concentration, alertness, arousal, 
vigilance and attention. 
Consequently, it appears that piracetam might be us~ful in the treatment 
of long term psychological deficits which result from alcoholism through 
a general raising of the level of arousal. While improvements might 
occur across the entire spectrum of psychological functions, whether intact 
or deficient, attention should centre on the deficient functions as 
elimination of these problem areas i~ of greater cl ini6al importance 
than the enhancement of normal functions. 
Two studies cited above have evaluated the utnity of piracetam in 
chronic alcohol ism: Both reported promising findings,·but the lssu~ is 
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far from settled, as both studies used limited batteries of tests and 
one study (Binder, 197.4) was only a single-bl ind clinical. trial, and this 
might have been susceptibletocontamination. Further,. both studies 
. . 
could be contaminated by testing being conducted too soon after de-
toxification, ,as this would probably yield spuriously low baseline 
scores. Subsequent improvements in levels of functioning would then 
erroneously be attributed to the treatments applied. ·In addition, the 
findings of Binder and Doddabela (1976) are not wholly convincing, as 
no differences between treatments were detected on a substantial number 
of methods used. 
The common claim of both Binder (1974) and Binder and Doddabela (1976) 
that piracetam improves co-ordination and co-operation 6f psychological 
funcdons is, however, in line with both the findings of improved 
interhemispheric communication (Guirgea, 1973; Dimond, 1975) and those 
. . . 
of improved cortical control of sub-cortical structures (Guirgea & 
Salama, 1977), reported earlier. 
Seen in terms of the model created by Hindmarch (1980): presented in 
Figure I, this action of piracetam would be on the central integrative 
and processing functions which are modulated by, inter alia, the level 
of arousal of the central nervous system. Although the model is 
expressly designed to account for psychomotor functions, it is capable of 
accounting for a wide range of test performances and it seems as though 
it can be extended to more verbal and abstract functions without 
difficulty in the case of piracetam as its action, being central in 
nature, can be pertinent to any test performance. 
Due to the Jack of clear cut findings in the study of piracetam's effect 
. ·.' 
on f~nctional deficits resulting from chronic alcoholism, studies in 
this area should be regarded as exploratory. The claims of an overall 
'arousing' effect appear to justify application of a wide range of 
measures in any such study, but these should be selected either on 
grounds of demonstrated deficient performance by alcoholics on these 
measures, or because the measures have been shown sensitive to brain 
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FIGURE\: Hindmarch's Model of Psychomotor Function. 
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Psychomotor performance results from the co~ordinatlon of sensory and 
motor systems through the tntegrative and organisational processes of 
the brain and central nervous system. The processing of sensory 
information is influenced by personality, memory and individual moti-
vation, while the overall function of the integrative mechanism is 
governed by the state of arousal of the central nervous system. Complex 
feedback and adaptive systems complete the process by which environmental 
stimuli produce appropriate, co-ordinated behavioural responses. 
damage in other populations. 
As psychometric performance might be influenced by acute intoxication 
effects, acute withdrawal effects or long term functional deficits of 
alcoholism, singly or in varying combinations, the former two sets of 
variables should be eliminated in order to study the latter without ' 
contamination. 
Consequently~ the ~ffects if piracetam should be evaluated on a wide 
range of measures of psychological functions in a sample of chronic 
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alcoholics currently free of problem drinking and which has been so 
for at least three months. A placebo controlled randomised double-blind 
crossover desi~n comprising two eight week periods should provide 
maximal internal validity. 
3. 1 EXP ER I MENTAL HY POTH ES IS 
The adminstration of piracetam arid placebo for two 8-week periods to 
the two treatment groups will result in systematic differences between 
groups in test scores obtained after each 8-week ~eriod, that is, 
differences are expected at assessments after 8 weeks ~nd after 16 
weeks, but not at baseline, and the direction of the differences should 
relate systematically to the relative effectiveness of placebo and 
piracetam in influencing functional perform~nce. {As this is exploratory. 
research, the hypothesis is non-directional). 
This design requires statistical analysis by means bf 2-way an~lysis of 
variance with repeated measures on the trials variable, thus systematic 
differences in test ~cores after 8 weeks and after 16 weeks, as functions 
of differential effects of treatments, can only be detected through 
significant interaction effects. Consequently, the null hypothesis can 
be stated as follows: 
3.2 NULL HYPOTHESIS 
There is no significant effect of interaction between the effects of 
treatment sequence and the trials variable on psychometric performance 
of abstinent chronic alcoholics. 
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4. · METHOD 
4.1 DESIGN 
A placebo-control led, randomised double-bl ind crossover design was used, 
with three assessments on the battery test. These assessments occurred 
for each subject at: 
( i ) 
( i i ) 
( i i i ) 
Group 
base 1 i ne 
after 8 weeks of treatment 
after 16 weeks of treatment 
received placebo treatment for a first 8 week period, followed by 
a crossover to piracetam for a further 8 weeks. Group 2 received 
piracetam for 8 weeks followed by placebo for a further 8 weeks. 
Subjects selected for the trial were randomly allocated to one of the 
two treatment groups as they entered the trial. The manipulated variable 
was drug treatment, which was varied along the trials variable, while 
the dependent variable was psychometric performance, represented by 
a wide range of psychological functions. Each pyschological function 
was statistically analysed separately. 
4.2 SUBJECTS 
All subjects in this study had received treatment for chronic alcoholism 
at the William Slater Hospital, Rondebosch, Cape, and all but three 
were still receiving outpatient treatment from this same institution. 
The remaining three subjects maintained contact with the hospital 
through attending meetings of Alcoholics Anonymous on the premises. 
The hospital was chosen as a convenient facility specialising in the 
treatment of alcoholism and possessing a large pool of potential subjects. 
Hospital staff checked hospital records to identify possible subjects, 
both White males and White females, according to the following criteria: 
(a) aged between 35 and 60 years 
(b) an estimated duration of problem drinking of at least 10 years 
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(c) apparent absence of problem drinking for at least 3 months. 
(d) having a record of reliability, in terms of regular adherence 
to hospital appolntments and of maintaining contact with the 
hospital. 
(The three subjects who were not outpatients were known to have good 
records of attendance at AA meetings on the premises). 
Potential subjects were excluded on the following criteria: 
(a) oresence of psychotic illness, including the Wernicke-Korsakoff 
syndrome. 
(b) presence of serious physical disease. 
One hundred and twenty-three eligible patients were approached, of 
whom 63 eventually participated. Of these, eight were female. The 
mean age of the entire sample at the commencement of the trial (years 
only) was ~8,01 with a sustained deviation of 6,99 years. 
An estimate of the length of history of problem drinking, based on 
hospital records and questioning of subjects, yielded a mean duration 
of 20,84 years, with a standard deviation of 7,37 years. 
4.3 TREATMENT MATERIALS 
Tablets for both piracetam and placebo treatments were idential in size, 
colour and overall appearance and were packed in quantities of 168 in 
identical metal canisters. Each canister contained a supply sufficient 
for exactly 4 weeks of treatment. 
There were four canisters per subject, two each of piracetam and two 
of placebo, each subject 1s supply being separately boxed. Each canister 
bore the subjects number and the period of the trial for which it was 
intended, ie - Per 1 (period 1) or Per 11 (period 11). In addition, each 
box contained a sealed, opaque envelope containing the treatment 
sequence data. This envelope was not opened until the end of the trial 
and after scoring had been completed for all subjects. 
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4.4 PHYSICAL APPARATUS 
The only non-standard apparatus used was an electronic reaction timer, 
assessing three-choice visual reaction time. This apparatus consisted 
of two units, an impulse gener.ator and a unit housing the response 
and me~surement consoles. The response console housed three response 
keys (one per 1 ight) and a· •starting 1 key, plus red, green and yellow 
st.imulus 1 ights. The measurement console consisted of a digital 
display registering milliseconds and a •reset' button. At one side was 
a switch inverting the red and green 1 ights1 response circuits for the 
•reversed' reaction timing condition. (For a fuller description see 
Appendices 1 and 2). 
4.5 TESTS 
4. 5. 1 Choice Reaction Time 
Choice Reaction Time (CRT) was chosen as a measure of psychomotor 
performance which is considered an index of attentional monitoring, 
far more so than Simple Reaction Time, which is much less reliant on 
central processes. CRT has been used frequently in drug research and 
has proved its sensitivity to a wide range of psychotropic substances 
(Hindmarch, 1980). Once the effects of practice have stabilised, the 
latency of response is dependent on the number of possible responses 
(Teichner & Krebs, 1974). 
Talland (1963) found alcoholics deficient relative to controls in all 
forms of Reaction Time that he tested. Bente (1977) has argued that 
piracetam probably acts to rectify impairments in vigilance regulatory 
mechanisms. Consequently, it appears that CRT might be the most 
powerful means of detecting these changes. Three-Choice Reaction Time 
was chosen as a sufficiently complex means of assessment, capable of 
offering chronic alcoholics large opportunities to demonstrate im-
provements under the influence of piracetam. 
In addition to CRT, it was considered possible to evaluate the effects 
of change of set on this variable by means of reversing response keys 
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such that for certain stimuli the responses required had to be changed. 
This has been done with two-choice reaction time (Lagergren & Levander, 
(1974). 
Change of mental set has been demonstrated, in studies of alcoholics 
on the Wisconsin Card Sorting Test, to increase the number of errors 
made (Tarter & Parsons, 1971; Tarter, 1973). Consequently, it was 
expected that the required alterations in responses to the same stimuli 
would result in greater latencies of response which would fluctuate 
as a function of piracetam or placebo treatment. 
As there were three response keys, the alteration of responses could 
have resulted in very complicated instruction in the reversed condition, 
as at least one stimulus 1 ight-response key relationship would have to 
change in the opposite direction to the other two, if all three relation-
ships were to change. It was thus decided to reverse the relationships 
between the left (red), and right (green), keys and stimuli, leaving the 
key-to-1 ight stimulus relationship in the middle (yellow) as it was. 
This condition was called the •reversed condition' and the former the 
'standard condition. 1 
Subjects were given ten practice trials in each condition, followed by 
30 test trials which were measured. The mean of the 30 trials was 
one performance measure, but this was broken down to allow comparison 
of the responses to red and green stimuli in the two conditions. The 
sequence of stimulus onsets was standard and randomly programmed, 
including in the test stimuli, 10 stimuli of each colour. (For further 
details of apparatus and procedure, see Appendices 1, 2 and 3). 
4.5.2 Purdue Pegboard 
This is a test of motor manipulative ability, which has been shown 
sensitive to centrally acting drugs (Hindmarch, 1980). Vaughan and 
Costa (1962) attempted to use the Purdue Pegboard to discriminate 
between lesions in the left and right hemispheres, but their data 
forced them to conclude that the "physiologic system underlying 
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performance on the Purdue Pegboard appears to be relatively diffuse. 
It is related to !:!ystems subserving both motor and somesthetic 
functions'' (p. 242). In a later study Costa et al. (1963)-using a short 
form were able to identify 93% of a sample of 80 consecutive referrals 
to a neurological clinic in terms of presence or absence of brain 
damage. Generally, the brain-damaged group scored lower than those 
who were adjudged on neurological, EEG and neuroradiological grounds 
as normal. Utilised later, it correctly identified 95% of referrals. 
This suggests that chronic alcoholics should score poorly on this test. 
The short form utilises 30-second trials during which the subject must 
place as many pins as he can, one at a time, in a row of holes set 
in a wooden board. Trials are conducted separately with the dominant 
and non-dominant hands, and then with both hands simultaneously. 
Standard instructions were given to the subjects from the manual 
(Tiffin, 1968). 
4.5.3 Wechsler Adult Intelligence Scale Sub-tests 
4.5.3.1 Information Sub-test: 
This is a test of long term memory (Maloney & Ward, 1974), 
loading on a general verbal comprehension factor (Anastasi, 1968). 
According to Lezak (1976), it is also influenced by mental 
alertness. The test is known to be a 'hold' test, but bearing 
in mind the equivocal nature of certain results relating to the 
general invulnerability of verbal skills in alcoholics (Fitz-
Hugh et al. ,1965: Grant et al., 1979; Adams et al., 1980 and 
Ron, 1982), it was decide to include it. Another reason for 
its inclusion was that its presence would permit an approximation 
of Full Scale IQ based on equal numbers of verbal and per-
formance sub-tests. 
4.5.3.2 Digit Span Sub-test: 
This assesses auditory rote (short term) memory and is 
susceptible to the effects of disturbances in attention and 
concentration (Maloney & Ward, 1976). Lezak (1976) claims it 
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is a good indicator of diffuse brain damage. Certainly, 
memory deficits are very commonly reported in chronic alcoholic 
populations (Kaszniak, 1975; Lezak, 1976; Lee et al., 1979; 
Ryan, 1980) and this test was chosen to assess possible 
improvements on these functions as a result of piracetam 
treatment. 
Griffin and Hefferman (1983) found that separating the 'Digits 
Forwards 1 and 'Digits Backwards' sections of this test resulted 
in differing relationships to global intellectual functioning, 
with the latter bearing a much greater relationship to this. 
They postulated that 'Digits Backwards' required a degree of 
'double tracking, 1 that is, holding an item whilst simultaneously 
manipulating it, while 'Digits Forwards 1 measured pure rote 
memory. It was decided to analyse results according to overall 
'Digit Span' and by the two sub-sections, i,n the expectation 
that the complexity of 'Digits Backwards 1 would make it more 
sensitive to disturbances of attention and concentration. This 
methodology has been successfully used in the study of acute 
intoxication effects in the past by Melges et al. (1970). 
This test has advantages in terms of speed of completion and 
simplicity of administration. 
4,5.3,3 Similarities Sub-test: 
Kleinknecht and Goldstein (1972) and Wechsler (1958) have 
reported consistent deficits in chronic alcoholics on the 
Similarities sub-test. It is, primarily, a test of abstract 
thought and verbal concept formation and, to an extent, involves 
remote memory, comprehension and associative thought (Maloney & 
Ward, 1976). Lezak (1976) claims that this test is most 
sensitive to damage to the frontal lobes of the brain, but is 
sensitive also to all other forms of brain damage. 
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4.5.3.4 Object Assembly Sub-test: 
A visual-motor performance sub-test, Object Assembly is said 
to be sensitive to perceptual deficits (Maloney & Ward, 1976), 
and scores reflect perception of wholes and rapidity of re-
cognition in particular (Matarazzo, 1972). In their review of 
the utility of WAIS sub-tests in assessing chronic alcoholics' 
functional deficits, Kleinknecht and Goldstein (1972) report 
Object Assembly as the most commonly reported test registering 
alcoholic deficits, along with Digit Symbol Substitution. 
More recently this has been supported by findings from Long 
and Maclachlan (1974) and O'Leary et al. (1979). 
4.5,3,5 Block Design Sub-test: 
Performance on the Block Design Sub-test reflects non-verbal 
concept formation, and depends on perceptual-motor integration 
and sustained effort (Maloney & Ward, 1976). Matarazzo (1972) 
reviewed literature indicating poor performance to be associated 
with frontal lobe atrophy, but Lezak (1976) argues that this 
test reflects any form of brain damage. 
Recent studies that have found poorer performance in alcoholic 
groups are Long and Maclachlan (1974), Maclachlan and Levinson 
(1974) and O'Leary et al. (1979). 
4.5.3.6 Digit Symbol Substitution Sub-test: 
Kleinknecht and Goldstein (1972), reviewing the literature of 
use of the WAIS in chronic alcoholic populations, concluded that 
Object Assembly and Digit Symbol Substitution were the most 
consistently reported tests upon which alcoholics were reported 
deficient. Maloney and Ward (1976) assert that performance 
depends upon eye-hand co-ordination, concentration, immediate 
memory and psychomotor speed, but the factor most frequently 
mentioned by other authorities is concentration or attention 
(Matarazzo, 1972; Lezak, 1976). 
4.5.4 
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On aggregate, Digit Symbol Substitution provides an ~ssessment 
of sensory processing ability. Hindmarch (1980) reviewed litera-
ture on drug trials and was able to show that this test is very 
sensitive to drug effects when these relate to central processes. 
Hindmarch admitted that there is a motor component to the task 
but he concluded that the principal determinant of results was 
the recoding of visual information. 
Modified Card Sorting Test 
The Wisconsin Card Sorting Test (WCST) may be classified as a psychomotor 
test (Hindmarch, 1980) where the motor aspect is of minimal importance 
and the emphasis falls on central processes. It is primarily a test of 
abstract thought,concentration and difficulty in changing mental set 
(Ron, 1982), and provides a strong evaluation of perseverative tendencies. 
Kleinknecht and Goldstein (1972) concluded that one of the areas in 
which alcoholics were deficient was in abstract reasoning and problem 
solving. This conclusion was largely based on consistently reported al-
coholic deficits on the Category Test of the Halstead-Retan Neuropsychological 
Battery, a test which is generally regarded as tapping the same functions 
as the WCST. Abstract thought and perseverative tendencies are most 
related to the frontal lobes (Lezak, 1976). 
Nelson (1976) modified the WCST because feedback on correct responses 
could be ambiguous, in that a card matched to a key card could be correct 
for either of two reasons in certain cases. She reduced the number of 
sorting cards from 64 to 48, eliminating those cards responsible for 
the ambiguity. The number of correct 11sorts 11 in a continuous seQuf'nce 
was reduced from 10 to 6, effectively reducing the administration time. 
Scoring of errors was unchanged, but the method of scoring 11perseverative 11 
errors was altered. A perserverative error was previously regarded as 
a response which conformed to the set used prior to the current set. 
However, Nelson (1976) re-defined a perseverative error to denote one which 
was preceded by another error, and was made according to the same set as 
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that previous error. (For details of administration procedures, see 
Appendix 4). 
Ron (1982) used Nelson~ Modified Card Sorting Test, finding that 
total errors discriminated chronic alcoholics from controls. 
This supported an earlier finding by Tarter and Parsons (1971). Other 
studies supporting the utility of the WCST in the study of chronic al-
coholics are Tarter (1971), Kl isz ~nd Parsons (1979) and Parker and 
/ 
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4.5.5 iSelective 1 & 1Restrictive 1 Reminding in List Learning 
Buschke (1973) and Buschke and Fuld (1974) have developed methods 
of analysing free recall over repeated trials to determine long term 
storage (LTS) and retrieval (LTR) as well as short term retrieval 
(STR). They argued that traditional free recall experiments in 
which an entire list of words is presented before each recall 
attempt do not permit distinctions between the contributions of 
long term memory and rote memory. 
11Selective Reminding•• involved reminding before a recall attempt 
of all items not recalled in the previous recall attempt, while 
11Restricted Reminding'' limited reminding to words not yet recalled 
on any prior recall attempt. While the former condition allows 
maximum opportunity to demonstrate learning, the latter might result 
in lower total recall scores but wi 11 provide a more stringent 
assessment of retrieval function uncontaminated by STR. Buschke 
and Fuld (1976) presented alcoholic case study data indicative of 
defective retrieval operations, as LTS had been demonstrated but 
LTR could not measure up to this. 
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On time considerations, it was not possible to replicate the 
Buschke and Fuld methodology which frequently inyolved more than ten 
recall attempts. It was therefore decided to limit recall trials 
to three, and to take LTR at trial three as both an adequate demons-
tration of retrieval and as an approximation of LTS, though this 
latter will usually be an underestimate, at best equal to LTR. The 
major emphasis fell on adequacy of retrieval. Buschke and Fuld argued 
that little of the retrieval in the case study material was consistent, 
the balance being random and disorganized. The inconsistent nature of 
retrieval argues for deficient organized search procedures, which should 
respond to centrally active drugs acting on higher integrative and 
associative mechanisms. Improvements in organized search procedures 
should reflect themselves in increasing LTR. 
Both methods assess retrieval, the latter more so. Selective Reminding 
also provides an estimate of learning ability. Overall scores of the 
three recall trials were used to assess the amount of learning which 
took place. 
Test materials consisted of three equivalent-difficulty lists of 20 
words, one for each assessment for each condition, yielding a total of 
six. All words used were nouns. For instructions to subjects, and 
list information, see Appendices 5 and 6. 
4.5.6 Serial 3s 
Serial subtraction of numbers has been used as a measure of attention 
and concentration extensively in drug trials (Hindmarch, 1980). It 
can be scored on time or errors(Lezak, 1976) and is very easily applied. 
It has been noted by Lezak that problems on this test are both more 
frequent and of greater magnitude in brain damaged populations than 
in others. 
It was decided to standardize the time of this test at 30 seconds, 
and to score according to errors, number of items correctly enumerated 
within the time limits, and total number of items enumerated. All 
three forms of scoring were adopted to check against each other as 
different test-taking styles might bias any one analysis. 
Three forms were used, starting at 100, 99, and 98 respectively. 
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4.5.7 Inglis Paired Associate Learning Test 
lngl is (1959) claims this test is most sensitive to the encoding phase 
of learning, and is independent of age and intelligence. It is a 
test of auditory verbal recall originally designed for use in the 
elderly populations. Inglis (1959) and Cai rd et al. (1962) claimed 
it useful in identifying memory-disordered patients. This type of task 
has been shown sensitive to alcoholic brain impairment (Acker, 1982). 
Paired associate learning tests are regarded as sensitive to drug 
effects, and as chro~ic alGohol ics have long been regarded as possessing 
their primary deficit in memory, this test was chosen. 
The test has two forms, each of three pairs of words. A third form, 
required for assessment three, was developed by Oblowitz (1982) and 
was matched to the former two forms in abstractness-concreteness, 
imagery and word association values, as well as Thorndike-Lorge noun 
frequency. (See Appendices 8 and 9). 
The subjects are initially presented with the three noun pairs at five 
second intervals and are then presented with the initial noun of the 
pair and are asked to provide the associate. Immediate feedback is 
given. Initial nouns are randomly alternated _in presentation until 
pairs are dropped when three consecutive presentations meet with the 
correct response. Scoring is in terms of total presentations required 
to either the meeting of criterion for the third pair, or 93, if the 
criteria cannot be met.· Initial presentation of the noun pairs is 
included, yielding a minimum score of 3. 
4.5.8 Hamilton Psychiatric Rating Scale for Depression 
Kabes et al. (1979) reported that piracetam exerted beneficial effects 
on drug-resistant depression. As alcoholic populations are frequently 
reported as containing many depressed individuals, it was considered 
desirable to include an instrument to assess this ~arlable, as any 
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systematic anti-depressant effect could exert an influence on test 
performance and, consequently, contaminate the findings of the study. 
The Hamilton Psychiatric Rating Scale for Depression consists of 17 
items, yielding a maximum (most depressed) score of 50 and a minimum 
of 0 (not depressed). The scale items assess the presence and severity 
of depressive symptomatology. All rating is done by the experimenter. 
Fo~ the sake of brevity, this scale is hereafter referred to as the 
'Hamilton Depression Scale' or 'HOS.' (See Apendix 10 for question-
ria i re) . 
4.6 PROCEDURE 
Hospital staff identified potential subjects from hospital records, 
using the criteria referred to above under 'Subjects.' These patients 
were then approached by mail and invited to participate in the trial 
(see Appendix 11). These patients were asked to contact the hospital 
and, if interested in participating, an appointment was made to see 
either Dr I Fraser, the consultant, or, after his departure from the 
hospital, Dr A Robins of the Department of Pharmacology, University of 
Cape Town. 
At this interview the patient's medical history was updated, as were the 
details of current medications. Patients were informed that the long 
term administration of alcohol was known to affect memory and other 
cognitive functions adversely, and that the drug under consideration, 
piracetam, was considered as 1 ikely to be of benefit in combating these 
problems. It was further explained that the drug was considered to be 
perfectly safe, that no side effects were known, that no interactive 
effects with other drugs had been observed, and that the study had been 
approved by the Ethical Review Committee of the University of Cape Town 
Medical School. 
Patients were informed that the trial would require their being assessed 
' 
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on a battery of tests on three occasions, at 8 week intervals, and that 
they would be required to take medication daily for a total of 16 weeks. 
Those patients who agreed to participate then signed an informed consent 
(see Appendix 12) and an appointment was made for baseline assessment. 
At baseline assessment clinical data relating to alcohol abuse and 
medication were gathered, as well as personal details considered 
relevant to contacting subjects in the event of difficulties (see 
Appendix 13). Subjects were informed that they would be given some 
qualitative feedback after termination of the trial. They were also 
assured of the confidentiality of all that transpired at assessments, 
and were instructed that all unconsumed tablets must be returned at each 
subsequent assessment, and that they were not to discuss the research, 
medication or test content in any way. Finally, subjects were required 
to report any changes in medication during the trial and, as far as 
possible, to avoid such changes. Subjects were given a ~ote to their 
doctors to this effect (see Appendix 14). 
Tests were then presented in the following order: 
1. Hamiltons· Psychiatric Rating Scale for Depression 
2. Choice Reaction Time 
3. Purdue Pegboard 
4 . \,/A I S (a ) I n f o rma t i on 
(b) Digit Span 
(c) Similarities 
(d) Object Assembly 
(e) Block Desf gn 
(f) Digit Symbol Substitution 
5. Modified Card Sorting Test 
6. List Learning-Selective Reminding 
7. Seri a 1 3s 
8. List Learning-Restrictive Reminding 
9. lngl is Paired Associate Learning Test 
All tests were administered according to standard procedures, where 
these existed. Procedures and instructions had to be formulated for 
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Reaction Time, List Learning and Serial 3s (see Appendices 3, 5 and 7). 
On completion of the test battery, the subject was given a 4 week 
supply of tablets for Period 1 of the trial, from the subject's 
respective medical supply and instructed to make arrangements to 
collect the second canister before the first supply was exhausted. 
Each subject was instructed to take two tablets three times daily, 
ie - 4,8gm/day, for convenience, preferably at mealtimes. 
The date of the second assessment was set at exactly 8 weeks from the 
date of baseline assessment and, as far as possible, fbr the same time 
of day. The same procedure was followed in setting the date of the 
third assessment. 
At subsequent assessments the battery was applied in the same order, 
with equivalent forms substituted in the cases of List Learning, Serial 
3s and Inglis Paired Associate Learning Test. Tablet returns were 
counted and new supplies issued at the second assessment and data 
concerning possible side effects and any changes in other medications 
were gathered. Where subjects omitted to return unused pills, they 
were asked to put these aside, not to use any and to return these for 
counting as soon as possible. 
Between assessments replacement supplies of medications were distributed 
either directly at arranged times, or through the hospital's outpatient 
medication distribution system, where the subjects could not pick these 
up during the day. The latter was the more common means of distribution. 
No scoring was done until all subjects had completed the trial, and all 
potentially useful means of scoring were employed before the codes were 
broken and the data were grouped for statistical analysis. Exclusion 
criteria were only operated upon after all subjects (excludi~g dropouts) 
had completed·the trial (see Appendix 15). 
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4.7 SCORING 
All scores used, with the exception of pro-rated WAIS IQ scores, were 
raw scores, including those on the WAIS sub-tests. It was considered 
that these WAIS sub-tests were primarily evaluated as assessments of 
group functions and that standardisation of these scores would serve 
no useful purpose but, on the contrary, lead to loss of fine dis-
crimination by reducing the range of scores. 
Although it is frequently claimed that individual sub-test scores are 
unreliable, the danger in interpreting these is greatest for individual 
cases. When data are grouped, however, fluctuations might reasonably 
be expected to average out. 
4.8 STATISTICAL ANALYSIS 
The data were analysed by means of two-way anovas with repeated measures 
on the 8 factor. Factor A was the drug sequence variable.for which 
there were two levels: the placebo-piracetam sequence (A}) and the 
piracetam-placebo sequence (All). Factor 8 was a trials (time of 
assessment) factor for which there were three levels: baseline (81), 
crossover (82) and termination (83), corresponding to weeks 0, 8 and 16. 
As subjects were randomly assigned to treatment groups, and as piracetam 
is not known to have long term after-effects, sequence effects were 
not expected to emerge. 
The two-way anova with repeated measures on the trials factor is, 
however, very sensitive to effects in the trials factor, and these 
were exp~cted in many analyses in the event of interactive effects 
not being found (Gilbert, 1977). 
Differing effects of piracetam and placebo could only be considered 
to have emerged when interaction became significant. In any other 
eventuality, the statistic allowed no conclusions to be drawn concerning 
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differential treatment effects of placebo and piracetam. 
A basic assumption of the analysis of variance is that of homogeneity 
of variance which, if violated, casts doubt as to the correctness 
of the value of the error variance which, in turn, implicates obtained 
F-values for interaction and B main effects in the case of violated 
residual error variance, and A main effects in the event of violation 
of subject error variance. 
Such violations can arise when the independent variable involves time, 
error scores or changes to or from an extreme (Gilbert, 1977). In 
the case of the present battery, this appears more applicable to the 
unstandardised methods of assessment, particularly the Modified Card 
Sorting Test and Serial 3s, but also possibly the Purdue Pegboard, 
List Learning Tasks and Inglis Paired Associate Learning Test, where 
the possibilities of large movements towards or away from extreme scores 
cannot be ruled out. 
In the event of such violations of F max, there are several means of 
correction available. Transformation scores are the best means of 
eliminating F max violations, but involve serious limitations in 
subsequent interpretability. Degrees of freedom may be divided by an 
arbitrary figure to make attainment of statistical significance more 
difficult, or a higher level of significance may be used~ which also 
makes for a more stringent test. 
Use of a higher level of significance is the most practical solution 
and for any F max violations, a level of significance of p ~ ,01 was 
used. This was not unduly strict, as the abundance of F values in 
the subsequent data enhanced the possibility of Type 1 errors, that is, 
of significance being att~ched to purely chance events. 
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5; RESULTS 
5.1 DESCRIPTIVE STATISTICS 
TABLE 1 Descriptive Parameters of Original and Final Tctal Samples 
Number of subjects 
Number of male Ss 
Number of female Sa 
Mean age (years) 
Estimated mean drinking 
history (years)· 
* Standard deviation 
Original Sample 
63 
55 
8 
48,01 (6,99~·-) 
20,84 (7,37~·-) 
Final Sample 
48 
40 
8 
48 ,00 (6 '73"•) 
20,79 (7,22~·-) 
Sixty three subjects commenced the trial, and 57 completed the three 
assessments, of whom a further 9 were excluded. on grounds of in-
adequate comp! lance to the treatment regime in terms of consumption 
of 11medications 11 or extreme deviance from prescribed inter-assessment 
intervals (see Appendix 15). 
Eight subjects in the original sample were female, and all were 
included in the final sample. All drop-outs and exclusions were thus 
male. 
The two samples mean ages, as at baseline assessment, are extremely 
similar, being 48,01 years in the original sample, and 48,00 years 
in the final sample. Similarly, values for estimated mean drinking 
histories are practically identical, being 20,84 years in the original 
sanple and 20,79 in the final sample. 
,,;~ 
These values (see Table 1) are so highly telated that statistical 
evaluation is considered irrelevant. The small magnitude of these 
differences are unlikely to be of practical significance. 
/ 
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TABLE 2 Details of Treatment Group Sizes, Composition by Sex and 
Mean Ages and Drinking History Values (standard deviations 
in brackets) 
Treatment Group Group 1 Group 2 
(Placebo-Piracetam) (Piracetam-Placebo) 
Initial number of subjects 33 30 
Final number of subjects 26 22 
Number of males in final group 18 22 
I 
Number of females in final group 8 0 
Final group mean age (years) 47,65 (6, 78*) 48,41 (6 ,84~':) 
Final group mean drinking history t 9' 12 (6,88*) 22,09 (7,10*) 
(years) 
"'~ Standard deviation 
Table 2 contains details of the two treatment groups. The groups 
differ significantly in composition by sex (chi-squared test of 
association= 6,06; df = 1; p (,05) despite random allocation to 
groups. However the groups do not differ significantly on age 
(t = 1,20; df = 46; n.s.) nor on mean drinking history (t = -1 ,47; 
df = 46; n.s.).· 
Rates of subject attition did not differ across the two groups 
(Chi-squared test of association= 0,04; df = 1; n.s.). Consequently 
it may be concluded that the two groups are comparable on all but 
composition by sex. This latter is a chance result. Information 
concerning drop-outs and exclusions can be found in Appendix 15. 
(Additional subject information is presented in Appendices 16 to 17). 
5.2 Two Way Analyses of Variance with Repeated Measures of Factor B 
All statistical analyseS;i utilized data from the final sample alone. 
Separate analyses are presented for each test or scoring method 
employed. Raw scores may be found in Appendix 20. 
In all the following analyses, for the sake of brevity the treatment 
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sequences will be referred to as Sequence 1, indicating placebo 
preceding piracetam, and Sequence 2, indltating piracetam preceding 
placebo. Sequence 1 is synonymous with level Al of Factor A (the 
Groups Factor), and Sequence 2 is synonymous with the level Al I 
of the Groups Factor. 
In addition, in all tables of cell means, bracketed figures behind 
the cell means indicate the standard deviation of scores in those cells. 
Any tabled F-values without probability values are not significant. 
Although interassessment intervals were not always rigidly kept at 
eight weeks, for simplicity in tables and figures, the levels of 
Factor B (trials) are described as "Basel ine 11 , "After 8 weeks" and 
"After 16 weeks". 
TABLE 3 Mean Hamilton Depression Scale (HDS) Scores 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1) 16,08 (12,94) 11 '62 (10,92) 12,46 (7,32) 
Sequence 2 (A2) 14,54 (10,66) 11,64 ( 8 '58) 14,46 (9,74) 
The mean depression scores of the two groups at each assessment 
are presented in Table 3, and illustrated in Figure 2. A drop 
of depression scores, indicating improvement, is evident after 8 
weeks in both groups, but this is reversed in both, though only par-
tially in the group receiving piracetam prior to assessment, at 
week 16. 
Depression 
rating. 
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FIGURE 2:Hamilton Depression Scale Cell Mean Profile. 
T-he cell mean profile indicates different trends for the groups. 
These are assessed for statistical significance by a two-way analysis 
of variance with repeated measures on Factor B, the results of which 
are presented in Table 4. 
There is no significant interaction effect, nor is there a significant 
A (sequence) main effect. The B (trials) main effect is significant 
(p <,05), requiring further investigation using Tukey HSD analysis. 
These results are presented in Table 5. 
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TABLE 4 Anova Summary Table for Hamiltons Depression Scale Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 0,23 0,00 
Subjects 46 59.99 
Within subjects 
B. Time of assessment 2 40,46 4,38 (p < ,05) 
AB. Interaction 2 9,30 1 '01 
Residual 92 9,24 
TABLE 5 Tukey HSD Results for HOS Overall Means at Each Assessment 
Baseline 
After 8 weeks 
After 8 weeks 
4, 18 (p < ,05) 
After 16 weeks 
. 2' 11 
-2,07 
The results shown in Table 5 indicate that the significant B (trials) 
main effect is due entirely to the improvement in scores between base-
1 ine and the second assessment (p <,05). This improvement occurs 
irrespective of the substance administered between these assessments, 
and argues for an unsustained placebo effect. 
5.2.2.1 Overall Mean Choice Reaction Time (CRT) Scores Under 
St~ndard Conditions 
, 
">.'! 
Mean scores for all reaction times measured (up to 30) under standard 
conditions are presented in Table 6, and illustrated in Figure 3. 
Differing trends are noticeable in the first half of the 'trial, but 
not in the second, although the decrease (improvement) in Sequence 2 
subjects' scores is more marked. 
CRT 
TABLE 6 
Sequence 
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Mean Choice Reaction Time (CRT) under Standard Conditions 
(mi 11 i seconds) 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
(A 1) 711 '77 ( 11 7' 1 7) 715' 96 ( 119' 78) 682' 54 ( 148 '89) 
Sequence 2 (A2) 68 3 '0 0 ( 11 0' 3 5) 712,41 (126,97) 657,68 (106,59) 
1l.O 
710 A, 
7110 
1>~0 
1l1 
bgo 
(millisec) 
b70 
i>bo 
~'"o 
bO.O 
/,3o 
lh. 
Bl B2 B3 
Baseline 8 weeks 16 weeks 
FIGURE 3: Choice Reaction Time (Standard Condition Overall Means) Cell 
Mean Profi 1 e. 
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Results of the evaluation of the trends in the data by means of two 
way analysis of variance with repeated measures on the B Factor are 
recorded in Table 7. Neither interaction effects nor main effects 
are significant, and no further analysis is possible. 
TABLE 7 Anova Summarv Table For CRT Scores under Standard Conditions 
Source df MS F ratio 
Between subjects . 
A. Treatment sequence 1 12987,68 0,62 
Subjects 46 20919,15 
Within subjects 
B. Time of assessment 2 23586,81 1 '95 
AB. Interaction 2 2193,78 0' 18 
Residual 92 12246,89 
5.2.2.2 Overall Mean CRT Scores Under Reversed Conditions 
Table 8 presents mean scores for all response latencies (up to 30) 
measured under reversed conditions, i.e., when the responses required 
to terminate two lights were interchanged compared to the standard 
condition. 
TABLE 8 Mean CRT under Reversed Condit ions (mi·l 1 i seconds) 
Base 1 i ne After 8 weeks After 16 weeks 
a'.1, 82 B3 
Sequence (Al} 806,92' (132,61) 761,50 (106,28) 724,31 (88,44) 
Sequence 2 (AZ) 799,50 (134,41) 738,91 ( 91,51) 740' 18 (98 ,46) 
81 82 83 
Baseline 8 '-'leeks 16 weeks 
FIGURE 4: Choice Reaction Time (Reversed Condition Overall Means) Cel 1 
Mean Profile. 
The trend of scores as shown in Figure 4 is the same in oath groups, 
for the first trial period, a marked improvement being observed. 
However, in the second trial period, the improvement is sustained 
by Sequence 1 subjects but improvement levels off for the other group. 
The analysis of the above trends is found in Table 9. Despite the 
apparent trends in figure 4, no significant intera~tion is observed. 
The main effect for treatment sequence is also not significant, but 
the B main effect (trials) is highly significant (p(,01) and 
requires further analysis by means of Tukey HSD statistics. The 
results of these are seen in Table 10. 
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TABLE 9 Anova Summary Table for CRT Scores under Reversed Conditions 
Source df MS F ratio 
Between subjects 1 795,44 0,03 
A. Treatment sequence 46 29068,07 
Subjects 
Within subjects 
-
B. Time of assessment 2 64895,93 17,60 (p c:: ,01) 
AB. Interaction 2 4472,47 1 '21 
Residual 92 3687,92 
TABLE 10 Tu key HSD Results for CRT Overall Means at Each Assessment 
under Reversed Conditions 
After 8 weeks After 16 weeks 
Base 1 i ne (Bl) 6,04 (p < '0,1 ) 8,09 ( p <. '01 ) 
After 8 weeks (B2) 2,05 
TheTukeys analyses clearly separate the baseline scores from the later 
scores (both p <,01) which do not differ between themselves. Clearly 
this reflects the large improvement noted between baseline and the 
second assessment on Figure 4, which is maintained to a lesser 
extent in the second trial period when the results of the two treat-
ment groups are considered together . 
...;, 
5.2.2.3 Mean CRT Scores Under Standard Conditions: Yellow (central) 
Stimuli Alone. 
Mean scores of the two treatment groups at the three times of assess-
ment for response latency related to yellow, or central, stimuli are 
recorded in Table 11, and illustrated in Figure 5. 
TABLE 11 
Sequence 
Sequence 2 
7go 
110 
1&0 
7SO 
CRT 1i+O 
(millisec) 
,!ill 
11.0 
110 
700 
"qo 
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Mean CRT for Yellow Stimuli under Stan.dard Conditions (milli-
seconds) 
Base 1 i ne After 8 weeks After 16 weeks 
Bl B2 B3 
(A 1 ) 710,96 (132,97) 775 '39 (284,91) 728,73 (279,17) 
(A2) 699,41 (143,67) 763,46 (244,70) 694,82 (163,09) 
A1 
Bl B2 B3 
Baseline 8 weeks 16 weeks 
FIGURE 5: Choice Reaction Time (Standard Condition Yei low Stimuli) 
Cel 1 Mean Profile. 
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The mean scores of subjects receiving Sequence I are a1ways higher 
than the mean scores of the other group. However, the trends are, 
with minor deviations, para11e1. Large increases in CRT ~re observed 
after 8 weeks, with a return to base1 ine at 16 weeks. 
Resu1ts of statistical analysis are presented in Table 12. 
TABLE 12 Anova Summary Table for,CRT for Yellow Stimuli under Standard 
Conditions · 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 13085,99 0,22 
Subjects 46 59222,33 
Within subjects 
B. Time of assessment 2 59523,75 1'39 
AB. Interaction 2 1952,10 0,05 
Residua] 92 42879,89 
No significant effects were detected in this analysis, despite the 
large deterioration in scores after 8 weeks, and thus no conclusions 
can be drawn as to any systematic variations in the data. However, 
homogeneity of residual variance was vio1ated in this analysis 
(F max= 2,32; df = 2 and 44; p <,OS). Subject variance was not 
vi o I ated. 
Use of a higher level of significance to correct for the violation of 
F max residua1 does not change the above conclusions of no significant 
effects. 
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5.2.2.4 Mean ·CRT Scores Under Reversed Conditions: Yellow 
(central) Stimuli Alone. 
TABLE 13 Mean CRT for Yellow St imu 1 i under Reve.rsed Condit ions 
(mi 11 i seconds) 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1) 756,46 (97,12) 701,19 (93,01) 654,23 ( 84, 41 ) 
Sequence 2 (A2) 738,os (96,11) 705, 77 (89,89) 683,05 (97,07) 
Mean values obtained for CRT for yellow stimuli alone, under reversed 
conditions, are presented in Table 13 and illustrated in figure 6. 
It is clear that in both groups the CRT scores decrease over time 
and that Sequence 1 subjects show consistently greater improvement 
over the two trial periods than do Sequence 2 subjects. In both 
groups the amount of improvement shown is approximately equal for 
each trial period. 
Assessments of statistical significance of the trends in this data are 
presented in Table 14. The only result to achieve significance· is 
the trials main effect (p ~,01). The results of Tukey HSO analysis 
of this main effect are presented in Table 15. All comparisons are 
significant at p <,01. The mean score at baseline is significantly 
greater than mean scores after 8 and 16 weeks (both p <.01) and 
the mean score after 8 weeks is significantly greater than the mean 
score after 16 weeks (p <,Ol). 
_) 
CRT 
(mi 1·1 isec) 
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FIGURE 6: Choice Reaction Time (Reversed Condition Yellow Stimuli) 
Cell Mean Profile. 
TABLE 14 Anova Summary Table for CRT for Yellow Stimuli under Reversed 
Condit i ans 
Source df MS F ratio 
Between subjects 
A. Treatment sequence ,,;\ . 890' 77 0,05 
Subjects 46 19121,28 
Within subjects 
B. Time of assessment 2 73966,38 21,80 (p(,01) 
AB. Interaction 2 6647,64 1'95 
Residual 92 3392,55 
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TABLE 15 Tu key HSD Resu 1 ts for CRT Overall Means for Ye 11 ow St imu 1 i 
under Reversed Conditions at each Assessment 
After 8 weeks After 16 weeks 
Baseline ( B 1 ) 5,21 (p < '01) 9,35 (p < '01) 
After 8 weeks (B2) 4' 14 (p <._,01) 
5.2.2.5 Mean CRT Scores Under Standard Conditions: Red and Green 
Stimuli Together 
TABLE 16 Mean CRT for Red and Green Stimu~i under Standard Conditions 
Baseline After 8 weeks After 16 weeks 
Bl 82 83 
Sequence (A 1 ) 712,96 (125,09) 697,42 (116,15) 651,96 (84,60) 
Sequence 2 (A2) 675,36 (106,93) 685,55 (104,17) 641,00 (94,07) 
Mean scores of the two treatment groups at the three times of 
assessment are recorded in Table 16 and the cell mean profile illus-
trated in Figure 7. The cell mean profile shows slightly different 
directions of trends in the first trial period, but parallel trends 
of improvement in the second trial period. The statistical evaluation 
of these trends is shown in Table 17. 
The effect of times of assessment alone is significant (p<,05) and 
requires further analysis by means of Tukey HSD comparisons to deter-
mine the structure of the und~rlying variation. The results of Tukey 
·'• HSD comparisons are pre~ented in Table 18. The mean score at baseline 
is not significantly different from the mean score after 8 weeks, but 
is significantly poorer than that after 16 weeks (p <',05). The 
difference between mean values after 8 weeks and after 16 weeks is 
also significant (p<,05). 
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FIGURE 7: Choice Reaction Time (Standard Condition Red And Green Lights) 
Cell Mean Profile. 
TABLE 17 Anova Summary Table for CRT for Red and Green Stimuli under 
Standard Conditions 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 14509,29 0,98 
Subjects 46 14804,07 
:,A-
Within subjects 
B. Time of assessment 2 34209,40 3,58 (p < ,05) 
AB. Interaction 2 2724,82 0,28 
Residual 92 9567,71 
TABLE 18 
Basel.ine (Al) 
After 8 weeks 
79 
Tu key HSD Results for CRT Over a 11 Means for Red and Green 
Stimuli under Standard Conditions at each Assessment 
After 8 weeks 
0. 19 
After 16 weeks 
3 • 3 8 (p < . 0 5 ) 
3, 19 (p < ,05) 
5.2.2.6 Mean CRT Scores Under Reversed Conditions: Red and Green 
Stimuli Together 
TABLE 19 
Sequence 
Mean CRT for Red and Green Stimuli under Reversed Conditions 
(mi 11 i seconds) 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
(Al) 830,92 (160,39) 
Sequence 2 (A2) 832,32 (162,33) 
789,27 (129,23) 
755,'18 (100,99) 
757,85 ( 98,93) 
767,77 (105,24) 
Mean CRT values for each group at the three times of assessment are 
recorded in Table 19, and illustrated in Figure 8. The eel l mean 
profile shows sharp drops in CRT scores in both groups in the first 
trial period, but differing trerids in the second trial period, the 
decline in scores not being continued in the Sequence 2 subjects. The 
analysis of these trends is reported in Table 20. 
The only effect to emerge significant is the B main effect, the 
trials effect which is highly significant (p<,01). Further analysis 
using Tukey HSD comparisons is required to investigate the under-
lying trends in this factor. 
The results of Tukey HSD comparisons are presented in Table 21. 
The differences between baseline scores and scores after 8 and 16 
weeks are both significant (p<,01) but the difference between scores 
80 
• 
after 8 weeks and those after 16 weeks is not significant. 
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FIGURE 8: Choice Reaction Time (Reversed Condition Red And Green Lights) 
Cell Mean Profile. 
TABLE 20 Anova Summary Table for CRT for Red and Green Stimuli under 
Reversed ConditJons 
Source df MS F ratio 
Between subjects ·'>;. 
A. Treatment sequence 2060,09 0,05 
Subjects 46 38864,04 
Within subjects 
' B. Time of assessment 2 66348,28 11 '79 (p < '01) 
AB. Interaction 2 6491'98 1 '15 
Residual 92 5627,78 
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TABLE 21 Tukey HSD Results for CRT Overall Means for Red and Green Stimuli 
under Reversed Conditions at Each Assessment 
Baseline 
After 8 weeks 
After 8 weeks 
5,48 (p < ,01) 
After 16 weeks 
6,35 (p < ,01) 
0,87 
5.2.3.1 Purdue Pegboard Test (PPT): Preferred Hand Task 
The means of the two treatment groups at the three times of assess·ment 
for three trial total scores on the PPT ~ Preferred Hand Task are 
presented in Tab 1 e 22 and illustrated in Figure 9. The ce 11 mean pro-
file shows similar moderate increases in both groups in the first 
trial period, followed by further moderate increases in the second 
trial period for the Sequence 2 group but a sharp decline is seen in 
the Sequence group for this period. Table 23 presents the results 
of statistical analysis of these trends. 
TABLE 22 Mean Purdue Pegboard Test Preferred Hand Task (PPT-PHT) Scores 
Baseline After 8 weeks After 16 weeks 
B1 B2 B3 
Sequence 1 (A 1) 42,31 (6, 19) 43,27 (5,23) 41,85 (8,81) 
Sequence 2 (A2) 42,23 (5,74) 43,68 (5,68) 44,68 (5,84) 
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FIGURE 9: Purdue Pegboard Test Preferred Hand Task Cell Mean 
Profile. 
TABLE 23 Anova Summary Table for PPT - Preferred Hand Task Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 39,87 0,52 
Subjects 46 76,67 
'~} 
With in subjects 
B. Time of assessment 2 19,84 0,86 
. 
AB. Interaction 2 29,03 1 ,25 
Residual 92 23. 18 
83 
The results presented in Table 23 indicate no significant trends 
in the data. However the assumption of homogeneity of residual 
, variance is violated (F max= 6,32; df = 2 and 44; p.(,01). As 
this might imply that a real interaction might be obscured, it is 
necessary to calculate Simple Main Effect;. These results are pre-
sented in Table 24. 
TABLE 24 Simple Main Effects Summary Table for PPT-Preferred Hand 
Task Scores 
Source 
A at B1 
A at B2 
A at s3 
Within 
B at A1 
B at A2 
Residual 
df 
138 
2 
2 
92 
MS 
0,00 
2,00 
95,43 
41 '07 
13 ,65 
33,33 
23' 18 
F Ratio 
0,00 
0,05 
2,32 
0,59 
1; 44 
None of the SMEs attain statistical significance and it can be con-
cluded that the violation of homogeneity of variance has not obscured 
any effects. There is no systematic variation in this data related to 
either independent variable nor to interaction effects. 
5.2.3.2 Purdue PegboardTe:st (PPT): Non-Preferred Hand Task 
Mean three trial total scores for PPT-Non-Preferred Hand performance 
for the two treatment groups at the three times of assessment are pre-
sented in Table 25 and illustrated in Figure 10. The eel 1 mean profile 
indicates slight increases throughout the full trial period for both 
groups. 
Pegs 
placed 
84 . 
TABLE 25 Mean PPT Non-Preferred Hand Task (PPT-NPHT) Scores 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1) 40' 15 (6,74) 41 '12 (4,96) 42,04 (4,77) 
Sequence 2 (A2) 41,59 (4,06) 42,27 (4,37) 42,64 (4,40) 
J/1t,o 
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FIGURE 10: Purdue Pegboard Test Non-Preferred Hand Task 
Cell Mean Profile. 
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TABLE 26 Anova Summary Table for PPT - Non-Preferred Hand Task 
Source df MS F ratio 
Between subject~ 
A. Treatment sequence 1 40,48 0,64 
Subjects 46 63,43 
Within subjects 
B. Time of assessment 2 25,71 4,27 (p < ,05) 
AB. Interaction 2 2,17 0,36 
Residual 92 6,02 
Results of statistical analysis yield only a significant trials effect 
(p <,05). This requires further analysis to determine the structure of 
differences underlying it by means of Tukey HSD comparisons. These 
results are presented in Table 27. 
Table 27 Tukey HSD Results for PPT-NPHT Overall Means at Each As~ess-
ment 
After 8 weeks After 16 weeks 
Baseline 
After 8 weeks 
-2,37 -5,06 (p < ,05) 
-1 '83 
Analysis of the significant B effect yields only one significant 
comparison between scores at bas~line and after 16 weeks (p ~.05), 
this being a cumulative total of two smaller non-significant increases 
over time. 
5.2.3.3 Purdue Pegboard Test (PPT): Simultaneous Hands Task 
Mean three trial total scores for PPT-Simultaneous Hands performance 
Pegs 
placed 
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for the two treatment groups at the three tlmes of assessment are pre-
sented in Table 28 and illustrated in Figure 11. The cell mean profile 
reveals different trends for the two treatment groups with Sequence 2 
subjects consistently achieving higher scores. The results of statis-
tical analysis of these trends are presented in Table 29. 
TABLE 28 Mean PPT - Simultaneous Hands Task (PPT-SHT) Scores 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1) 33,04 (5,46) 32,56 (5,35) 33,12 (5,14) 
Sequence 2 (A2) 33,59 (4' 52) 34,32 (5,07) 34,32 (4,03) 
31!,~ 
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3lt ,i. 
31,.,o 
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FIGURE 11: Purdue Pegboard Test Simultaneous Hands Task Cell 
Mean Profi 1 e. 
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TABLE 29 Anova Summary Table for PPT-Simultaneous Hands Task 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 47,99 0,73 
Subjects 45 65,90 
Within subjects 
B. Time of assessment 2 2,00 0,48 
AB. Interaction 2 4,27 1 '01 
Residual 90 4,21 
Analysis reveals no significant relationships between variables on 
this subtest. No further analysis may be attempted. 
5.2.4 Wechsler Adult lntell igence Scale Subtests 
All scores usedin these analyses are untransformed raw scores. 
5.2.4.1 Information Subtest 
Mean Information subtest raw scores for the two treatment groups at 
the three times of assessment are presented in Table 30, and illustrated 
in Figure 12. The trends- shown by the cell' mean profile reveal 
parallel marginal increases in scores throughout the trial period in 
the groups. The results of statistical analysis of these scores are 
presented in Table 31. 
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TABLE 30 Mean WAIS Information Subtest Scores 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1) 16 '69 ( 3' 7 4) 17'19 (3,49) 17 ,62 (2,98) 
Sequence 2 (A2) 15,55 (3,83) 15,86 (3 '88) 16,23 (3,88) 
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FIGURE 12: WAIS Information Subtest Cell Mean Profile. 
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TABLE 31 Anova Summary Table for WAIS Information Subtest 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 59,30 1 '63 
Subjects 46 36,39 
Within subjects 
B. Time of assessment 2 7,67 '4 ,98 (p < ,01) 
AB. Interaction 2 0' 19 0' 12 
Residual 92 1'54 
The results shown in Table 31 indicate no interaction or A (treat-
ment sequence) effects, but a highly significant B (trials effect 
(p <,01) which requires further analysis by means of Tukey HSD 
comparisons. These statistical results are presented in Table 32. 
TABLE 32 Tukey HSD Results for Information Subtest Overall Means ~t 
Each Assessment 
After 8 weeks After 16 weeks 
Baseline 
After 8 weeks 
-2,28 -4,50 (p < ,01) 
-2,22 
Only one Tukey HSD comparison is statistically significant. This 
is the comparison between scores at baseline and after 16 weeks (p (,01) 
which reflects the cumulative effects of consistent smaller though 
non-significant increases in trial periods one and two, as seen in 
Figure 12. 
5.2.4.2 Digit Span Subtest 
Mean Digit Span raw scores for the two treatment groups at the three 
' 
Raw 
score 
poi nt·s 
90 
times of assessment are presented in Tabl~ 33 and illustrated in 
Figure 13. The cell mean profile reveals parallel slightly 
increasing scores throughout the trial. The differences between 
the treatment groups at all times of assessment are extremely 
small. Results of statistical analysis of the data are presented 
·in Table 34. 
TABLE 33 Mean WAIS Digit Span Subtest Scores 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1 ) 10,88 (2,16) 11 '38 (2,47) 11 '42 (2,34) 
Sequence 2 (A2) 11 '00 (1,90) 11 '55 (2,04) 11 '64 (2,34) 
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FIGURE 13: WAIS Digit Span Subtest Cell Mean Profile. 
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TABLE 34 Anova Summary Table for Digit Span Subtest 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 \ 0 '95 0 '08 
Subjects 46 12,24 
Within subjects 
B. Time of assessment 2 4,95 3, 77 (p < ,05) 
AB. Interaction . 2 0,03 0,02 
Residual 92 1 '31 
Stat~stical analysis of Digit Span subtest data only reveals a 
significant B (trials) effect (p <,05) which requires further analysis 
be means of Tukey HSD comparisons. These results are presented in 
Table 35, The sole significant difference underlying the significant 
effect of time of assessment is the difference between scores at base-
1 ine and those after 16 weeks (p < ,05). This reflects accumulated 
consistent, smaller and non-significant score increases in trial periods 
one and two. 
TABLE 35 
Baseline 
After 8 weeks 
Tukey HSD Results for Digit Span Overall Means at Each 
Assessment 
After 8 weeks After 16 weeks 
-3,06 -3,41 (p < ,05) 
-0,35 
5.2.4.2a Digit Span: Digits Forwards Only 
Mean raw scores for the two treatment groups at the three times of 
assessment for the Digits Forward section of Digit Span are presented 
Raw 
score 
92 
in Table 36 and illustrated in Figure 14. The cell mean profile 
reveals very similar, minimal changes in scores during the trial 
period. Slight increases are seen in all cases except that a s,l ight 
decrease in scores is seen for Sequence 2 subjects in the second 
trial period. Results of analysis of the data are presented in 
Table 37. 
TABLE 36 Mean Digits Forwards Scores 
Baseline After 8 weeks After 16 weeks 
Bl 82 B3 
Sequence (Al) 6' 15 ( 1 '56) ,6,42 ( 1 '30) 6,50 (1,14) 
Sequence 2 (A2) 6' 18 ( 1 '22) 6,55 ( 1 '22) 6,41 (1,37) 
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FIGURE 14: WAIS Digits Forwards Cell Mean Profile. 
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TABLE 37 Anova Summary Table for Digits Forwards Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 0,01 0,00 
Subjects 46 3,03 
W i th i n subjects 
B. Time of assessment 2 1'46 1'89 
AB. Interaction 2 0' 14 0' 18 
Residual 92 0, 77 
The anova summary table reveals no significant effects operating on 
Digits Forwards scores. No further analysis is possible. 
5.2.4.2.b Digit Span: Digits Backwards Only 
Mean raw scores for the two treatment groups at the three times of 
assessment for the Digits .backwards section of Digit Span are presented 
in Table 38 and illustrated in Figure 15. 
TABLE 38 Mean Digits Backwards Scores 
Sequence (A 1) 
Sequence 2 (A2) 
Baseline 
Bl 
4,73 (1,48) 
4,82 (1,18) 
After 8 weeks 
B2 
4,96 (1,68) 
5,00 (1,27) 
After 16 weeks 
B3 
4,92 (1 ,60) 
5,23 (1,31) 
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FIGURE 15: WAIS Digits Backwards Cell Mean Profile. 
It can be seen from Figure 15 that the trends for the two treatment 
groups are almost para! lei in both trial periods. Except for Sequence 
1 subjects in the second trial period, all score changes are increases. 
Results of statistical analysis of the data are presented in Table 39. 
TABLE 39 Anova Summary Table for Digits Backwards Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence t 0,73 0, t 4 
Subjects 1 46 5,30 
With in subjects 
B. Time of assessment 2 t ' t 3 2,29 
AB. Interact ion 2 0,24 0,48 
Residual 92 0,49 
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Statistical analysis reveals no significant effects operating on 
Digits Backwards scores. No further analysis is possible. 
5.2.4.3 Similarities Subtest 
Mean scores for the two treatment groups at the three times of 
assessment on the Similarities subtest are presented in Table 40 and 
illustrated in Figure 16. The cell mean profile reveals similar 
changes in scores, with the differences between treatment groups 
being very small at all times of assessment. Scores tend to increase 
till 8 weeks but to decline after 16 weeks. Results of statistical 
analysis of these scores are presented in Table 41. 
TABLE 40 Mean WAIS Similarities Subtest Scores 
Baseline After 8 we~ks After 16 weeks 
B1 B2 B3 
Sequence (A 1) 15,85 (4,09) 16,58 (3,67) l 6' 54 ( 3 '60) 
Sequence 2 (A2) 15,68 (3,63) 16,55 (3,89) 16 '41 (3,61) 
TABLE 41 Anova Summary Table for Similarities Scores 
Source df MS F ratio ... 
Between subjects 
A. Treatment sequence 1 0,42 0,01 
Subjects 46 37,26 
Within subjects 
B. Time of assessment 2 9' 11 3,62 (p < ,05) 
' AB. Interaction 2 0,06 0,02 
Residual 92 2,52 
. 
81 82 B3 
FIGURE 16: WAIS Similarities Subtest Cell Mean Profile. 
Table41 reveals only one significant effect operating on Similarities 
This is the trials effect (p (,05), which requires further analysis 
by means of Tukeys HSD comparisons to determine the underlying structure 
of differences. The results of these comparisons are presented in 
Table 42. 
TABLE 42 
Baseline 
After 8 weeks 
Tukey HSD Results for Similarities Subtest Overall Means· at 
Each Assessment 
After 8 weeks 
-3,48 (p < ,05) 
After 16 weeks 
-3,09 
0,39 
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From Table 42, it can be seen that the significant effect of time of 
assessment reflects only the improvement of scores between baseline 
and those obtained after 8 weeks (p <,05). 
5.2.4.4 Object Assembly Subtes.!_ 
Mean raw scores for the two treatment groups at the three times of 
assessment on the Object Assembly subtest are presented in Table 43 
and illustrated in Figure 17. The cell mean profile reveals parallel 
increases in both treatment groups throughout the trial, more 
marked in the first trial period. 
TABLE 43 Mean WAIS Object Assembly Subtest Scores 
Baseline After 8 weeks After 16 weeks 
B1 B2 B3 
Sequence (A 1) 14,81 (3,64) 17.54 (3,91) 18,62 (3,24) 
Sequence 2 (A2) 16,32 (3,58) 18,41 (2,94) 19,45 (3,05) 
Results of statistical analysis of Object Assembly scores are pre-
sented in Table 44. The sole significant result is a highly 
significant trials effect (p(,01). This requires further analysis by 
means of Tukey HSD comparisons to determine the structure of under-
lying differences. 
TABLE 44 Anova Summary Table for Object Assembly Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 41 • 19 1 • 55 
Subjects 46 26,62 
With in subjects 
B. Time of assessment 2 150,89 34,92 (p < • 01 ) 
AB. Interaction 2 1 • 71 0,40 
Residual 92 4,32 
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FIGURE 17: WAIS Object Assembly Subtest Cell Mean Profile. 
TABLE 45 
Baseline 
After 8 weeks 
Tukey HSD Results for Object Assembly Subtest Overall Means 
at Each Assessment 
After 8 weeks After 16 weeks 
-8,03 (p < ,01) -11,57 (p <,al) 
- 3,53 (p < ,05) 
Results of Tukey HSD comparisons are presented in Table 45. All 
comparisons yield significant differences reflecting significant 
increases in scores in both trial periods. The increase is greater in 
the first trial period (p < ,01). 
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5.2.4.5 Block Design Subtest 
Mean Block Design scores for the two treatment groups at the three 
times of assessment are presented in Table 46 and illustrated in 
Figure 18. Inspection of the cell mean profile reveals a large ~ 
difference between groups at baseline, and differing trends for the 
two treatment groups. Sequence 1 subjects' scores improve markedly in 
the first trial period but decline slightly in the second, while 
Sequence 2 subjects' scores remain approximately constant over the first 
trial period but improve substantially over the second trial period. 
At no time of assessment are scores of the treatment groups similar. 
Results of the statistical analysis of the Block Design scores are 
presented in Table 47. 
TABLE 46 Mean WAIS Block Design Scores 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence 1 (A 1) 20' 19 (6,82) 22,35 (6,62) 22,00 (6,09) 
Sequence 2 (A2) 24,55 (5,66) 24,5 (6,08) 26,68 (5,73) 
TABLE 47 Anova Summary Table for Block Design Scores 
' 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 497,28 4,64 (p < '05) 
Subjects 46 107'19 
Within subjects 
B. Time of assessment 2 46,42 10,82 (p < '01) 
AB. Interaction 2 22,51 5,25 (p<,01) 
Residual 92 4,29 
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FIGURE 18: WAIS Block Design Subtest Cell Mean Profile. 
/ 
Results of statistical analysis of Block Design scores, as presented 
in Table 47, indicate significant interaction (p <,01) a~d treatment 
main effects. The interaction requires further analysis by means 
of calculation of simple main effects. These are presented in Table 48. 
TABLE 48 Simple Main Effects Summary Table for Block Design Subtest 
Scores 
Source df MS F ratio 
A at Bl 222,33 5,76 (p <,05) 
A at B2 55,52 1 '44 
A at B3 1 260,94 6,76 (p<,05) 
Within 138 38,59 
B at A1 2 34,97 8' 15 (p(,01) 
,B at A2 2 34' 10 7,95 (p <,01) 
Residual 92 4,29 
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The analysis of simple main effects yields significant results for 
the effect of treatments, at baseline and after 16 weeks (both p <,OS), 
but not after 8 weeks, and for the tr i a 1 s effect for · each treatment 
group (both p <, 01). 
The results of inter-cell comparisons to determine the structures of 
scores underlying these results, and to assess their degree of 
significance, are presented in Table 49 for the effects of treatment 
on time of assessment, and in Table 50 and Table 51, for the effects 
of time of assessment on treatments. 
TABLE 49 
Source 
Tukey HSD Results for the Effects of Treatments on 
Block Design Subtest Scores at Specific Assessments 
(two levels only). 
Tu key Level of 
value df. Significance 
A at Bl (Difference at baseline) -10,38 2;92 p < '01 
A at B3 (Difference after 16weeks) -11,14 2;92 p <,01 
TABLE 50 
Base 1 i ne 
After 8 weeks 
TABLE 51 
Baseline 
After 8 weeks 
Tukey HSD Results for Effects of Treatments on Block Design 
Subtest Scores within Group 1 (piracetam-placebo order), 
After 8 weeks 
-5,26 (p < ,01) 
After 16 weeks 
-4,42 (p < ,01) 
0,85 
Tukey HSD Results for Effects of Treatments on Block Design 
Subtest Scores within Group 2 (placebo-piracetam order) 
After 8 weeks After 16 weeks 
0' 11 
-4,84 (p < ,01) 
-4,96 (p < ,01) 
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The effect of treatments at baseline and after 16 weeks only involve 
two levels in each case. The effect at baseline is highly significant 
(p <,01) and indicates scores of Sequence 2 subjects are signifi-
cantly higher than those of Sequence 1 subjects. The effect after 
16 weeks is also highly significant (p <,Ol) and also indicates 
scores in Sequence 2 subjects are significantly higher than those 
of Sequence 1 subjects. 
The significant effect of time of assessment in Sequence 1 is based 
on significant differences between scores at baseline and the scores 
after 8 and 16 weeks (both p (,01) but the difference between scores 
after 8 and 16 weeks is not significant. Both significant differences 
reflect increases over baseline scores, though the trend was 
partially reversed in the second trial period. 
The significant effect of time of assessment in Sequence 2 is 
based on a significant increase in scores after 16 weeks relative to 
scores at baseline and after 8 weeks (both p (,01). Scores at 
baseline and after 8 weeks do not differ significantly. 
5.2.4.6 Digit Symbol Substitution Test (DSST) 
Mean DSST scores for the two treatment groups at the three times 
of assessment are presented in Table 52 and illustrated in Figure 19. 
The cell mean profile reveals similar increasing trends in the first 
trial period but this only continues in trial period two for the 
Sequence 2 subjects, while the trend for Sequence 1 subjects flattens 
off. 
TABLE 52 Mean WAIS Digit Symbol Substitution Test (DSST) Scores 
Sequence (A 1) 
Sequence 2 (A2) 
Baseline 
B1 
33,73 (9,84) 
3 3' 1 4 ( 8 '66) 
After 8 weeks 
B2 
37,29 (9,76) 
35,91 (9,48) 
After 16 weeks 
B3 
3 7' 58 ( 1 0 '24) 
38,18 ( 9,97) 
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FIGURE 19: WAIS Digit Symbol Substitution Test Cell Mean Profile. 
TABLE 53 Anova Summary Table for DSST Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 7,24 0,03 
Subjects 46 261'65 
\ Within subjects 
B. Time of assessment 2 249,36 24,56 (p < ,01) 
AB. Interaction 2 11 '69 1 '15 
Residual. 92 10.15 
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Table 53 presents the results of statistical analysis of DSST scores. 
Only a significant trials effect emerges (p <,Ol). This requires 
further analysis by means of Tukey HSD comparisons, the reiults of 
which are presented in Table 54. 
TAB~E 54 Tukey HSD Results for DSST Overall Means at each Assessment 
After 8 weeks After 16 weeks 
Baseline 
After 8 weeks 
-6,85 (p (,01) 
-9,65 (p < ,01) 
-2,80 
From Table 54 it emerges that the significant effect of time of 
assessment is due to significant increases over baseline scores 
after 8 weeks and after 16 weeks (both p (, 01). The change in scores 
between weeks 8 and 16 represents a further increase but this is not 
significant in itself. 
5.2.4.7 Pro-Rated WAIS IQ (PIQ) 
Mean PIQ scores for the two treatment groups at the three times of 
assessment are presented in Table 55 and illustrated in Figure 20. 
The cell mean profile reveals consistent score increases by Sequence 
2 subjects throughout the trial, while Sequence 1 subjects show 
increases in scores in the first trial period but not in the second, 
where scores level off. The results of statistical analysis of the 
data are presented in Table 56. 
TABLE 55 Mean Pro-Rated WAIS IQ (PIQ) Scores 
Sequence (A 1) 
Sequence 2 (A2) 
Baseline 
Bl 
103,58 (14,68) 
106,05 (11,36) 
After 8 weeks 
B2 
11 0 '69 ( 15 '5 2) 
111,23 (12,15) 
After 16 weeks 
B3 
110,96 (13,73) 
114,73 (14,28) 
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FIGURE 20: WAIS Pro-Rated IQ Cell Mean Profile. 
TABLE 56 Anova Summary Table for PIQ Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 182 '01 0,35 
Subjects 46 
·526,35 
Within subjects 
B. Time of. assessment 2 841 '24 38,54 (p < '01) 
AB. Interact ion 2 31 '50 1'44 
Residual 92 21'83 
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Statistical analysis reveals only a significant trials effect 
(p<",01). This requires further analysis by means of Tukey HSD 
comparisons to determine the structure of differences underlying 
this effect. Results of these comparisons are presented in Table 57. 
TABLE 57 
Baseline 
After 8 weeks 
Tukey HSD Results for PIQ Overall Means at Each Assessment 
After 8 weeks After 16 weeks 
-9' 16 ( p < '01 ) -11 '99 ( p < '01 ) 
- 2,82 
The results presented in Table 57 reveal that scores after 8 weeks 
and after 16 weeks both differ significantly from scores at baseline 
(both p<,01), but do not differ significantly between themselves. 
The scores reflect a trend of increasing scores throughout the trial, 
with the major increase occurring in the first trial period. 
5.2.5.1 Modified Card Soring Test (MCST): Total Presentations 
Mean numbers of presentations for the two treatment groups at the 
three times of assessment are presented in Table 58 and illustrated 
in Figure 21. The cell mean profile reveals that the treatment 
groups differ at baseline and appear to follow differing trends 
thereafter. While Sequence 1 subjects require more presentations 
at baseline, but show progressively decreasing scores after 8 and 
16 weeks, Sequence 2 subjects require fewer presentations at base-
1 ine, but show a slight increase in required presentations after 
8 weeks. This is followed by a decrease after 16 weeks. 
At no time do Sequence 1 subjects require as few presentations as the 
highest number required at any time by Sequence 2 subjects. Results 
of statistical analysis of this data are presented in Table 59. 
Present-
at ions 
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TABLE 58 Mean Modified Card Sorting Test (MCST) Total Presentations 
Sequence (A 1) 
Sequence 2 (A2) 
S'O 
ltq 
48 
41 
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41 
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Bl 
Baseline 
Bl 
45,42 (4,37) 
42,27 (4,99) 
After 8 weeks 
B2 
44,08 (4,75) 
42,82 (4,93) 
B2 
After 16 weeks 
B3 
43,35 (4,24) 
41,45 (4,45) 
I 
"· 
B3 
FIGURE 21: Modified Card Sorting Test - Total Presentations 
Cell Mean Profile. 
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TABLE 59 Anova Summary Table for MCST Total Presentations Scores 
Source . df MS F ratio 
Between subjects 
A. Treatment sequence 1 157,70 3,57 
Subjects 46 44' 17 
Within subjects 
B. Time of assessment 2 26,64 2,69 
AB. Interaction 2 11 '0 5 t '18 
Residual 92 9,89 
The results of statistical analysis presented in Table 59 indicate 
that there are no significant effects acting upon the number of 
~resentations required to complete the MCST. There is a violation 
of homogeneity of residual error variance (Fmax = 2,51; df = 2 and 44; 
p (,05), but as no trends in Table 59 are significant, use of higher 
levels of significance does not change the conclusions drawn. 
5.2.5.2 Modified Card Sorting Task (MCST): Sets Completed 
Mean numbers of sets completed for each treatment group at each time 
of assessment are presented in Table 60 and i I lust rated in Figure 22. 
From the cell mean profile it can be seen that Sequence 2 subjects 
complete more sets at all times of assessment than do Sequence t sub~ 
jects. In both treatment groups there is a continuing trend of slight 
increases throughout the trial. The results of statistical analysis 
of these data are presented in Table 61. 
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TABLE 60 Mean MCST Completed Sets 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1) 
Sequence 2 (A2) 
4,08 (1,94) 
5,45 (1,34) 
4,46 (1 ,98) 
5,41 (1,01) 
4,65 (2,0.2) 
5 '64 ( 1 '14) 
5 
Sets .3 
----------------------~· A, 
Bl B2 B3 
FIGURE 22: Modified Card Sorting Test - Co~pleted Sets Cell 
Mean Profile. 
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TABLE 61 Anova Summary Table for MCST Sets Completed 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 43,46 6' 11 (p < ,05) 
Subjects '. 46 7' 11 
Within subjects 
B. Time of assessment 2 1,72 3,00 
AB. Interaction 2 0,68 1 '18 
Residual 92 0,57 
The results of statistical analysis, as presented in Table 61, indicate 
there is only one significant effect. This is the main effect of 
treatment sequence (p <,05). For both subUect variance and residual 
variance, the assumption of homogeneity of variance is violated 
(f max-subjects= 2,99; df = 2,22·;. p<,05 and F max-residual= 2,33; 
df = 2,44; p<,05). To compensate for this, a higher level of signifi-
cance namely the ,01 level may be used. Using this level of signifi-
cance, the treatment sequence effect does not attain significance, and 
it must be concluded that there are no effects systematically influencing 
the number of sets completed. 
5.2.5.3 Modified Card Sorting Test (MCST): Total Error Scores 
Mean MCST total error scores for the two treatment groups at the 
three times of assessment are presented in Table 62 and illustrated 
in. Figure 23· 
From Figure 23 it can be seen that the groups differ at baseline 
and the difference persists throughout the trial, though it narrows 
Errors 
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TABLE 62 Mean MCST Total Error Scores 
Sequence (A 1) 
Sequence 2 (A2) 
,,.o 
,, 
1<:. 
14 t\1 
IZ. 
10 
' &I,_ 
" 
" 
.t 
Bl 
Baseline 
Bl 
14,65 (11,54) 
7,36 (10,74) 
After 8 weeks 
B2 
11,77 (11,48) 
5,36 (5,37) 
B2 
After 16 weeks 
B3 
9,19 (11,01) 
4,32 (5,43) 
At 
Ai. 
B3 
FIGURE 23: Modified Card Sorting Test - Total Errors Cell 
Mean Profi 1 e. 
, 
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slightly after 16 weeks. Subjects in Sequence 1 make more errors 
than subjects in Sequence 2 at al 1 times of assessment. Results of 
statistical analysis of these scores are presented in Table 63. 
TABLE 63 Anova Summary Table for MCST Total Error Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 1369' 79 5,82 (p < ,05) 
Subjects 46 235,44 
Within subjects 
B. Time of assessment 2 217,18 8' 11 (p < '01 ) 
AB. Interaction 2 17'81 0,67 
Residual 92 26, 77 
The results shown in Table 63 indicate significant effects due to 
treatment sequence and to time of assessment (trials). However, these 
findings are complicated for the effect of treatment sequence by a 
violation of the assumption of homogeneity of subject error variance 
(F max-subjects= 2,45; df = 2 and 22; pc(,05). The assumption of 
homogeneity of subject variance being violated, a higher level of 
significance is used to evaluate the treatment sequence Fvalue. Using 
a significance level of ,01, the obtained F value does not attain 
significance (F. crit = 7,21) and it is concluded there is no effect 
due to treatment sequence. 
The significant trials effect (p (,01) is not affected by the above 
violation of the homogeneity of subject variance, and requires further 
analysis by means of Tukey HSD comparisons. The results of these 
comparisons are presented in Table 64. 
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TABLE 64 Tukey HSD Results for MCST Total Error Overall Means at 
Each Assessment 
After 8 weeks After 16 weeks 
Baseline 
After 8 weeks 
3,25 5 ' 6 7 (p < ' 0 1 ) 
2,41 
The results of Tukey HSD comparisons presented in Table 64 indicate 
that the significant trials effect is solely dependent on the decrease 
in total error scores between baseline assessment and assessment after 
16 weeks (p <,Ol). 
5.2.5.4 Modified Card Sorting Test (MCST): Total Perseverative Error 
Scores 
Mean MCST total perseverative error scores for the two treatment 
groups at the three times of assessment are presented in Table 65 and 
illustrated i.n Figure 24: The cell mean profile reveals similar 
scores for both groups at baseline and similar trends throughout the 
trial, with a sharp drop in the first trial period and a levelling 
off of this trend in the second trial period. The drop in the 
Sequence 2 group is much sharper than that in the Sequence 1 group. 
The results of statistical analysis of these mean perseverative 
error totals are presented in Table 66. 
TABLE 65 Mean MCST Perseverat ive Error Scores 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
Sequence (A 1 ) 4' 19 (4, 12) 2,42 (3,04) 2,00 (2 '98) 
Sequence 2 (A2) 4,38 (9,76) 1 ,43 (2,06) 0,90 (1,37) 
Bl B2 B3 
. 
FIGURE 24: Modified Card Sorting Test - Perseverative Error 
Cell Mean Profile. 
TABLE 66 Anova Summary Table of MCST Perseverative Error Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 14,00 0,41 
Subjects 45 33,93 
Within subjects 
B. Time of assessment 2 107,11 7,00 (p t.. ,01) 
AB. Interaction 2 5,92 0,39 
Residual 90 15,31 
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From Table 66 it can be seen that only the trials effect attains 
significance (P<,01). The assumption of homogeneity of residual 
error variance is violated ( Fmax-residual = 4,48; df = 2 and 44; 
p (,01). As before, a stricter test of significance is used (p' ,01), 
but the effect of time of assessment still attains significance using 
this stricter test of significance. Thus it is concluded that the 
effect due to time of assessment is real and that this therefore 
requires further analysis by means of Tukey HSD comparisons to determine 
the underlying structure of differences between levels of this factor. 
The results of these Tukey HSD comparisons are presented in,Table 67. 
TABLE 67 
Base 1 i ne 
After 8 weeks 
Tukey HSD Results for MCST Overall Perseverative Error Means 
at Each Assessment 
After 8 weeks 
4, 14 (p < ,05) 
After 16 weeks 
4,97 (p < ,01) 
0,83 
The results presented in Table 67 indicate that mean numbers of 
perseverative errors at baseline are significantly greater than those 
after 8 weeks (p(,05) and after 16weeks (p<,01) although there is 
no significant decrement between 8 and 16 weeks. The major decrease 
in mean perseverative error scores occurs thus in the first trial period. 
5.2.6.1 Selective Reminding List Learnings (SRLL): Mean Three Trial 
Total Scores 
Mean SRLL three trial total scores for the two treatment groups at 
the three times of assessment are presented in Table 68 and illustrated 
in Figure 25. The eel I mean profile reveals similar trends for both 
treatment groups, with a marked increase in total scores after 8 weeks 
followed by a greater decrease in total scores after 16 weeks, the gross 
effect over the entire trial being a moderate reduction in total scores. 
At both baseline and 16 weeks Sequence 1 subjects obtain higher scores, 
but at all times of assessment these intergroup differences are not 
Words 
reca 11 ed 
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marked. The results of statistical analysis of these scores are 
presented in Table 69. 
TABLE 68 Mean Selective Reminding List Learning Three Trial Totals 
(SRLL-TTT) 
Baseline 
Bl 
After 8 weeks 
B2 
After 16 weeks 
B3 
Sequence (A 1) 
Sequence 2 (A2) 
41 ,62 (8 ,66) 
39,95 (8,23) 
45,19 (6,87) 
45 ,59 (7 ,82) 
37,77 (6,44) 
35 '95 (8' 34) 
""'" 
"s 
Hit 
£t3 
"~ 
41 
lfo 
3C\ 
3t 
~1 
A, 
z. 
Bl B2 B3 
FIGURE 25: Selective Reminding List Learning Three Trial Total 
Cell Mean Profile. 
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From Table 69 it can be seen that only one effect attains significance. 
This is the trials effect (p <,01). To ascertain the structure of 
differences underlying this effect, analysis by Tukey HSD comparisons 
is required. The results of these comparisons are presented in Table 70. 
TABLE 69 Anova Summary Table for SRLL-TTT Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence t 37,61 0,29 
Subjects 46 130,04 
Within subjects 
B. Time of assessment 2 868,87 35' 15 (p<,01) 
AB. 'Interaction 2 18,20 0,74 
Residual 92 24, 72 
TABLE 70 Tukey H.SD Results for SRLL-TTT Overall Means at Each 
Assessment 
Base 1 i ne 
After 8 weeks 
After 8 weeks 
-6,39 (p < ,01) 
After 16 weeks 
5,44 (p <,01) 
11,83 (p <,Ol) 
The results of Tukey HSD comparisons, presented in Table 70, indicate 
that highly significant differences exist between all times of assess-
ment (all p<,01). There is a significant increase in scores between 
base! ine assess~ent and that after 8 weeks (p<,Ol) followed by a more 
highly significant decrease in scores between 8 and 16 weeks (p< ,01). 
The difference between baseline assessment scores and those after 16 
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weeks also reflects a significant difference, in this case a decrease 
i n scores ( p <, 01 ) . 
5.2.6.2 Restrictive Reminding List Learning (RRLL): Mean Three 
Trial Total Scores 
Mean RRLL three trial total scores for the two treatment groups at 
the three times of assessment are presented in Table 71 and illustrated 
in Figure 26. The cell mean profile shows that scores in both treat-
ment groups follow similar trends throughout the trial. In both 
groups scores after 8 weeks reflect increased scores, but between 
the assessments at 8 and 16 weeks scores decrease by more than th~ 
degree of increase in the first 8 weeks, yielding an overall marked 
decrease in scores over the full trial period. At each time of assess-
ment, Sequence 1 subjects achieve higher scores, though the differences 
a re very sma 11 . 
The results of statistical analysis of these scores are presented in 
Table 72. 
TABLE 71 
Sequence 
Sequence 2 
Mean Restrictive Reminding List Learning Three Trial Totals 
(RRLL..,TTT) 
Baseline After 8 weeks After 16 weeks 
Bl B2 B3 
(A 1) 42,73 (7,51) 46,08 '(6,33) 38,00 "(7,92) 
(A2) 42,36 (8,82) 44,68 (8,89) 36,09 (8,77) ' 
From Table 72 it can be seen that there is only a significant trials 
effect (p<,Ol). This requires further analysis by Tukey HSD 
comparisons to determine the underlying structure of differences in 
this factor. The results of these Tukey HSD comparisons are presented 
in Table 73. 
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FIGURE 26: Restrictive Reminding List Learning Three Trial Total 
Cell Mean Profile. 
TABLE 72 Anova Summary Table for RRLL-TTT Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 53,54 0,35 
Subjects 46 153,09 
Within subjects 
B. Time of assessment 2 855,97 42,65 (p < '01) AB. Interaction 2 7,34 0,37 
Residual 92 20,07 
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TABLE 73 Tukey HSD Results for RRLL-TTT Overall Means at Each 
Assessment 
After 8 weeks After 16 weeks 
Baseline 
After 8 weeks 
-4,35 (p < ,01) 8,46 (p < ,01) 
12' 82 ( p < '01 ) 
The results shown in Table 73 indicate that all comparisons yield 
highly significant differences (all p<,01). There is a significant 
increase in scores after 8 weeks, but a significant marked decrease 
is observed after 16 weeks, which goes beyond the baseline level of 
scoring. The comparison between baseline scores and those after 
16 weeks is also highly significant. 
. 
5.2.6.3 Selective Reminding List Learning (SRLL): Long Term Retrieval 
Scores 
Mean SRLL long term retrieval scores for the two treatment groups at 
the three times of assessment are presented iri Table 74 and illustrated 
in Figure 27. The cell mean profile reveals similar trends through-
out the trial in the two groups, but a greater difference is visible 
after 16 weeks than at baseline of after 8 weeks, at which, for 
practical purposes, the two treatment groups score identically. 
At all times, Sequence 1 subjects achieve higher scores. 
TABLE 74 Mean SRLL-Long Term Ret r i eva 1 (SRLL-L TR) Scores 
Sequence (A 1) 
Sequence 2 (A2) 
Baseline 
Bl 
11,19 (4,61) 
10,95 (3,66) 
After 8 weeks 
B2 
13,65 (3,84) 
13,23 (4,32) 
After 16 weeks 
B3 
10,46 (3,26) 
8,18 (4,23) 
Words 
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FIGURE 27: Selective Reminding List Learning Long Term Retrieval 
Cell Mean Profile. 
Table 75 contains the results of statistical analysis of the SRLL 
long-term recall scores. Only the trials effect is significant 
(p<,01). This is analysed by Tukey HSD comparisons to determine 
the differences underlying this significant effect. 
Table 76 presents the results of Tukey HSD comparisons for SRLL 
long-term retrieval as a function of differences of time of assessment. 
All comparisons are significant. Scores increase significantly between 
base Ii ne and assessment after 8 weeks (p <, 01) but dee Ii ne to a 
greater extent between 8 and 16 weeks (p<,01). The result of these 
two trends is a mean score after 16 weeks which is significantly lower 
than that at base I ine (p <,05). 
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TABLE 75 Anova Summary Table for SRLL-LTR Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 21 '1 5 0,62 
Subjects 46 33,92 
Within subjects 
B. Time of assessment 2 175'60 24,78 (p .( '01) 
AB. Interaction 2 6,93 0,98 
Residual 92 7,09 
TABLE 76 Tukey HSD Results for SRLL-LTR Overall Means at Each 
Assessment 
Baseline 
After 8 weeks 
After 8 weeks 
-8,84 (p<.01) 
After 16 weeks 
3 ' 79 ( p < ' 0 5 ) 
10,00 (p < ,01) 
5.2.6.4 Restrictive Reminding List Learning (RRLL): Long Term 
Ret r i eva 1 Seo res 
Mean RRLL long term retrieval scores for the two treatment groups' 
at the three times of assessment are presented in Table 77 and illus-
trated in Figure 28. The cell mean profile indicates parallel trends 
in the two groups during both periods of the trial, with Sequence 1 
subjects attaining slightly higher scores at each time of assessment. 
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TABLE 77 Mean RRLL Long Term Retrieval (RRLL-LTR) Scores 
Sequence (A 1) 
Sequence 2 (A2) 
B1 
Baseline 
B1 
13,77 (4,08) 
13,18 (3,97) 
After 8 weeks 
B2 
15,58 (3,07) 
14,55,(4,08) 
B2 
After 16 weeks 
B3 
ll,54 (3,72) 
10,27 (3,51) 
B3 
FIGURE 28: Restrictive Reminding List Learning Long Term Retrieval 
Cell Mean Profile. 
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Table 78 presents the results of statistical analysis of the above 
data. The only slgnificant effect is that of t~ia)s {p (,01), which 
requires further analysis by Tukey HSD comparisons to determine 
the structure of underlying differences. 
TABLE 78 Anova Summary Table for RRLL-LTR Scores 
Source - df MS F ratio 
Between subjects 
A. Treatment sequence 1 33,05 1, 02 
Subjects 46 32,31 
Within subjects 
B. Time of assessment 2 209,64 42,64 (p < ,01) 
AB. Interaction 2 1 , 41 0,29 
Residual 92 4,92 
TABLE 79 Tukey HSD Results for RRLL-LTR Overall Means at Each 
Assessment 
Baseline 
After 8 weeks 
After 8 weeks 
-4,97 (p < ,01) 
After 16 weeks 
8,03 (p < ,01) 
13,00 (p <.01) 
From Table 79 it is evident all comparisons are highly significant. 
There is a significant increase in scores between baseline assessment 
and the assessment after 8 weeks (p<" ,01) and a highly significant 
decrease in scores between 8 weeks and 16 weeks which more than 
negates the preceeding increase (p<,01). The final score after 
16 weeks is significantly lower than that at baseline (p<,01). 
Total 
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5.2.7.1 Serial 3s: Total Enumerations 
Mean Serial 3s total enumeration scores for the two treatment groups 
at the three times of assessment are presented in Table 80 and 
illustrated in Figure 29. 
TABLE 80 Me~n Serial 3 Total Enumerations Scores 
Sequence (A 1) 
Sequence 2 (A2) 
to 
,, 
IS 
11 
,,,, 
Baseline 
Bl 
1 3 '6 9 ( 7' 27) 
15,00 (6,35) 
After 8 weeks 
B2 
14,65 (7,79) 
16,18 (7,00) 
After 16 weeks 
B3 
15,38 (7,27) 
14,86 (6,56) 
R, 
enumeration /S Ri. 
l'f ~, 
I~ 
12. 
,, 
Bl B2 B3 
FIGURE 29: Serial 3s Total Enumeration Cell Mean Profile. 
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The cell mean profile (Figure 29) shows that at baseline Sequence i 
subjects obtain higher scores, with this difference carrying through 
to the assessment after 8 weeks, at which both mean scores are mod-
erately increased. Between the second and third assessments, differing 
trends are evident. Sequence 1 subjects continue to moderately 
increase scores while Sequence 2 subjects scores decrease to their 
previous baseline level. Results of statistical analysis of these 
scores are presented in Table 81. 
TABLE 81 Anova Summary Table for Serial 3s Total Enumeration Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 21 '28 0' 15 
Subjects 46 138,58 
Within subjects 
B. Time of assessment 2 14,62 2,38 
AB. Interaction 2 15,08 2,46 
Residual 92 6' 14 
The results presented in Table 81 show that no significant influences 
I 
are active on Serial 3s total enumeration scores. No further analysis 
is possible. 
5.2.7.2. Serial 3s: Error Scores 
Mean Serial 3s total error scores for the two treatment groups at 
the three times of assessment are presented in Tab1e 82 and illustrated 
in Figure 30. 
Errors 
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TABLE 82 Mean Serial 3s Error Scores 
Baseline After 8 weeks 
Bl B2 
Sequence (A 1) 
Sequence 2 (A2) 
0,65 (0,89) 
0,59 (1,01) 
0,85 (0,97) 
0,82 (1,01) 
1,0 
o,q 
o.r 
o,i 
R, 
°'"" 
o,S 
o,1r 
0,'3. 
O,l. 
0,1 
Bl B2 
After 16 weeks 
B3 
0,46 (1,03) 
0,77 (1,11) 
a .. 
fl' 
B3 
FIGURE 30: Serial 3s Error Scores Cell Mean Profile. 
128 
The cell mean profile (Figure 30) reveals slightly higher scores at 
baseline in the Sequence 1 group. Error scores increase approximately 
equally in each treatment group between the base] ine assessment and 
' 
assessment after 8 weeks. After the eighth week the group trends 
differ, with scores of Sequence 1 subjects dropping sharply to a 
level below the baseline score for this group, while scores of 
Sequence 2 subjects drop very slightly and remain above the baseline 
scores. The results of statistical analysis of the data are presented 
in Table 83. 
TABLE 83 Anova Summary Table for Serial 3s Error Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 0' 19 0' 16 
Subjects 46 1'23 
Within subjects 
B. Time of assessment 2 0, 72 0,81 
AB. Interaction 2 0,51 0,57 
Residual 92 0,89 
I 
The results presented in Ta.ble 83 indicate that no significant trends 
are active in Serial 3s total error scores. No further analysis is 
possible. 
5.2.7.3. Serial 3s: Total Correct Enumerations 
Mean Serial 3s correct enumeration total scores for the two treatment 
groups at the three times of assessment are presented in Table 84 
and illustrated in Figure 31. 
Total 
correct 
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TABLE 84 Mean Serial 3s Correct Enumeration Totals 
Sequence (A 1 ) 
Sequence 2 (A2) 
n,o 
lb.~ 
11..;0 
1!:i,S 
15)0 
1i.,s 
A,_ 
i~ .. o 
13)5 
i !>,o R, 
I 1. ,-:, 
Bl 
Baseline 
Bl 
. 13,04 (7,66) 
14,41 (7,03) 
After 8 weeks 
B2 
13,81 (8,02) 
15,36 (7,27) 
82 
After 16 weeks 
B3 
14,92 (7,47) 
14,09 (7,10) 
~I 
A ;_ 
B3 
FIGURE 31: Serial.3s Correct Enumeration Cell Mean Profile. 
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The cell mean profile (Figure 31) indicates that scores are markedly 
greater at baseline in the Sequence 2 group. Scores in both groups 
are equally increased after 8 weeks, _but differing trends are evident 
between the assessment at 8 weeks and that at 16 weeks. Sequence 
subjects' scores continue to increase at a slightly sharper rate 
than previously, while Sequence 2 subjects' scores decrease sharply 
to score slightly below that obtained for this group at baseline. 
The results of statistical analysis of the data are presented in 
Table 85. 
TABLE 85 Anova Summary Table for Serial 3s Correct Enumeration Scores 
Source df MS F ratio 
Between subjects 
A. Treatment sequence 1 17'42 0' 11 
Subjects 46 153,36 , 
Within subjects 
B. Time of assessment 2 10,82 1 '61 
AB. Interaction 2 21 '03 3' 14 (p < ,05) 
Residual 92 6, 70 
Table 85 reveals a significant interaction effect (p<'.',O~;) which 
requires analysis of simple main effects. The results of these 
analyses are presented in Table 86. 
1 31 
TABLE 86 Simple Main Effects Summary table for Serial 3s 
C6rrect Enumerations Totals 
Source 
A at B1 
A at B2 
A at B3 
Within 
B at A1 
B at A2 
Residual 
df 
1 
138 
2 
2 
92 
MS 
22,4 
28,6 
9 '77 
55,99 
23' 14 
10,56 
6,70 
F ratio 
0,40 
0,51 
0' 18 
3,45 (p<,05) 
1 '58 
Table 86 reveals that only the simple main effect of Bat A1, that is, 
the effect of time of assessment in the Sequence 1 treatment group, 
is significant (p<,05). The results of Tukey HSD comparisons of 
cell means for this treatment group are presented in Table 87. 
TABLE 87 
Baseline 
After 8 weeks 
Tukey HSD Results for the Effects of Treatments on Serial.3s 
Correct Enumerations Total Scores in Group 1 (pi racetam-placebo 
order) 
After 8 weeks After 16 weeks 
-1 '51 -3,69 (p <.ol) 
-2' 18 
The results presented in Table 87 indicate that the significant simple 
main effect of time of assessment in the Sequence 1 treatment group 
is solely dependent on the differenc~ between scores at baseline 
and scores after 16 weeks (p <,01). 
5.2.8 lngl is Paired Associate Learning Test (IPALT) 
Mean numbers of presentations of stimulus words required to complete 
the Inglis Paired-Associate Learning test for the two treatment 
groups at the three times of assessment are presented in Table 88 
and illustrated in Figure 32. 
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TABLE 88 Mean lngl is Paired Associate Learning test Presentations Scores 
Sequence (A 1 ) 
Sequence 2 (A2) 
1o 
tB 
II:. 
'" 
Presentations,0 
J. 
B1 
Baseline 
B1 
8. 88 ( 5. 54) 
111 • 9 5 ( 1 3' 4 5) 
After 8 weeks 
B2 
6,27 (4,49) 
9,09 (6,42) 
B2 
After 16 weeks 
B3 
6,46 ( 4,28) 
8,95 (12,63) 
B3 
FIGURE 32: Inglis Paired-Associate Learning Test Presentations 
Cell Mean Profile. 
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The cell mean profile indicates that Sequence 2 subjects require 
substantially more presentations at baseline, but the difference is 
reduced after 8 weeks. Between baseline and the assessment at 8 weeks 
numbers of presentations are reduced in both groups but more so in 
the Sequence 2 group. Between assessments after 8 and 16 weeks the 
required numbers of presentations level off equally in both groups. 
The results of statistical analysis of the data are presented in 
Table 89. 
TABLE 89 Anova Summary Table For IPALT Presentations Scores 
Source df MS F ratio 
Between subjects 
A. Treatment seqyence 1 514,84 5,42 (p .( ,05) 
Subjects 46 95,06 
Within subjects 
B. Time of assessment 2 283,71 4,86 (p < ,05) 
AB. Interaction 2 46,58 0,80 
Residual 92 58,36 
The results presented in Table 89 show that there is no significant 
interaction but that there are significant effects of treatment 
sequence (p (',05) and time of assessment (p <'.,05). 
However, the assumption of homogeneity of error variance is violated 
for both subject error variance (F max = 3,35; df = 2 and 22; 
p <,01) and residual error variance (F max= 9,76; df = 2 and 44; 
p<,01). 
A more stringent test of significance is required to compensate for 
the violation of F max. Using a probability level of p.{,01, neither 
main effect achieves significance. No further analysis is possible. 
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6. DISCUSSION 
6.1 EVALUATION OF STATISTICAL RESULTS 
Of the 31 statistical analyses of test data, only two yielded the 
interaction effects required to support a contention of differential 
effects of piracetam and placebo on functional performance as assessed 
by psychometric instruments. The two analyses concerned were those 
for scores on the WAIS Block Design test (p .(_ ,01) and for scoring of 
total correct responses on the Serial 3s subtraction task (p < ,05). 
Inspection of the cell mean profile for the Block Design test (Figure 
18) reveals moderate increases, reflecting improvements, in.both 
groups after placebo treatment. In both groups, performance after 
piracetam treatment remained roughly constant, in fact, from Table 46 
it can be seen that performance in both groups deteriorated slightly 
after piracetam treatment. 
The significant interaction effect thus reflects superior (improved) 
performance on the Block Design test when placebo was administered, 
while piracetam treatment prov~d less useful. It is notable however 
that the simple main effect for A at B1 (Table 48), r.e. the comparison 
between the two groups at baseline, is significant (p < ,05). As 
subjects were randomly assigned to treatment groups this result is 
unexpected, cs the groups should be approximately equal at baseline on 
all measures. This simple main effect can thus be attributed to the 
chance factors (RSV). 
The difference between the mean Block Design scores of the groups after 
16 weeks was approximately equal to that at baseline, reflecting equal 
gains over the trial period, the full extent of these gains being due 
to the effects of placebo alone. While the similarity of the trends in 
both groups under each treatment, is clear from Figure 18, the influence 
of the pre-existing difference Jn baseline scores on the significance of 
the interaction effect is not clear. It might be this difference en-
hanced an otherwise non-significant interaction effect. This result 
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should therefore be interpreted with caution. 
Inspection of Figure 31, the cell mean profile for the total of correct 
responses in the Serial 3s subtraction task, indicates no differences 
in trends during the first trial period, where equal score increases, 
reflecting improvements, were observed. Trends differed in the latter 
trial period, however, where scores for the group receiving piracetam 
treatment continued to improve, while scores for placebo-treated sub-
jects deteriorated. Analysis of simple main effects (Table 86) reveals 
that the difference underlying the significant interaction effect was 
solely to be found within the scores of the group receiving piracetam 
after the placebo. Table 87 reveals that this was the cumulative 
difference alone between base! ine scores and those after 16 weeks 
within this group. 
This result provides partial support for an interpretation that piracetam 
increases concentration, when compared to placebo. However, the fact 
that this only occurred in one half of the trial, while no difference 
was observed in the first period of the trial, weakens this argument, 
and suggests the possibility that this too is a result of chance factors. 
As the 5% level of significance was used for the 31 analyses,~tatistically_ 
sig~ificant values , resulting purely f~om the operation of chance may 
be expected in 1 ,55 of the interaction effect values. As these events 
are discrete however, it is probable that two such results should be 
obtained. It thus appears that the sole two significant interaction 
effects can be attributed to chance factors. This interpretation is 
supported by the fact that opposed findings result from these analyses, 
the analysis of Block Design scores indicating superiority of placebo 
over piracetam, while the analysis of total correct response scores for 
the Serial 3s subtractiqn task indicates marginal superiority of 
piracetam over placebo.' Although a non-directional hypothesis was used, 
uniformity of the direction of differences could be expected if real 
differences existed between effects. 
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Of the remaining analyses, 10 yielded no significant effects whatsoever, 
while a further 18 results indicated score changes over the trial period 
irrespective of treatments administered. Should the interaction effect 
for Block Design scores be regarded as non-significant, the main effects 
for this analysis may be interpreted, in which case the number of sig-
nificant B-effects is increased to 19. 
Significant A-effects were not anticipated in this study, as the use of 
randomized group assignment procedures should have made the groups 
approximately equal at baseline, and subsequent treatments administered, 
though in opposite sequences for the two groups, were equivalent. 
Taking into account the significant A-effect in the 
three A-effects attained statistical significance. 
cell mean profiles for these analyses (Figures 18, 
Block Design analysis, 
Inspection of the 
22 and 23) reveals 
marked differences between groups at base! ine in all cases. The mag-
nitude of the difference is seen to persist, with minor variations, 
throughout the trial period. Thus the base I ine differences, which are 
chance effects, are the sole determinants of the significant A-effects. 
The number of these A-effects, three, differs only slightly from the 
expected value of two, determined on statistical grounds. Consequently, 
these significant A-effects may all be attributed to chance. 
The above results show no differences between the effects of piracetam 
and those of placebo on the functional capacities of chronic alcoholics. 
All the interaction effects and effects reflecting overall differences 
between treatment groups may be attributed to chance. The single 
regular, though by no means consistent, finding is that of significant 
changes in scores over time irrespective of treatments administered. 
This was expected, as the two way anova with repeated measures is known 
to be extremely sensitive to such changes (Gilbert, 1977c). 
In a repeated measures design improvements must be anticipated to 
degrees varying with the nature and difficulty of each measure, due to 
the effects of practice, subtle shifts in the nature of functions 
assessed at retests, growing test sophistication including changing 
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test-taking attitudes and lessening anxiety, and perceived demand 
effects, quite apart from any real effects due to treatments. In this 
study the failure to achieve significant interaction effects indicates 
that varying the treatments administered failed to significantly 
influence test performance, and thus the changes in scores in each 
group for each period are attributable to the same factors, and to all 
intents, the two groups can be joined and their scores contrasted at 
the three assessments. 
Further interpretation of significant effects due ·to changes in scores 
over the trial period falls outside the scope of this study, as it is 
implicit in these analyses that there are no differences between the 
treatments administered. 
Overall, the results of statistical analyses indicate that no differences 
exist between the effects of piracetam treatment and placebo treatment. 
The interaction effects observed may be attributed to chance, as can 
the apparent effects of treatment sequences (A-effects) which on inspec-
t ion are found to depend almost exclusively on baseline differences 
between treatment groups. The only authentic effects (including,. 
however one or two anticipated· but unidentifiable chance effects) a.re 
those reflecting changes between assessments, indicative of practice 
and the above mentioned related effects, while denying any differences 
between subjects treated with piracetam and those treated with placebo. 
These results indicate that piracetam has no effects beyond those 
'perceived demand 1 effects engendered by the receipt of treatment of any 
kind, that is, the effects of piracetam on scores obtained from this 
psychometric battery appear equivalent to placebo effects, and no more. 
6.2 £VALUATION OF THE INTERNAL VALl.OITY. OF TH.i's STUDY 
The placebo-controlled, randomized double blind cross-over design 
constitutes probably the most powerful test of drug effects in chronic 
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conditions. This is especially so in the case of piracetam, which has 
no known side effects to betray the double-bl ind procedure. The design 
controls bias in test administration and holds subject expectations 
constant. In addition, the delay, in this study, in scoring test data 
until all subjects had completed the trial prevented bias in test 
administration at later assessments. Added to this, subject protocols 
were broken only after the completion of scoring, thus eliminating the 
possibility of bias in scoring. Consequently, it may be assumed that 
objectivity was ensure~ in both test administration and scoring. 
In terms of I ife events which might have influenced subjects' performan-
ces, it is presumed that, while these can not be eliminated in a long 
duration trial involving out-patients, these influences should be 
equally distributed across the two groups as a consequence of randomized 
assignment. Similarly, it is hoped that any undetected non-comp! iance 
should be held constant across groups by the same procedure. It was 
intended to use unconsumed pill returns as a check on consumption, 
albeit this is a poor method vulnerable to deliberate falsification, 
However, many subjects omitted to return these, despite reminders, but 
confirmed they had consumed the bulk of their supplies. (As subjects 
were selected for reliability, the probability of deliberate falsi-
fication of consumption is I ikely to be minimal.) Once again, random-
ization serves to hold the uncertainty of comp! iance constant, as its 
elimination was not possible. The high dosages given in this trial 
also militate against minor non-comp! iance. The question of conducting 
blood assays was investigated, as this would be the best check on 
recent comp I iance, though it could not provide information~about the 
full 6 week period. However the facilities were not available locally, 
and such were the difficulties and costs of preserving and trans-
porting samples, as well as analysing these, that it was decided not to 
proceed with these. 
While high degrees of variability of scores might result from the 
heterogeneity of influences and degrees of comp! iance possible under the 
randomization control, these should mainly influence between-subject 
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variance, which is not used to assess the significance of interaction 
and trials effects, so it does'nt seem that this has suppressed any 
interaction effects. This may be argued in any event from the fact 
·that so many trials effects attained statistical significance, despite 
changes in scores of very minor magnitude, as seen in cell mean profile 
graphs (e.g. see Figures 12, '13 and 16). Further, the absence of 
differences between treatment effects can not be ascribed to test 
insensitivity, as the statistical significance of so many B-effects 
demonstrates, at the very least, that the measures in question were 
capable of reflecting performance changes. Thus treatment effects 
should be detectable on these measures, if not on the rest. This was 
not the case. Another methodological strength is that the periods 
between assessments were long enough (6 weeks plus or minus 10 days} to 
ensure that each assessment was uncontaminated by the effects of the 
alternative treatment. (This point pertains only at the final assess-
ment, when both treatments have been administered.) 
The majority of subjects were receiving some form of medication before 
entering the trial, and they were instructed not to change these for 
the duration of the trial. No major medication changes were reported, 
and consequently it can be assumed that this could not have biased 
results. As the subjects had proved themselves "reliable" to the 
satisfaction of the hospital, the possibility of unreported medication 
changes must be very small. Groups did not differ significantly in 
terms of numbers of subjects receiving psychotropic medication (see 
Appendix 18). Statistically, there is 1 ittle chance any real inter-
action effects were missed, as the sample size and the nature of the 
design combine to 1 imit the possibility of both Type I and Type I I 
errors to 5%, while the analysis was capable of detecting·relatively 
smal 1 differences (see Appendix 19) . 
... _,I'' 
Consequently there is 1 ittle possibility of systematic bias influencing 
test scores, and on statistical grounds there is 1 ittle chance of 
incorrect decisions being made in individual statistical analyses, 
although collectively chance significant results can be expected due 
I 
... 
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to the number of analyses performed. 
There appear to be insufficient grounds to challenge the internal 
validity of this study. This being so, the question of the external 
validity of the findings requires consideration. 
6.3 THE EXTERNAL VALIDITY OF THESE ~INDINGS 
Within the alcoholic population, alcoholics free of episodes of problem 
drinking for long periods constitute a minority. In addition to this, 
advancing age has frequently been shown to interact with the effects of 
alcohol abuse in producing morphological and functional deficits, and 
hence it would be advisable to restrict generalisations to alcoholics 
of similar ages. As can be seen in Table 1, the mean age of this 
sample at commencement of this study was 48 years. In terms of the 
studies on alcohol ism reviewed previously, this should be described as 
a sample of 11middle-aged 11 or 11older 11 alcoholics. It would be expected 
that this sample would exhibit greater deficits relative to premorbid 
status than would a sample of younger alcoholics. 
Generally, studies have not consistently reported significant relation-
ships of drinking variables with the extent of functional and morpho-
logical abnormalities. Very probably this is due to the fact that the 
relevant information has to be obtained from the alcoholic personally, 
and as a consequence of the deficits suffered by the alcoholic, this 
information is vague and inaccurate. In addition, it is known that 
alcoholics frequently de! iberately minimize in reports of consumption 
and related variables (Knox, 1980). As a result, it is unlikely that 
it be necessary to restrict these findings to alcoholics with similar 
' . ~ 
drinking histories. The criteribn of a minimum of 10 years history of 
problem drinking used in this study should be considered merely as a 
guarantee of the accuracy of a diagnosis of chronic alcohol ism. 
Subjects were selected for this trial if they were considered by the 
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hospital to be reliable in attending hospital appointments. This 
criterion was regarded as desirable to counteract the possibility of 
a high drop-out rate, as these are frequently encountered in studies 
involving alcoholics (e.g. Clarke and Haughton, 1975; Kl isz and 
Parsons, 1979; Ron, 1982). This means that the alcoholics in this 
study constituted a selected group. While it is probable that the 
variables related to 11 rel iabil ity 11 are predominantly personality 
variables, it is possible that cognitive variables might be implicated. 
It can be argued, however, that even should cognitive variables relate 
to this criterion, this should reflect a difference, relative to other 
alcoholic groups, in the degree of impairment suffered, rather than a 
total absence of impairment. No accurate measures of premorbid levels 
of functioning are available, but it can be contended from previously 
cited 1 iterature, indicating widespread prevalence of both morpho-
logical and functional deterioration in chronic alcoholfcs, the 
incidence of detection of which rises with age, that, at the mean age 
of the present sample, the occurrence of impairments in the majority 
of subjects should be beyond question. 
The issue under investigation here is the extent of change possible 
under the action of piracetam. Consequently, even if this sample 
should prove to be functionally more normal than other alcoholics, 
this in no way detracts from the findings, as improvements have been 
claimed even for normal subjects (Lagerg~en and Levander, 1974; 
Dimond, 1975; and Demay and Bande, 1980). Subjects suffering 
functional deficits merely offer greater opportunity of avoiding 
'~eiling effects'' 1 imiting the extent of improvement. The possibility 
of this sample differing markedly on functional variables from other 
alcoholic samples seems 1 imited, as the I iterature indicates I imited 
and protracted im~rovement with continuing abstinence, with marked 
deficits compared to normal subjects after as much as 30 or more months 
of abstinence (Adams et al., 1980; Ron, 1982). Thus it appears 
warranted on these grounds to accept that the alcoholic sample used in 
this study was indeed functionally impaired, and thus still represents 
the abstinent alcoholic population. 
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Finally, it must be noted that the sampling method used was not random, 
thus it is possible that the sample was biased in some unknown way, 
and may not accurately represent the abstinent alcoholic population. 
Indeed some bias is almost certain, as all subjects were drawn from 
one institution. While this may be so, it must be stated that samples 
of convenience are the rule rather than the exception in drug trials, 
and that truly random sampling is extremely rare in studies of clinical 
populations. On these grounds it may be stated that the claims of 
this study are of equivalent stature to other studies in related 
fields. In a case of this nature, where it appears 1 ikely that 
morphological abnormalities underlie the observed functional deficits 
in an unknown way, it appears probable that the contention of presence 
of abnormalities is less contestable, and thus inaccuracies resulting 
from differences between samples should at most reflect quantitative 
rather than qualitative differences at a functionaJ level. 
6.4 IMPLICATIONS FOR PIRACETAM 1 S EFFICACY IN TREATING 
FUNCTIONAL DEFICITS IN CHRONIC ALCOHOLISM 
This was the first study of piracetam 1 s effects on abstinent alcoholics, 
that is, alcoholics free of the acute effects of drinki~g. As such, 
the study is unique, and the conclusions drawn from it should be 
regarded as tentative until replication studies have been performed. 
As is the case with the majority of drug trials, this is especially 
the case as non-random sampling was used, and thus the representative-
ness of the sample is uncertain. The results indicate no differences 
between piracetam and placebo in treatment of functional deficits in 
abstinent alcoholics, the two statistically significant interaction 
effects resulting from the effects of chance. The conclusion drawn 
from this, that piracetam has no beneficial effects for abstinent 
alcoholics over and above those motivational and psychological effects 
resulting merely from receipt of treatment in itself, is at variance 
with those drawn by Binder (1974) and Binder and Doddabela (1976), 
but as implied above, there are differences between these studies and 
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the present one which might account for this. 
It appears that Binder (1974) and BinderandDoddabela (1976) both 
studied recently detoxified alcoholics, although this was not explicitly 
stated in the latter study. While this might mean that gross with-
drawal symptoms had subsided it does not mean that subjects had com-
pleted that sharp improvement in functional capacities which is known 
to occur in the first two to three weeks of abstinence (Page and 
Linden, 1974; Page and Schaub, 1977). Thus, differing rates of 
improvement, possibly resulting from random sampling variation, might 
erroneously be attributed to treatment effects. This might particularly 
be the case in Binder's (1974) bl ind one-period clinical trial, while 
Binder and Doddabela's (1976) double-bl ind cross-over study, though 
Jess susceptible to this failing, may still have been influenced by it. 
Dosages do not vary between these studies, nor do sample sizes and 
treatment periods vary much. Binder's (1974) sample was exclusively 
male, making it very similar to that used in the present study, but 
Binder and Doddabela (1976) neglected to mention the sexual composition 
of their sample. As both studies utilized in-patients, it might be 
possible to assume similar composition. (General Jy the vast majority 
of alcoholic in-patients are male.) If this is so, it is uni ikely 
that the cause of the different results originated here. The present 
study however involved out-patients, and this could contribute to the 
differing findings. Out-patients are subject to a wide range of 
environments and experiences, and hence their performance may be more 
variable, and less treatment-related. On the other hand, should any 
form of contamination occur, e.g. a negation of the bl ind procedures, 
the effects would more easily spread through the greater contact 
between in-patients. 
The possibility of contamination of these in-patient studies is sub-
stantial, as, if pills were chewed instead of being immediately 
swallowed (as recommended), it would be found that piracetam tasted 
different to the placebo, though in all other respects the two were 
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identical. The communication of this difference among in-patients 
during the various periods of the trial; combined with their inter-
pretations of the demand characteristics of these differences, could 
result in total negation of subject blindness. It is not impossible 
that subjects might reason that a placebo or "sugar pill" might be 
bland and near tasteless, and that the pill with the bitter taste was 
more likely to be the active substance, as was indeed the case. This 
would result in greater motivation in the latter case. In Binder 1 s 
(1974) study subjects were informed that confirmation of beneficial 
effects of piracetam treatment could result in early discharge, so 
subjects can be considered to have been highly motivated to respond 
11correctly 11 • 
A related failure in Binder 1 s (1974) study is the fact that after 
baseline testing subjects themselves drew lots to decide which subjects 
-
received placebo and which received piracetam. As the design was 
described as "bl ind", it should be possible to assume that the subjects 
were not informed of the purpose of drawing lots. Howev.er, the proce-
dure has demand characteristics, and should not have been adopted, as 
in conjunction with the above-mentioned factors, it increased the 
chances of contamination of the results. It is also possible that, 
owing to the absence of double-bl ind procedures, scoring might have 
been less objective than in Binder and Doddabela 1 s (1976) and the pre-
sent trials. Binder 1 s (1974) conclusions were based on significant 
results obtained on two of the four tests administered. As with the 
Benton Visual Retention and Beck tests, which yielded non-significant 
results, were claimed to measure "stimulus-response" abilities, 
Binder concluded that piracetam had no effect on such narrowly 
circumscribed functions, but acted on more complex cerebral functions, 
characterized by co-ordination and co-operation of discrete function~. 
These were measured by the Pauli and Chapius tests. However, Binder 
provided no details for scoring these tests, though the results were 
presented in categorizations of 11 deteriorated 11 , "improved" and "un-
changed". Most significant results barely achieved the 5% level of 
significance, and the question must be raised, in the 1 ight of the 
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single blind design used, as to the objectivity of these categoriza-
tions. It might be argued that raw scores derived from complex 
measures frequently involve a measure of discretion, which might be 
subtly influenced by prior knowledge of drug regimen. 
Binder and Doddabela's (1976) double-bl ind cross-over study consti-
tuted a stronger test of piracetam's efficacy. They repeated 
Binder's (1974) findings, although the tests used were mostly not 
directly comparable. One of the measures used however was a "guessing 
test 11 by which they attempted to identify whichever regimen was being 
applied to each subject, and this test yielded highly significant 
results (p <.. ,01). These guesses were based on the performance of 
subjects in therapeutic group situations, but nevertheless this points 
to some observable, though not necessarily measurable, result of 
piracetam treatment. 
This result must militate against the efficacy of the double-bl ind 
methodology however, and consequently the 1 ikelihood of bias in test 
scoring is very strong. 
The distinction made by these authors between simple 11stimulus-
response11 functions and more complex ones, for which piracetam is 
claimed to show differential efficacies, does not appear to be a sound 
one, as within the former category they included .a mirror drawing task, 
and an enumeration task, both of which do not conform to a 11 stimulus-
response11 description. 
In the present study, no differences, even in trends, were seen between 
simple and complex function~ responses to piracetam treatment. In 
particular, measures reflecting accuracy rather than speed, did not 
respond positively to piracetam as might have been expected from 
reading certain piracetam studies (e.g. Binder 1974; Binder and 
Doddabela, 1976; Demay and Bande, 1980). 
It thus seems inadvisable to dismiss non-significant results in this 
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fashto~ and to accept the test scores as a unified group, some of 
which attain signifi~ance while others do not. In any event,. the 
authors may be faulted for contending in summing up that piracetam 
raised the general level of all performances, while not relating this 
to their failure to attain significance on half their tests. 
While it is not possible (due to insufficient details being reported) 
to determine to what extent these samples were comparable, it can be 
seen that several factors can account for the divergent findings 
between those of Binder (1974) and Binder and Doddabela (1976) on 
one hand, and tne present study on the other, even were the issue of 
abstinence to be glossed over. The present study has the strongest 
design, the lessened degree of contact with subjects protecting the 
double-blind procedure. 
The study, and the conclusions of Binder (1974) have been (aulted on 
several grounds, and though the Binder and Doddabela (1976) study was 
much sounder, the double-blind procedure was betrayed and hence its 
results should be treated as contaminated. In both cases, the 
authors appear to have exceeded the claims of their results in their 
strong endorsement of piracetam's efficacy. It must be emphasized, 
however, that there exists the possibility that during the first few 
weeks after detoxification there might exist an interaction of the 
effects of piracetam and that of absence of alcohol, which might lead 
/ 
to accelerated recovery. If very large, t~is could just conceivably 
account for Binder and Doddabela's (1976) positive findings, but on 
balance these still appear suspect. The possibility of such interaction 
in the present study is however practically nil, as a minimum period 
of 3 months' abstinence from problem drinking was required prior to 
entry into this trial. By such a time, recovery of equilibrium is 
complete, and the·only changes should be extremely small protracted 
ones related to long-term, not acute, deficits. 
It thus appears that in piracetam studies concerning chronic alcohol ism 
the findings of Binder (1974) and Binder and Doddabela (1976) can 
largely be dismissed. The failure to find any significant effects due 
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to treatments, or even trends, other than expected chance effects, 
in so large a number of analyses, appears to argue most forci~ly 
that treatment with piracetam was totally without measurable effects. 
6.5 THE RELATIONSHIP OF THESE FINDINGS TO THE 
GENERAL LITERATURE ON PIRACETAM 
Consideration of the internal validity of this study did not reveal 
any factors which might have given rise to erroneous conclusions, 
and in consequence it must be accepted that in the present sample of 
abstinent alcoholics, piracetam did not exert any effects differing 
from those of the placebo. 
However, being the first study of its kind, this study must be regarded 
as exploratory, and its conclusions should be checked against those of 
replication studies. It is normal practice to treat such conclusions 
as tentative, as it is conceivable, for instance, that the use of a 
non-random sample might have resulted in unknown biases. 
On the other hand, though, the uniform nature of the large number of 
results argues most strongly against a contention of sampling bias. 
It is inconceivable, bearing in mind the sample size and the repeated 
measures design combined to en~ure detection of relatively small 
differences, that the alcoholic population should vary so widely on 
morphologically-based functional impairments that one non-random 
sample should reflect no differences between placebo and piracetam on 
an extensive range of 31 measures whilst another non-random sample 
might do so. On such sensitive analyses, differences would have to 
be found on the majority of measures, and plausible reasons would 
have to be offered for those results failing to attain significance, 
before a conclusion supporting differences between placebo and piracetam 
could be accepted. The obtained results differ so much from this that 
it is highly improbable that this could be the result of sampling 
i 
bias. The conclusion has to be accepted that the results unambiguously 
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and incontestably showed that piracetam and placebo treatments did 
not differ. Bearing in mind the strength with which this conclusion 
is supported, it is _dHfic.uH-.:to be tentative in this regard. In as 
sound a design, this result is unlikely to be contradicted in repli-
cation. 
This finding runs counter to numerous others which support the conten-
tion that piracetam yields beneficial effects on functional capacities, 
in non-alcoholic as well as in alcoholic samples. 
Negative findings have been reported frequently, however. In a review 
of controlled and randomized double-bl ind studies conducted in elderly 
populations, Bogaert (1979) found that of 12 such studies, 6 ret~rned 
negative results. Bogaert went further, scrutinizing the remaining 
I 
6 studies, and concluded that the magnitude of improvements observed 
in these did not justify the strength of the claims made for pirace-
tam's efficacy, based on these changes. 
It is important to note that Bogaert (1979) chose to ignore all drug 
studies which did not conform to the randomized double-blind design, 
as all other designs could be faulted. In spite of this rigorous 
selection, however, he still found ample examples of what might be 
termed 11errors of enthusiasm11 in interpretat.ion of results. It can 
only be presumed that if such willingness can be found in rigorous 
trials, its potential for biasing less controlled studies is immense. 
Thus it appears wise to examine all drug studies not utilizing random-
ized double-blind designs with care. Examining the 1 iterature on 
piracetam 1 s effects in the no~mal population, reports of the use of 
double-bl ind cross-over designs are made by Lagergren and Levander 
(1974), Wedi and SuchenJfrth (1977) and Demay and Bande (1980), but 
none of these explicitly mentions using randomized allocation to groups, 
in fact it seems probable that Demay and Bande (1980) used a single 
group repeated measures design (the authors do not make this matter 
clear). If so, it appears piracetam treatment was given last. 
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Assuming increasing longitudinal learning effects, while acknowledging 
that these are indistinguishable from the treatment effects, it is 
evident that in the absence of real differences between treatment 
effects, there will nonetheless appear to be differences, which in 
reality represent differing degrees of learning and carryover effects. 
In the·present case, this would appear to indicate that piracetam 
treatment resulted in superior performance to that resulting from the 
prior placebo treatment, but this would be a spurious conclusion. 
Lagergren and Levander (1974) were more guarded in concluding that 
piracetam had 11 some protective effect 11 or 11 some cortical arousing . 
effect 11 on their pacemaker subjects. However, no baseline measure-
ments were taken, and as the differences resulting from the differing 
treatments are so small, it might be contended that the results 
obtained are the results of ·random sampling variation. Certainly, 
the conclusions drawn were supported by only 2 of the 4 tests applied, 
which weakens them somewhat. Wedi and Suchenwirth (1977) appear open 
to the same charge, reporting 5 significant results while ignoring 
another 16 which failed to attain significance. As several tests used 
in this study are not known .here, it Is not possible to assess how 
objective the scoring may be. The major criticism concerns the 
questioning of _subjects as to whether they received active medication 
or·placebo. As the trial lasted 10 days (2 periods of 5 days each) 
even were this question to be asked at the very end of testing, since 
the trial lasted a. total of 28 days it is possible the study could have 
been confounded by communication about this matter from early 
finishers to later starters. As the subjects were all nursing 
students, it is very possible they had sufficient opportunity to do so. 
In addition, nur~ing students would be aware of the major role placebo 
treatment plays in drug trials, and hence even without confirmation 
from early finishers 'liheir 11blindness 11 must be suspect. 
Of other studies in the normal population, that of Dimond (1975) is 
open to many forms of contamination and bias. While reporting 
significant improvements in verbal learning under piracetam treatment, 
150 
Dimond provided too few details of methodology, statistical treat-
ments and directionality of his hypothesis to support any criticisms 
of his research. However, he used psychology students as subjects. 
These should have similar knowledge of the use of placebos to that 
possessed by nursing students, and thus again the possibility of 
contamination via reduced placebo efficiency has to be considered. 
Also, Dimond reported one statistically significant result, but 
mentioned conducting studies on other aspects of learning, not mention-
ing the number of these. It is thus again possible that an isolated 
positive finding has been misinterpreted as showing real drug effects 
when it reflects chance factors, the majority of negative findings 
simply being ignored. 
It can be seen, then, that much of the 1 iterature supporting the claims 
of piracetam may be faulted on procedural and methodological grounds. 
Of much of the rest of such literature no specific criticism is 
possible due to insufficient details being supplied, but the possi-
bility exists that similar criticisms to those given above might well 
apply equally to these, were all relevant details known. It appears 
that the type of criticism levelled by Bogaert (1979), namely that 
researchers are overkeen in ~hese drug trials to interpret positive 
findings from their data, minimizing negative results, can be extended 
from those studies on elderly subjects reviewed by Bogaert to those of 
Lagergren and Levander (1974), Dimond (1975), Wedl and Suchenwirth 
(1977) and Demay and Sande (1980). Consequently, much of the litera-
ture favourable to piracetam is open to dispute. 
It would however be arrogant to assert that the findings of the 
present study are sufficient to negate all this previous work. 
Despite the uniformity of the results obtained, which appears to allow 
only one, unambiguous in;~erpretation, to. wit, that piracetam was no 
more beneficial than placebo, and despite this conclusion being drawn 
from a study of great internal validity and sensitivity to small 
differences, the fact, that this study had unique characteristics in 
terms of the subject selection criteria used and the particular aspect 
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of chronic alcoholism investigated, namely that of abstinence from 
problem drinking .for upwards of three months, forces one to require 
replication of this study before unreservedly accepting its findings. 
A larger sample might make for detection of even smaller differences, 
for instance, but even were such differences to be found, it would 
have to be asked whether such small differences were of practical 
significance. 
Replication, albeit almost certainly requiring the use of another non-
random sample, is desirable because all subjects used in this study 
were solicited volunteers, drawn from a single institution and thus 
constituting a selected non-random sample; because of the inevitable 
number and diversity of uncontrolled variables in the lives of out-
patients; and because of the difficulties inherent in accurately 
ascertaining the degree of non-compliance witb the treatment regimen, 
in terms of pill consumption. On this last point, it was hoped that 
by using a selection criterion of patient 11 rel iability 11 that difficulties 
with non-compliance would be minimized, and that random allocation to 
-
groups would spread undetected non-compliance across the two groups. 
However, there was an extensive failure on the part of subjects to 
return unused drug supplies as requested, and hence in such cases it 
was not possible to accurately assess compliance, aside from obtaining 
assurances that most of the supplies had been consumed. Even in those 
cases of returned drug supplies, a researcher cannot be sure that the 
missing pills have been consumed rather than disposed of in some other 
way. It can only be hoped that the highly motivated behaviour 
associated with volunteer subjects mitigates against extensive non-
compliance. The only exclusion criterion which could be applied 
relating to drug use was therefore related exclusively to excessive 
drug returns.· This provides the strongest grounds for requiring 
replication of this studyf>}as extensive non-compliance, had it occurred, 
could have diluted differences between treatments to non-significant 
levels. This could then have given rise to the results seen in this 
study. 
It is not believed that this occurred, however, as very large dosages 
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(4,8gm/day) were used, which were double the size of normal long term 
dosages. Thus, were the odd dose missed, extensive effects from the 
previous dose could still be expected to be present. In addition, the 
combination of characteristics associated with volunteer subjects, and 
the "rel iabil ity 11 criterion applied in selecting subjects should have 
combined to militate against non-compl lance. Finally, examinatio~ of 
the cell mean profile graphs fails to reveal more than a handful of 
graphs which might be interpreted as showing 11diluted 11 differences 
between treatments. Many graphs show approximately parallel 1 ines 
over the entire trial period, which can not fit the above interpreta-
tion. Ignoring the hon-directional hypothesis used in this study, 
and accepting that according to the 1 iterature, piracetam should have. 
improved performance, it can be seen that only Figures 4, 6, 8,, 
11 and 29 could conceivably lend support to this idea, and only weakly. 
Overall, then, it is believed that although this study should be 
repeated, it is most improbable that differing conclusions could 
result, and in all probability the results obtained would echo those 
obtained in the present study.· 
J 
6.6 IMPLICATIONS FOR FUTURE RESEARCH ON PIRACETAM 
Criticisms levelled at much of the existing research findings on 
piracetam have made it plain that rigorous design is an absolute 
necessity in such research, as without it the relationships between 
drug treatments and the dependent variables become obscured and con-
taminated. Placebo-controlled double-bl ind studies offer the purest 
t~st of such relationships, but such designs must be two group 
designs. It appears that in some cases 11double-blind 11 studies as they 
are described are nothi~g other than single group repeated measures 
designs, and in these cases sequence effects play a major role, better I 
performances being yielded at each successive assessment. These 
studies, then, do not permit accurate evaluation of the effects of 
preceding treatments, and can give rise to totally misleading 
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conclusions. 
The addition of a cross-over to placebo con~rolled, double-bl ind 
studies adds to their strength by reducing the impact of intersubject 
differences, each subject acting as his own control in both treatment 
conditions. As random sampling will continue to be the exception in 
drug trials using clinical populations, randomized assignment to groups 
is the best guarantee of the equality of groups, but the representa-
tiveness of the samples drawn will always be open to question. 
It is not advisable that sample sizes be increased, though in theory 
this would make it easier to attain significant results. Not only 
would sample sizes have to increase enormously to achieve minor gains 
in sensitivity, but the question of practical significance of such 
small differences would be raised. Consideration could be given to 
increasing the initial sample size in a replication of this study, 
however, with a view to eliminating those subjects who do not return 
their unused drug supplies. As pointed out earlier, this is no 
guarantee that unreturned pills, originally issued to those subjects 
who do return some pills, have been consumed. It would however provide 
a slightly more stringent control on non-compliance, though it is 
doubtful whether the gains would outweigh the additional costs and 
work involved. 
A better solution to this non-comp! iance problem involves the use of 
l 
blood assays on a regular basis. With out-patients however this would 
be difficult to arrange, as their contact with institutions though 
regular, frequently is separated by long intervals. Many experience 
great difficulty, arising out of their 1 ife situations, in reaching 
such institutions, through, for instance, loss of a driving 1 icence, 
or the need to disguis~ from an employer the fact that they receive 
treatment for alcohol ism. Blood samples could be taken at the times 
of assessment, but this would not guarantee that the drug had been 
consumed regularly for the treatment period, merely that it had been 
consumed within the previous two days. In addition, this would 
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necessitate the addition of an inert traceable element to the placebo, 
as it would be as important to check on this consumption. 
It is apparent that there are numerous difficulties inherent in running 
a long term drug trial involving alcoholic out-patients. More control 
can be exerted in an in-patient situation, but the possibilities of 
contamination are so much greater. Also, subjects in an in-patient 
situation do not remain so for the duration of this type of trial in 
this country, and even were this so, the necessity of stabilizing the 
physiological and functional parameters before beginning to investi-
gate this drug's effects on long term deficits would probably 
necessitate an even longer in-patient treatment. Were an in-patient 
study possible, it would not be necessary to insist on a sele~tion 
criterion of 11 reliability 11 to guard against a high drop-out rate. 
However, it would be necessary to induce patients to participate 
without motivating them too strongly to find the 11correct 11 way to· 
respond (e.g. t? gain early discharge from hospital) i and it would be 
very important to minimize demand effects. 
It is desirable that researchers minimize contact with subjects, so 
as not to jeopardize the double-bl ind, and refrain from guessing tests 
for the same reason, and because this might influence scoring. Where 
there is a likelihood of contact between subjects, when some finish 
well before others, post-trial questionnaires should not be adminis-
tered if the questions separately or in combination lend themselves to 
the suggestion of a placebo treatment having been given. Scoring 
should be completed before breaking of any protocols, and should only 
occur after termination of the trial, to prevent early scores 
influencing later ones. 
The above recommendations should be considered in planning future 
piracetam trials involving alcoholics, though many of these suggestions 
could apply to research in other fields. 
Should sound replications of the present study repeat these findings, 
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t:t-e indications for the continued use of piracetam in se_veral fields, 
not merely in that of alcoholism, would be very poor. Most studies 
supporting piracetam's usefulness in chronic alcoholism, the psycho-
organic syndrome of aging and in the normal population may be 
criticised on methodological grounds, and it is doubtful that collect-
ively their conclusions could gainsay opposed findings from a few well 
designed studies. 
There are several reasons why replication of this study's findings 
would hold implications for piracetam's use in other fields of study. 
Once the acute effects of alcohol toxicity and of withdrawal have 
been removed, impaired brain cells quickly re-attain healthy status. 
Thus there should be no differences in the action of piracetam on cell 
metabolism in the brains of alcoholics and non-alcoholics, provided 
the alcoholics have passed through the withdrawal phase. The two 
populations may differ in the extent of the effects piracetam exerts 
on them, but they should nonetheless appear to be similar. Though 
these populations will differ in the amounts of healthy cell matter in 
their brains, it cannot be stated with certainty that the superiority 
in this regard of non-alcoholics will result in their showing a better 
response to piracetam, based simply on their larger capacity to 
process piracetam. The relationship between changes at a physio-
loqical l~vel and those at a functional level is complex and little 
understood, and it does not follow that a change at the physiological 
level must lead to an observable change at a functional level (Lyons, 
196 5) • 
Thus, conclusions drawn from sound studies of piracetam's effects on 
alcoholics should bear some resemblance to its effects on the normal 
population. If the rese~rch on alcohol ism finds itself yielding 
extreme results which are irreconcilably at odds with those obtained 
in studies of the normal population, the difference must be accounted 
for. Opposing sound studies against questionable ones, one must 
inevitably conclude that the results of the alcoholism studies are more 
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1 ikely to reflect reality, and the conclusions drawn from studies in 
the normal population must be discarded and those of the alcohol ism 
studies extended in a qualified form to cover the normal population 
until well controlled appropriately designed studies of piracetam's 
efficacy in the normal population are completed. It is doubtful 
that a sound piracetam trial in the normal population would arrive at 
findings much different from those obtained in the present study, 
however. 
The 1 iterature surveyed in the Introduction to this study clearly 
indicated that chronic alcoholics exhibit a clinical picture of 
advanced cortical atrophy, particularly in the frontal lobes, but 
extending somewhat to the temporal and parietal lobes, with a common 
incidence of ventricular enlargement. Memory, attention and con-
centration, complex thought and general response speed all deteriorate 
(Le~ak, 1976). Kish and Cheyne (1969) noted that relative to non-
alcoholics, alcoholics presented a clinical picture similar to that 
of advanced aging. The most striking similarity between alcoholics 
and the aged 1 ies in the marked diffuse, symmetrical cortical atrophy 
present. In the aged, this is the cumulative result of the normal 
loss of brain cells over many years, but alcoholics achieve a similar 
status at much younger ages due to the toxic effects of alcohol, and 
to an unmeasurable but probably lesser extent, to minor head injuries 
which are fairly common among alcoholics. 
This clinical similarity suggests that alcoholics and the aged are 
more similar than are alcoholics and normal subjects. To some extent 
they may differ in that the aged's cell loss is part of a markedly 
progressive condition in which poor circulation results in inefficient 
oxygenation of brain cells, and therefore cell metabolism might not 
be as efficient as could be expected in abstinent alcoholics and in 
normal subjects. Howevir the findings of Herrschaft (1979) on the 
effects of piracetam in rectifying circulatory imbalances means that 
the effectiveness of piracetam treatment should be the same in the 
aged as in alcoholics and normal subjects. 
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Support via replication for this study 1s findings would therefore have 
to be related to. findings in the area of the psycho-organic syndrome 
of aging. Negative findings in alcoholism studies would seem to imply 
that piracetam should not prove effective in the treatment of the 
effects of advanced aging either .. As it happens, Bogaert (1979) in 
reviewing the most rigorous trials in this area concluded that half 
the studies had found no effects of piracetam, while the remainder had 
reported weak positive results which had subsequently been over-
interpreted. Overall then the findings of the present study are similar 
to those found in the area of advanced aging, although the latter 
studies must be regarded as slightly more favourable to piracetam, 
in that the weak positive findings can not be dismissed totally without 
further close scrutiny of these results. It can be stated however 
that piracetam's effects in this population are at best extremely 
weak and unlikely to represent any worthwhile clinical or functional 
improvement. 
It can therefore be seen that the findings of the present study under-
mine the conclusions drawn from studies of piracetam 1 s efficacy in 
the normal population and in the population afflicted by the effects 
of advanced aging, and replication of these findings, resulting from 
completion of a wel 1 designed and executed trial, would make it 
extremely difficult to maintain the standpoint that piracetam can be 
of benefit to subjects of fairly stable functional status. This 
would not however. necessarily hold any implications for piracetam 1 s 
use in acute conditions such as drug overdosages, cerebral trauma 
and post-anaesthetic recovery, which seem more closely related to 
piracetam•s demonstrated activity in cell metabolism. In these cases 
piracetam 1 s claimed protective effect might well reduce cerebral eel l 
damage and death, resulting in more rapid and positive resolution of 
these acute states. lt·'appears more likely that piracetam might be 
of clinical benefit in these areas, and this is where further research 
might be most usefully directed. 
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A P P E N D I X 
REACTION TIMER, TECHNICAL DETAILS 
This apparatus consisted of the timer itself and an impulse gene-
rator which connected into it. Both were electrically operated. 
The impulse generator was a motor-driven device which rotated two discs 
in the horizontal plane. The uppermost disc had two sets of pins set 
into its perimeter, one on the uppermost and one on the lower surface, 
.while the second disc carried a single set of pins on its upper surface. 
As the discs rotated, each set of pins triggered its respective micro-
switch, which then initiated onset of the respective visual stimulus 
(in each case a different coloured light). Pins were arranged in an 
order such that when the discs rotated simultaneously, at any one time 
only one impulse would be triggered, and that the intervals between 
impulses would be four seconds. This device had its own on/off switch 
to commence testing, and an automatic cut-out at the end of pr~ctice 
and the end of testing. 
The reaction timer was a portable device made specially for this trial 
by Mr. A. Reynolds, (technician,.Department of Psychology, UCT). 
It bears no technical relation to other reaction timers. It was 
constructed in such a way that when 'set on a table, the subject would 
sit on one side facing a console, while the experiment 
On the subjects 1 s console were three lights:red, yellow and green, from 
left to right, across the upper portion of the console. At the bottom 
of this same console was a brass "starting point11 button, on which the 
subject had to keep his finger until required to respond to onset of a 
stimulus. In an arc above this button were three response keys, also 
. in the order of red, yellow and green, from left to right. 
The console facing the experimenter consisted of a digital display in 
the uppermost portion, which registered latency of response from onset 
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of stimulus in milliseconds. Below this was a reset button which had 
to be pressed before the onset of the next stimulus. This set the 
registered time back to nought milliseconds. 
At the right side of the machine on the experimenters side, was an 
inverting switch, used to interchange the connections between the red 
and green response keys and the red and green 1-ights, as required in 
the 11 reversed 11 timing condition. 
To summarize: the reaction timer is a three-choice visual reaction 
timer, utilizing touch sensitive response keys and a digital display 
registering milliseconds for latency of response from onset of stimulus. 
The machine had a capacity for inverting two of the response systems to 
their respective stimuli. 
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A P P E N D I X 2 
REACTION TIME LIGHTING SEQUENCE. 
Practice Sequence: 
1. Red 
2. Yellow 
3. Red 
4. Red 
5. Green 
6. Green 
7. Yellow 
8 •. Green 
9. Green 
10. Yellow 
Test Sequence: 
1. Green 16. Yellow 
2. Green 17. Red 
3. Yellow 18. Yellow 
4. Red 19. Green 
5. Red 20. , Yellow 
6. Green 21. Green 
7. Yellow 22. Red 
8. Red 23. Green 
9. Yell ow 24. Ye 11 ow 
10. Red 25. Green 
11. Green 26. Red 
12. Green 27. Red 
l3. Red 28. r" Green 
14. Red 29. Yellow 
15. Yellow 30. Yellow 
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A P P E N D I X 3 
INSTRUCTIONS GIVEN TO SUBJECTS FOR REACTION TIME TESTING 
A. Standard Condition: 
The test you are about to do measures your reaction time., On the 
console in front of your are three 1 ights: red, yellow and green, 
from left to right, and below these, in an arc, are three corres-
pondingly coloured push buttons which turn these 1 ights off. Thus, 
for example, the yellow 1 ight is terminated by the yellow push 
button and cannot be terminated by either the red or the green push 
buttons. 
Below the push buttons is a brass button. The index finger of your 
dominant hand (that is, your writing hand) must be placed on this 
before any 1 ight might come on. 
When a 1 ight comes on, move your index finger to the relevant push 
button and press this as fast as possible. This will turn the 1 ight 
off. Then immediately put your index finger back on the brass button 
in preparation for the next Light coming on, and repeat the procedure. 
The first few times the I ights come on will be for practice, to allow 
you to get used to the procedure. 
Remember the object of this test is to press the right button as fast 
as possible, but your finger must be on the brass button when the 
light come on. 
Concentrate on the lights: please do not talk during the test. Do 
you understand the procedure? If not, you may ask questions now. 
Are you ready? I am starting the machine now. 
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B. Reversed Condition: 
Now the task is slightly different. The procedure is the same as 
last time, except that now you must press the green push button to 
extinguish the red 1 ight, and you must press the red push button to 
extinguish the green light. You must still press the yellow, push 
button to extinguish the yellow light. It is only the red and green 
push buttons which have been reversed. Otherwise the procedure is 
exactly the same. 
Do you understand the instructions? Would you 1 ike the instructions 
repeated? Have you any questions about the procedure? If so, you 
may ask questions now. 
Are you ready? I ani starting the machine now. 
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A P P E N D I X 4 
PROCEDURE OF ADMINISTRATION AND INSTRUCTIONS GIVEN TO SUBJECTS 
RELATING TO THE MODIFIED CARD SORTING TEST 
(For a full description of the cards used, see Nelson, 1976) 
Four key cards are placed in line before the subject, in increasing 
order of items appearing on each, from his left to right. He is given 
a shuffled pack of forty eight cards to match against the key cards. 
The subject is instructed: "Here we have four key cards. 11 (The 
examiner indicates the cards on the table). 11 1 want you to sort these 
cards 11 (indicating those held by the subject) "under the key cards 
according to certain rules, but the whole point of the test is that 
shal 1 not tel 1 you what the rule is. I want you to find that out by 
trying out different rules, and each time I shall tell you whether ,it's 
right or wrong. Now go ahead and try to find out the rule". 
The subject commences piling cards beneath the key cards using a set 
of either colour, shape or number. That used in placing the first card 
is deemed correct, and the subject is informed after each placement 
whether he is correct or not under the operative set. 
When six consecutive placements have been deemed correct, the set is 
changed. The subject is instructed: 11The rules have now changed. 
want you to find a different rule". The subject must now adopt a diffe-
rent sorting set to that hitherto used, the procedure being otherwise the 
same. 
When six consecutive placements of the second set have been deemed 
correct, the set is changed again, the subject being instructed: "The 
rules have now changed again. I want you to find another rule you have 
not used before". This precise wording is used to prevent the subject 
from returning to his first sorting set. 
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At the completion of the third set, the subject is instructed to 
repeat the cycle. He is instructed: 11The rules have now changed. 
want you to use the rule you first used 11 • At the ends of the fourth 
and fifth sets, the words 11first used 11 are r·eplaced by 11 used the 
second time 11 and ••used the third time•• respectively. 
Sorting ceases either when six sets have been completed, or when all 
forty eight cards have bee.n sorted. At no time are the sets named by 
the examiner. 
Scoring 
Sorting is scored in terms of number of cards required to complete the 
~ 
task, number of sets completed, total number of errors and total number 
of perseverative errors, using for the latter, Nelson's (1976) criterion. 
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A P P E N D I X 5 
INSTRUCTIONS GIVEN TO SUBJECTS FOR LIST LEARNING TASKS 
A. Under Selective Reminding Conditions: 
am going to read you a list of twenty words. \Jhen I have finished 
want you to verbally recall as many of the words as you can, in 
any order. After you have done this, I will remind you only of those 
you have omitted to recall, and then I want you to recall as many of 
these words, and those that you recalled the first time, as you can. 
When you have done this, I will remind you of all those words you 
have omitted to recall, and then I want you to again attempt to 
recall as many of these words as you can as well as those you recalled 
the previous time. 
Before I start reading the list I will say: '~re you ready? Here 
are the words". 
Hhen I finish the list, I will say: "Now recall as many of the words 
as you can". 
There is no time 1 imit. Do you have any questions. 
B. Under Restricted Reminding Conditions: 
He are now going to do a test very similar to the one we have just 
done, but there will be one difference. 
I will only remind you of words you have not yet recalled on any 
trial. If you recall a word on the first trial, you will not be 
reminded of it even if you fail to recall it the second time. 
Do you understand the instructions? Do you have any questions? 
SELECTIVE REM I ND r.~G RESTRICTED REMINDING 
r 
ASSESSMENT ASSESSMENT V'l -I 
V'l 
1 2 3 1 2 3 .. 
0 
...., 
~ 
Chair AA Shoulder AA Swa 11 ow 48 Window AA Co 11 a r 44 Field AA 
0 
;:;o 
0 
Table AA Foot AA Fly AA Door AA Blouse 9 Gorge 9 
V'l 
c:: 
(J') 
Sofa 14 Tooth 47 "P. 44 Roof AA Ring AA Glen 10 . 19 IT1 0 
-f Desk A Lung 15 'Grasshopper. 14 Wa 11 AA Jersey 21 Hi 11 AA 
Lamp A Arm AA ::Centipede 
-- Floor AA Shirt 47 Equator 8 
:::c 
0 :z 
;:;o l> 
z r 
0 
-0 
V'l 
Dresser 7 Kidney 5 Jackal 2 Ce i 1 i ng 23 Garter 5 Stream AA ;;.io; -f -0 IT1 I r FTI 
Television 1 Mouth AA Dog AA Room AA Tie AA Bay AA 
Stool 16 Trunk 48 locust 7 Basement 8 Overcoat 12 Jungle 16 
Carpet 24 Knee AA Goat A Brick 49 Ski rt A Valley AA 
Bookcase 3 Heart AA Lamb 45 Ha 11 AA Blazer 
-- Desert A 
r !Tl 
0 l> :z 
;:;o ;:;o 
G') :z 0 
!Tl 1: co ;:;o l> x -I 
l> 
z V'l 
G') A. CJ"\ 
Kist -- Shin 5 Horse AA Staircase 9 Sock 12 River AA 
(J') V'l 
. .. 
Piano 26 Knuckle 5 Rabbit 43 Chimney 30 Shoe AA Tropic 9 
)> 
z 
0 
Radio 41 Toe 35 Spider 24 Foundation A Scarf 14 Bank AA -I :::c 
Picture. AA Ear AA Okapi 
-- Attic 12 Glove 43 Meadow 47 FTI ;:;o 
Bed AA Neck AA Bear AA Cement 17 Cap A Island AA l> V'l 
Mirror 46 Ankle 21 Hawk 22 Wood AA Shorts 2 Mountain AA V'l 0 n 
Refrigerator 11 Tongue A Bee A Bathroom 9 Cardigan -- Continent 45 )> 
-I 
Chest 
* 
41 Liver 10 Donkey 16 Glass AA Trousers 21 Ditch 28 FTI 0 
/ Hi-f i 
-- Hair AA 3eetle 11 Beam 42 Belt 48 Plain AA 
Stove 40 Leg AA Giraffe 1 Kitchen AA Hat AA Gulf 33 
' 
* Chest of Drawers 
- Denotes unlisted word 
AA 
A 
Moderate 
Low 
) 100 
> 50 
11-49 
1-10 
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Frequency Characteristics of Lists 
Selective Condition 
ASSESSMENT 2 3 
AA Frequency 4 10 4 
A Frequency 2 1 2 
Moderate Frequency 9 5 9 
Low Frequency 3 4 3 
Unlisted Frequency 2 2 
Restricted Condition 
2 3 
10 4 10 
1 2 1 
6 9 4, 
. 
3 3 5 
2 
Testing for qual itive differences in the lists frequences by means of 
x2, the following values are found for the lists used at Assessment 2: 
AA and A combined x2 = 1,47, df = 1 ' not significant 
Moderates x2 = 1 ' 14' df = 1 ' not significant 
Low and uni isted combined x2 = 0' 11 ' df = 1 ' not significant 
AA alone x2 = 2,57, df = 1 ' not significant 
It can therefore be concluded that the I ists do not differ significantly 
in difficulty. 
Jointly in a 3 x 2 x2, the difference between the lists is x2 = 12,96 
(df = 2) which is not significant. 
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A P P E N D I X 7 
SERIAL 3 s INSTRUCTIONS TO SUBJECTS 
The subject is told: 11When I say 11 Begin 11 , I want you to start at 100 -
you must say 11one hundred 11 - and count backwards in threes as rapidly 
as you can. Are you ready? Begin". 
After 30 seconds the Subject is told: 11Stop11 • 
Serial 3 s Scoring 
Scoring in terms of (a) the number of items covered in 30 seconds, 
irrespective of whether these are right or wrong, (b) the number of 
errors made (accuracy) and (c) the number of items correct in 30 
seconds. 
Notes: 
1. At assessments 2 and 3, the numbers commenced at are 99 and 98 
respectively. 
2. An item is deemed correct if the subtraction from the previous 
number uttered, be that correct or not, is correct. 
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A P P E N D I X 8 
INGLIS PAIRED ASSOCIATE LEARNING TEST: THREE ALTERNATE FORMS 
FORM A FORM B FORM c 
Stimulus Response St imu·l us Response Stimulus Response 
Cabbage Pen Flower Spark Tree Fork 
Knife Chimney Table River Cloud Drum 
' 
Sponge Trumpet Bott le Comb Kett le Book 
Form C is an unstandardized.form, based on equivalent word frequencies 
to Forms A and B. (H. Oblowitz, 1982). 
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A P P E N D I X 9 
PROCEDURE OF ADMINISTRATION AND INSTRUCTIONS GIVEN TO SUBJECTS RELATING 
TO THE INGLIS PAIRED-ASSOCIATE LEARNING TEST 
The subject is told: 11 1 am going to read you a list of words, two at 
a time. Listen carefully, because after I finish I shall expect you 
to remember the words that go together. For example, if the words were 
11 East - West 11 11 Go l d - Sil ver11 then when I said the word 11 East 11 I 
' ' , 
should expect you to answer 11West 11 , and when I said the word 11Gold 11 , 
you would of course answer •••.•••• ?11 The examiner pauses here to 
allow the subject to supply the word 11Silver11 • Should the subject not 
be able to supply the word, the examiner tells him. 
The examiner then continues: 11 Do you understand? 11 Should the subject 
indicate lack of understanding, the instructions are repeated to this 
point, and when confirmation is given the examiner proceeds: 1 'Now 
listen carefully to the list as I read it 11 • 
The examiner then presents the appropriate form of the test for the 
particular testing session. Word pairs are presented without temporal 
lapses between the two elements, and five seconds elapses between the 
end of presentation of one pair and the commencement of the next. Three 
pairs are presented and five seconds after the last pair, the first 
stimulus word is presented in the form: "What went with ••..• ?". 
Subjects are given ten seconds to respond. In the cases of a correct 
response within the time limit, the subject is told: 11That 1 s right" 
before presentation of the next stimulus word. Should the subject 
exceed the time limit or give the wrong associate, he is told the 
correct associate before presentation of the next stimulus word. 
Paired associates are presented to a criterion of three consecutive 
'-
correct responses. Pairs are presented in random order and once the 
first pair is eliminated, the remaining two pairs are alternated. 
When two pairs have been learned, and only one remains, the stimulus 
word of the remaining pair is presented in alternation with one of 
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the stimulus words from an already-learned pair, but only the former 
is scored. The maximum presentations of any stimulus word is thirty. 
Scoring 
Scoring is in terms of the number of times the response word has to be 
~upplied to the subject, including the original presentations of full-
paired associates, yielding a minimum (best) score of three and a maxi-
mum (worst) score of ninety three. 
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A P P E N D I X 10 
HAMILTON PSYCHIATRIC RATING SCALE FOR DEPRESSION 
For each item select the 'cue' which best characterizes the patient 
Item Scores Cue 
1. Depressed [Q] Absent 
mood m These felling states indicated only on questioning (Sadness, hope-
less, helpless, ~ These feeling states spontaneously reported verbally 
worthless) [J] Communicates feeling states non-verbally ... i.e., throught facial expression, posture, voice, and 
tendency to weep 
@] Patient reports virtually only these feeling states in his spontaneous verbal and non-verbal 
communication ' 
2. Feelings [Q] Absent 
of guilt Self-reproach, feels he has let people down 
~ Ideas of guilt or rumination over past errors or sinful deeds 
[J] Present illness is a punishment. Delusions of guilt 
@] Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations 
3. Suicide [Q] Absent 
OJ Feels life is not worth living 
Wishes he were dead or any thoughts of possible death to self 
[J] Suicide ideas or gesture 
@] Attempts at suicide (any serious attempt rates 4) 
4. Insomnia - [Q] No difficulty falling asleep 
early m Complains of occasional difficulty falling asleep-Le., more than 1 /2 hour 
~ Complains of nightly difficulty falling asleep 
5. Insomnia - [Q] No difficulty 
middle m Patient complains of being restless and disturbed during the night 
~ Waking during the night-any getting out of bed rates 2 (except for purposes of voiding) 
6. Insomnia - I]] No difficulty 
late m Waking in early hours of the morning but goes back to sleep 
~ Unable to fall asleep again if gets out of bed 
7. Work and [Q] No difficulty 
activities m Thoughts and feelings of incapacity, fatigue or weakness related to activities: work or hobbies 
Loss of interest in activity; hobbies or work-either directly reported by patient, or indirect in 
listlessness, indecision and vacillation (feels he has to push self to work or activities) 
[J] Decrease in actual time spent in activities or decrease in productivity. In hospital, rate 3 if 
patient does not spend at least three hours a day in activities (hospital job or hobbies) exclusive 
of ward chores 
@] Stopped working because of present illness. In hospital, rate 4 if patient engages in no activities 
except ward chores, or if patient fails to perform ward chores unassisted 
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A P P E N D I X 10 
(Cont ... ) 
Item Scores Cue 
8. Retardation [Q] Normal speech and thought 
(Slowness of m Slight retardation at interview thought and 
speech; impaired [11 Obvious retardation at interview ability to con-
centrate; @) Interview difficult decreased motor 
activity) @] Complete stupor 
9. Agitation [Q] None 
OJ 'Playing with' hands, hair, etc. 
11] Hand-wringing, nail-biting, hair-pulling, biting of lips 
10. Anxiety [Q] No difficulty 
psychic m Subjective tension and irritability 
[11 Worrying about minor matters 
@) Apprehensive attitude apparent in face or speech 
@] Fears expressed without questioning 
11. Anxiety [Q] Absent Physiological concomitants of anxiety, such as: 
somatic m Mild Gastro-intestinal-dry mouth, wind, indigestion, diarrhea, cramps, belching 
~ Moderate Card io-vascu lar-palpitat ions, headaches Respiratory-hyperventilation, sighing 
@) Severe Urinary frequency 
@] 1 ncapacitating Sweating 
12. Somatic [Q] None 
symptoms OJ Loss of appetite but eating without staff encouragement. Heavy feelings in abdomen gastro-
intestinal ~ Difficulty eating without staff urging. Requests or requires laxatives or medication for bowels or medication for G. I. symptoms. 
13. Somatic [Q] None 
symptoms m Heaviness in limbs, back or head. Backaches, headache, muscle aches. Loss of energy and general fatiguability 
11] Any clear-cut symptom rates 2 
14. Genital [Q] Absent Symptoms such as: Loss of libido 
symptoms m Mild Menstrual disturbances 
~ Severe lli] Not ascertained 
15. Hypochon- [Q] Not present 
driasis m Self-absorption (bodily) 
[11 Preoccupation with health 
@) Frequent complaints, requests for help, etc. 
@] Hypochondrical delusions 
lt!!m Scores 
1G. Los~ of 
weight [QJ 
[JJ 
[2J 
[Q] 
[JJ 
[2J 
17. Insight [Q] 
[JJ 
[2J 
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A P P E N ·D I X · 10 
(Cont ... ) 
Cue 
A. When rating by history: 
No weight loss 
Probable weight loss associated with present illness 
Definite (according to patient) weight loss 
B. On weekly ratings by ward psychiatrist, when actual weight changes 
are measured: 
Less than 1 lb. (500 g) weight loss in week 
Greater than 1 lb. (500 g) weight loss in week 
Greater than 1 lb. ( 1 kg) weight loss in week 
Acknowledges being depressed and ill 
r 
Acknowledges illness but attributes cause to bad food, climate, overwork, virus, 
need for rest, etc. 
Denies being ill at all 
-
. 
G.S.H.-M/15/4/1 
TEL.: 65-5116 
REPLY ro. 
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AP P END I X 11 
PARTICIPATION SOLICITING LETTER TP. I 0/79/4000 
WILLIAM SLATER HOSPITAL/HOSPITAAL 
W~~~,~~ $~N GROOTE SCHUUR HOSPITAL/HOSPITAAL} 
PLEASE QUOTE I MELD ASB. 
I Section Private Bag I Ptivaatsak x9, Rondebosch, noo 
SICIYF AAN. MED. SUPERINTENDENT I 
Seltio 
~-•-•w_. __ 
C/o-H/V Milner & Park Roads I Wd, 
Rondebosch, Cape I Kaap. 
This hospital is co-opera tine with the Dep<:~rtment 
of Phr1rmacolOGY, Groote Schu.ur Hospital, in a re-
search project. 
A new medication has recently been developed \'<ltich 
is claimed to have a very positive effect on memory 
and other brain functions. 
As you are probably aware, alcohol used in excess 
over a period of time can have adverse effects 
upon brain functioning. We would like to test 
this medication which is called Piracetam and rJe 
would appreciate your co-operation. In partici-
pating in the trial you could only benefit from 
the drug which is completely safe and without 
side-effects. You wouJ.d take the medicatL-m for 
a limited ·period of time and then its benefit would 
be re-assessed. 
Would you kindly drop in to see Dr. Fraser at this 
hospital on at to discuss this 
matter. If you are unable to koep this appoint-
ment or if you have any questions, Iilease tele-
phone 655116. 
Looking forwurd to seeing you, 
Yours sincerely, 
IAIN s. FRASER, M.B.,Ch.B.,F.F.Psych.(S.A.) 
Consultant-in-Chage. . 
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A P P E N D I X 12 
INPORl\rnD COI1~SENT FORM. 
-
I, o•••e••••O••·········~·· have been 
adequately informed of the purpose and 
risks of the clinical trial to be pe .. "-
formed by Drs. I.S. Fraser and A.Hn Robins 
and A.E. Price. 
I understand that my participation in this 
trial is entirely voluntary and that no 
pressure will be applied to enlist my co-
operation. Refusal to participate n:i.J.l 
in no ~ay affect the quality of my medical 
treatment and care. 
I am free to withdraw from the trial at 
any stage. 
With regard to the above, I hereby agree 
to act as a subject in this trial which 
evaluates the use of Piracntam in chronic 
aleoholism. 
Signed•••••••••••••••••• Date ••••••••8 
Vii tnesses 1. • ••••••••••••••••• 
2. • • • • • • • • • • • • • • • • • • 
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A P P E N D I X 13 
CLINICAL AND DEMOGRAPHIC DATA ITEMS RELATING TO ·SUBJECTS 
Inquiries were made of the Subjects as to: 
·Name 
Current Address 
Age 
Telephone Numbers 
Employer 
Home Language 
Level of Income 
Current Medical Complaints 
Current Medications 
Subjective Problems Taking Medication 
Length of Drinking History 
Date of Last Drink 
Smoking Behaviour 
Addiction to Any Non-Medical Drugs 
Employer's Awareness of Subjects Alcoholism 
Difficulties at Work regarding Making Appointments at William 
Slater 
Handedness 
Level of Education 
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DROP-OUTS AND EXCLUSIONS 
Criteria of exclusion applicable to subjects completing the tri~I 
were formulated as below: 
a. deviation of ten days or more from the pre-determined inter-assess-
ment interval of 56 days. 
b. tablet returns for any inter-assessment period exceeding 134, i.e. 
over 40% of expected consumption. 
c. last trial medication taken more than two days prior to assessment, 
(i.e. after elimination of trial substance from the body (ha1f·~life 
of Piracetam is 7 hours). 
Subject attrition per group was as below: 
CAUSES GROUP 1 GRP!JP 2 
Dropping out 4 2 
Excessive deviation from 
inter-assessment interval 1 2 
Excessive tablet returns 2 4 
' 
Absence of medication for more than 
two days prior to assessment 0 0 
TOTAL: 7 8 
Exclusion criteria were applied in descending order (a to c). The 
failure of criterion c to excise any subjects was due to the prior 
exclusion of several subjects on criteria a and b. 
194 
A P P E N D I X 16 
SUBJECT DESCRIPTIVE DATA 
Subject No. Handedness Sex Age Treatment Group /\ l 1 oc;:i t ion 
R M 57 2 
2 L M 45 
3 R M 53 
4 R M 50 2 
5 R M 44 
6 R M J.12 2 
7 R M 38 
8 R M 55 2 
9 R M 54 2 
10 R M 41 
11 R F 42 
12 L M 54 
13 R M 43 2 
14 R M 52 2 
15 R M 45 2 
16 R M 58 2 
17 R M 58 2 
18 R M 54 
19 L M 48 
20 R M 49 1 
21 R M 38 2 
22 R M 51 
23 R M 39 1 
24 R M 35 1 
25 R M 58 2 
26 R M 51 2 
27 R M 46 2 
28 R M 49 1 
29 R M 49 
30 R M 56 2 
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Subject No. Handedness Sex Age Treatment Group Allocation 
31 R M 55 2 
32 R M 36 
33 R M 43 
34 R F 56 
35 R M 53 2 
36 R M 48 
37 R M 46 2 
38 R M 42 2 
39 R M 53 2 
40 R F 44 
41 R M 48 2 
42 R M 61 2 
43 L M 54 
44 R F 39 
45 R M 45 2 
46 R F 54 
47 R F 56 
48 R M 45 2 
49 R M 46 
50 R M 35 2 
51 R M 57 1 
52 R M 34,5 2 
53 R M 49 2 
54 R M 36 ( 
55 R M 50 
56 R M 41 
57 .R M 40 2 
58 R M 45 2 
59 R M 45 1 
60 R M 47 2 
Subject No. Handedness Sex Age Treatment Group Allocation 
61 R F 55 
62 R M 59 
63 R F 54 
KEY: 
L = Left handed 
R = Right handed 
M = Male 
F = Female 
1 = Placebo - Piracetam order 
2 = Pi race tam - Placebo order 
I 
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A P P E N D I X 17 
APPROXIMATE LENGTH OF DRINKING HISTORY, SERIOUS MEDICAL CONDITIONS 
AND CURRENT MEDICATION OF FULL SAMPLE 
Subject A.D.H. S.M.H. MED I CATI ON 
37 Coronary thrombosis E.,J.,R. 
2 24 T.L.E.; Pancreatitis N,A, Evadyne 
3 28 Ulcer c, Q, p. 
4 25 B. 
5 15 A. L. 0. 
6 22 C,H,L. 
7 15 Asthma K,L,C, Ventolin 
8 35 
9 20 Cancer of throat L ,Q .. 
1 0 28 Peptic ulcer; Aneurism ( 1976) E,K,C. 
11 15 0 
12 25 L.B. p. B,R. 
13 23 Peptic ulcer H,R,A. 
14 16 L. 
15 15 Peptic ulcer A,R. 
16 41 Emphysema 
17 20 
18 33 Diabetes; cancer of tongue Q,R. 
19 27 A,L,M. 
20 15 
21 24 L, Q. 
22 18 E,F,Q. 
23 18 
24 10 
25 30 T.B. Q. 
26 15 R. 
Subject 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
A.D.H. 
15 
30 
12 
20 
25 
15 
15 
22 
25 
13 
20 
15 
30 
12 
20 
35 
25 
15 
18 
11 
12 
20 
20 
10 
35 
15 
16 
11 
25 
20 
15 
S.M.H. 
H.B.P. 
H.B.P. 
T.L.E. 
H.B.P. 
H.B.P. 
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Spastic colon 
Pancreatitis, T.B. 
Emphysema 
Coronary thrombosis; H.B.P. 
Peptic ulcer; Hiatus hernia 
H.B.P. 
MED I CATI ON 
A,B,L,O,Lexotan 
Syndol 
Moducren 
, H9 L,Q, Moducren 
H ,A. 
.A 
B,C,D, 
G,O,R. Hygroton, 
lmipramine 
Q, R. 
A, R. 
R,C. 
B,M. 
H. 
A,K. 
B,C,K. 
Q, Lithium 
L ,Q. 
H,K,L,C. 
L,Q,C. 
A, Q, Norm i son, 
Tryptanol 
A,L,Q,H, Peterphylin, 
Mogodon 
B 
B,C, Zyloprim 
B,C,Merasyn Fabahistin 
Q,R. 
A,B,E,L,Q 
C,E,R. 
Q,R,A, Navidrex 
Lopressor 
A,Q,R. 
B,C. 
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Subject A.D.H. S.M.H. 
58 
59 
60 25 Chronic diarrhoea 
61 25 H.B.P. 
62 1 5 Asthma 
63 20 
Abbreviations: 
T.L.E. = Temporal ·lobe epilepsy 
H.B.P. = High blood pressure 
L.B.P. = Low blood pressure 
A.D.H. = Approximate drinking history 
S.M.H. = Serious medical history 
T.B. = Tuberculosis 
Medication Key: 
A Di su l f i ram K Dothiepin. 
B Lorazepam L Oxazepam 
c Calcium carbimide M Trimipramine 
D Phenytoin N . Ca rbamazep i ne 
E Proprano lo I 0 lmipramine 
F Chlorpromazine p Clorazepate 
G Thioridazine Q Amitriptyl ine 
H Nitrazepam R Diazepam 
J Perhexiline 
MEDICATION 
K, Eglonyl 
E,A,B,M, Triazolam, 
Pertofrin, Halcion; 
Desipramine 
L, Meticortin 
Subjects free of Medication:- Subjects 8,16,17,20,23,24,52,63 
Note: Many of the drugs reported above are not issued by William Slater 
Hospital. Their use has been· reported by subjects, and these 
reports may be both incomplete and inaccurate. 
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A P P E N D I X 18 
THE INFLUENCE OF PSYCHOTROPIC DRUGS ON RESULTS OBTAINED: STATISTICAL 
EVALUATJ.ONS OF DIFFERENCES BETWEEN GROUPS 
In total, 42 of the final 48 subjects were taking psychotropic drugs as 
regular medication. Exactly 21 of each group of subjects (Groups 1 and 
2) were receiving these. 
Chi-squared analysis (Two-by-two test of association) yielded a value of 
1,198, for df = 1, which is not significant at ,05 (critical chi-square 
= 3,841). 
It can therefore be con~luded that there was no sigrrificant difference 
in proportions of subjects receiving psychotropic drugs in each group. 
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A P P E N D I X 19 
ISSUES RELATED TO SAMPLE SIZE 
Bearing in mind the exploratory nature of this research, it was decided 
that a significance level of ,01 could not be used, and that bearing in 
consideration the numerous analyses involved, neither could the ,10 
level, frequently used in exploratory research, be used. Consequently, 
the ,05 level of significance was chosen. 
It was also desirable that Type I I errors be avoided, and that this indi-
cated the power of the test should be set at 0,95. The most important 
comparisons possible involve interaction. Consequently, (Gilbert, 1977a) 
a value of k = 3 was used to obtain a value of ¢ = 2,3. A relatively 
small z-value, denoting great accuracy in detecting small differences, was 
chosen; z = 0,75. 
All this allowed for a sample size of approximately 56, derived from the 
formula: 
N = 
The choice of such a balance of factors was considered reasonable in 
terms of cost-benefit ratio. 
However, it was not possible to obtain the required initial number of 
subjects to arrive at a final figure of 56 after normal subject attrition, 
and the final sample size was, for most analyses, 48. Using the same 
values of , 1-B, and k, this need only reduce the value of z used to 
approximately 0,85, using the above formula. 
Thus, values used in this study are: c< = 0,05 
1-B = 0,95 
+ 
z = - 0,85 
. I 
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A P P E N D I X 20 
RAW DATA 
Hamilton Rating Scale for Depr~ssion 
I 
Group 1 
( Placebo-Piracetam) 
Subject Subject 
Number 1 2 3 Number 
2 15 1 6 1 
3 28 12 14 4 
5 4 2 5 6 
1 0 18 13 16 8 
11 1 0 1 9 
12 6 2 7 1 3 
18 10 5 8 14 
20 2 . 0 5 15 
22 2 3 4 21 
23 7 3 8 25 
24 5 4 8 27 
29 10 7 4 30 
33 0 3 0 35 
34 8 16 1 0 37 
36 2 3 4 41 
40 1 1 5 42 
43 8 11 6 45 
44 18 21 12 48 
46 2 2 4 50 
47 14 6 4 53 
49 9 7 5 57 
51 9 2 4 60 
54 6 4 4 
56 11 12 4 
61 7 1 0 9 
63 6 1 5 
Group 2 
( Piracetam•Placebo) 
1 2 3 
1 3 4 
11 4 6 
7 6 . 8 
3 6 7 
9 4 7 
13 9 15 
5 0 6 
13 14 13 
7 2 7 
9 6 7 
22 19 21 
1 2 0 
6 7 3 
.• 
11 8 0 
1 5 9 
0 0 4 
3 5 6 
6 2 4 
9 7 8 
5 7 3 
4 6 13 
14 6 8 
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Choice Reaction Time (Overall, Standard Condition) 
Group 1 Group 2 
(Placebo-Pi racetam ) (Piracetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 712 636 612 1 803 751 487 
3 720 812 791 4 686 731 690 
5 570 659 '917 6 560 651 682 
1 0 792 749 716 8 655 840 807 
11 507 682 616 9 801 690 565 
12 620 736 665 1 3 651 745 801 
18 662 857 951 14 639 688 834 
20 555 507 600 15 619 776 800 
22 674 673 669 . 21 505 476 688 
23 642 752 724 25 619 761 627 
24 681 496 620 27 635 623 560 
29 689 754 644 30 576 616 538 
33 699 708 627 35 694 915 696 
.-
34 663 698 702 37 639 702 575 
36 664 775 600 41 604 731 767 
40 925 716 571 42 749 714 599 
43 1008 . 894 680 45 1000' 1100 781 
44 742 656 550 48 703 645 586 
46 601 972 669 50 624 713 608 
47 837 964 732 53 756 636 
0 
706 
49 637 662 543 57 860 578 515 
51 745 700 659 60 648 591 557 
54 793 540 528 
56 930 575 504 
61 677 734 653 
63 761 708 1203 
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. ! 
Choice Reaction Time (Overall, Reversed Condition) 
Group 1 Group 2 
( Placebo-Piracetam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 ·2 3 Number 1 2 3 
2 787 782 755 1 705 721 738 
3 728 831 711 4 876 . 753 809 
5 758 797 732 6 704 686 625 
1 0 . 951 760 745 8 966 758 690 
11 683 643 635 9 754 746 713 
12 779 ·717 771 13 1145 924 979 
18 882 868 827 14 694 685 710 
20 677 592 577 15 829 673. 673 
22 887 729 723 21 585 647 638 
23 792 671 666 25 762 712 668 
24 649 616 572 27 811 675 673 
29 770 821 728 30 644 638 643 
33 870 767 705 35 990 784 776 
.. 
34 849 815 742 37 839 796 778 
36 1158 889 789 41 791 841 822 
40 756 666 649 42 784 738 830 
43 1052 . 803 764 45 994 975 944 
44 648 702 648 48 847 818 797 
46 558 737 772 50 791 690 752 
47 914 1014 941 53 680 733 776 
49 672 565 594 57 769 676 620 
51 838 894 826 60 629 587 630 
54 692 655 612 
56 884 761 734 
61 852 897 762 
63 894 807 852 
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Choice Reaction Time (Yellow, Standard Condition) 
Group 1 Group 2 
( P 1 acebo-P i race tam ) ( Piracetam-Placebo) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 715 634 671 1 754 759 478 
3 734 721 855 4 761 700 725 
5 621 630 1185 6 543 621 630 
1 0 766 946 623 8 741 738 959 
11 504 851 738 9 773 751 567 
12 593 . 710 608 13 571 700 928 
18 703 874 1422 14 644 760 797 
20 500 443 561 15 605 900 1117 
22 683 747 800 21 520 506 717 
23 604 787 691 25 613 808 568 
24 483 602 597 27 738 636 593 
29 734 747 662 30 637 687 607 
33 658 837 579 35 669 1211 776 .. 
34 666 636 631 37 640 695 635 
36 688 845 541 41 592 721 789 
40 817 893 620 42 829 613 599 
43 1007 - 896 700 45 1133 1671 850 
44 673 603 557 48 690 678 571 
46 698 2001 569 50 713 759 641 
47 810 955 758 53 821 657 718 
49 635 594 557 57 907 581 468 
51 778 584 655 60 493 644 553 
54 1000 537 514 
56 930 560 479 
61 693 779 708 
63 792 748 1666 
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Choice Reaction Time (Yellow, Reversed Condition) 
Group 1 Group 2 
(Placebo-Pir~cetam ) ( Piracetam-Placebo) 
Subject Subject 
Number 1 ·2 3 Number 
1 2 3 
I 
2 742 808 683 1 687 689 679 
3 769 785 ·, 737 4 816 633 677 
5 641 720 637 6 741 708 548 
1 0 881 658 636 8 870 829 707 
11 661 640 566 9 685 617 673 
12 772 ·706 682 1 3 869 846 . 875 
18 965 851 736 14 664 669 641 
20 651 592 548 15 801 612 614 
22 744 751 604 21 543 703 619 
23 786 616 599 25 717 733 629 
24 646 556 536 27 .890 679 643 
29 682 825 621 30 567 632 544 
,.. 
714 601 35 821 789 742 33 701 .. 
34 733 699 676 37 729 723 664 
36 926 744 718 41 744 768 728 
40 637 587 585 42 692 677 814 
43 942 . 710 700 45 879 956 886 
44 673 600 562 48 785 744 747 
46 634 671 . 626 50 742 624 707 
47 832 776 807 53 679 691 768 
49 691 567 550 57 666 609 532 
51 818 728 704 60 650 596 590 
54 790 714 613 
56 725 555 638 
61 .. 782 876 779 
63 831 795 866 
. 
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' 
Choice Reaction Time (Red and Green, Standard) 
Group 1 Group 2 
( Placebo-Pi racetam ) (Pi racetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 711 637 583 1 824 747 490 
3 744 852 763 4 649 752 673 
5 540 670 802 6 569 666 705 
1 0 801 665 756 8 612 883 731 
11 509 598 554 9 817 668 564 
12 629 749 690 13 696 768 746 
18 642 849 749 14 637 651 853 
20 579 534 616 15 625 714 664 
22 669 642 604 21 498 462 676 
23 661 739 740 25 622 740 652 
24 795 450 630 27 591 618 546 
29 669 758 637 30 549 569 504 
33 719 655 652 35 
.• 
705 788 661 
34 661 729 738 37 638 705 551i 
36 653 745 629 . 41 608 736 756 
40 979 627 553 42 715 765 599 
43 1009 . 894 662 45 942 856 747 
44 772 666 544 48 708 629 594 
46 560 659 736 50 580 671 592 . 
47. 852 971 719 53 718 616 694 
49 637 729 536 57 840 531 539 
51 731 805 661 60 715 547 562 
54 689 542 542 
56 93·0 586 516 
61 663 711 598 
63. 733 671 741 
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Choice Reaction Time (Red and Green, Reversed) 
Group 1 Group 2 
( P 1 acebo-P i race tam ) (Pi racetam-Placebo ) 
Subject Subject ' 
Number 1 ··2 3 Number 1 2 3 
-
2 812 770 786 1 715 737 768 
3 709 848 700 4 907 796 866 
5 816 824 773 6 723 677 663 
10 985 811 785 8 1001 723 681 
11 693 644 665 9 788 793 733 
12 782 ·723 809 13 1305 958 1024 
18 847 875 866 14 705 691 7l.f4 
20 688 592 591 15 841 699 698 
22 949 719 783 21 610 615 645 
23 795 695 700 25 785 703 680 
24 651 641 591 27 782 673 686 
29 807 820 761 30 685 641 679 
33 937· 796 757 35 
.. 
1075 782 793 
34 907 873 766 37 886 826 835 . ' 
36 1257 962 825 ·41 819 872 885 
40 815 700 677 42 829 773 846 
43 1108 . 850 828 45 1043 982 973 
44 638 733 691 48 877 852 823 
46 525 761 845 50 812 755 774 
47 954 1134 . 1008 53 681 775 780 
49 663 565 616 57 820 709 664 
51 846 976 887 60 622 582 651 . 
54 643 625 612 
56 953 864 783 
61 . 899 907 754 
63 925 813 845 
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Purdue Pegboard Test - Preferred Hand Task 
Group 1 Group 2 
(Placebo-Piracetam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 38 46 4t 1 42 39 43 
3 44 43 45 4 47 46 48 
5 42 36 41 6 47 51 49 
1 0 47 48 49 8 48 49 51 
11 51 47 48 9 38 44 41 
12 47 . 45 41 13 33 34 37 
18 43 42 42 14 49 47 50 
20 48 46 48 15 44 39 40 
22 52 54 51 21 48 50 48 
23 45 53 48 25 48 48 53 
24 55 50 49 27 . 37 41 45 
29 36 38 43 30 36 40 41 
33 .41 41 38 35 33 33 36 
.-
34 40 42 41 37 39 42 48 
36 38 44 44 41 48 49 52 
40 39 45 42 42 32 35 34 
43 38 41 39 45 38 42 47 
44 52 48 49 48 49 49 52 
46 40 39 41 50 46 52 46 
47 30 33 34 53 39 39 39 
49 33 38 39 57 44 44 36 
51 44 39 42 60 44 48 47 
54 39 43 47 
56 37 42 44 
61 36 35 38 
63 45 47 49 
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Purdue Pegboard Test - Non-Preferred Hand Task 
Group 1 Group 2 
( Placebo-Pi racetam ) (Pi racetam-Placebo ) 
Subject Subject 
Number 1 ·2 
·3 Number 1 \ 2 3 
2 31 35 37 1 37 38 40 
3 46 42 45 4 42 48 44 
5 42 36 42 6 47 46 45 
10 39 46 36 8 46 45 43 
11 51 45 50 9 42 46 43 
12 42 . 44 4'0 1 3 34 36 37 
18 36 39 . 37 14 47 47 49 
20 45 46 43 15 39 38 41 
22 47 51 49 21 46 45 47 
23 48 47 47 25 47 48 51 
24 54 51 50 27 39 40 40 
29 38 38 38 30 42 39 43 
33 32 38 36 35 .• 36 39 39 
34 41 41 43 37 47 41 47 
36 36 43 46 41 44 47 46 
40 40 43 42 42 37 34 35 
43 33 41 38 45 38 40 40 
44 54 47 51 48 40 47 45 
46 33 35 37 50 44 45 46 
47 33 32 35 53 40 36 41 
49 37 39 40 57 38 42 33 
51 34 36 42 60 43 43 43 
54 39 39 45 
56 32 38 39 
61 40 37 41 
63 41 40 44 
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Purdue Pegboard Test - Simultaneous Hands Task 
Group 1 Group 2 
( Placebo-Piracetam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 25 31 28 1 34 34 37 
3 32 35 31 4 36 34 33 
5 34 33 30 6 35 42 38 
1 0 37 33 39 8 37 35 37 
1 i 44 41 38 9 32 35 34 
12 37 . 35 33 1 3 24 23 24 
18 34 35 35 14 42 40 38 
"20 35 31 36 15 32 29 31 
22 42 45 44 21 37 39 38 
23 38 36 39 25 39 38 40 
24 43 41 41 27 31 31 35 
29 35 31 31 30 31 31 31 
33 28 30 30 35 
.. 27 24 29 
34 32 29 33 37 35 35 38 
36 29 33 35 41 42 41 40 
4cr 33 37 34 42 30 29 29 
43 30 28 27 45 30 33 33 
44 48 32 38 ( 34 
46 28 25 28 50 38 40 36 
47 24 27 25 53 29 33 -· 33 
49 26 30 26 57 32 36 31 
51 30 28 29 60 34 35 36 
54 32 34 37 
56 31 28 31 
61 28 21 28 
63 39 37 40 
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WAIS Information Subtest 
Group 1 Group 2 
(Placebo-Piracetam ) (Piracetam-Placebo ) 
Subject Subject 
1 2 3 Number 1 2 3 Number 
2 17 16 17 1 17 14 17 
3 15 16 17 4 22 22 22 
5 24 23 22 6 12 16 15 
1 0 13 15 16 8 19 19 18 
11 22 22 20 9 13 11 1 3 
12 19 17 18 1 3 13 14 1 3 
18 14 14 16 14 19 18 20 
20 20 19 20 15 10 11 11 
22 21 19 18 21 15 15 16 
23 18 22 21 25 18 16 15 
24 16 16 16 27 17 Hl 21 
29 21 18 19 30 16 16 20 
33 17 19 17 35 16 20 20' 
34 11 14 15 37 10 11 11 
36 15 16 16 41 18 18 16 
40 19 21 23 42 18 19 21 
43 12 - 11 11 45 11 9 1 0 
44 14 15 17 48 18 18 17 
46 19 20 21 50 21 23 21 
47 15 15 16 53 15 13 13 
49 24 25 24 57 7 1 0 1 0 
51 12 12 13 60 17 18 17 
54 14 16 17 
56 16 18 17 
6.1 1 3 13 15 
63 1 3 15 16 
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WAIS Digit Span Subtest 
Group 1 f Group 2 
( Placebo-Piracetam ) ( Pi racetam-P 1 acebo · ) 
Subject Subject 
Number 1 ·2 3 Number 1 2 3 
2 12 13 11 1 14 14 14 
3 11 1 0 11 4 11 1 0 10 
5 11 11 12 6 10 12 15 
1 0 10 14 13 . 8 12 12 12 
11 15 16 16 9 10 10 12 
12 14 . 13 14 1 3 11 11 11 
18 9 7 8 14 9 10 8 
20 12 17 16 15 11 11 12 
22 10 13 13 21 12 15 1 5 
23 10 12 11 25 11 11 11 
24 13 13 13 27 9 11 11 
29 12 12 . 13 30 11 14 14 
33 7 9 . 9 35 10 9 10 
" 
34 10 1 0 11 37 8 9 7 
36 9 . 9 9 41 13 9 13 
40 10 1 0 13 42 8 ·9 10 
43 8 9 9 45 12 13 13 
44 13 12 12 48 9 11 11 
46 11 11 12 50 16 15 16 
47 11 1 0 l1 53 12 10 8 
49 16 15 13 57 12 14 11 
51 9 9 8 60 11 14 12 
54 11 12 13 
56 9 9 9 
61 8 8 7 
63 12 12 10 
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WAIS Digits Forwards 
' 
Group 1 Group 2 
( Placebo-Pi race tam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 ·2 3 Number 1 2 3 
2 7 7: 5 1 8 7 8 
3 6 5 6 4 6 6 5 
5 6 6 7 6 5 7 9 
10 7 8 7 8 7 8 7 
11 7 8 8 9 4 5 6 
12 7 6 7 1 3 8 7 7 
18 5 4 5 14 5 6 4 
20 7 9 9 15 6 7 7 
22 5 8 8 21 7' 8 8 
23 6 7 7 25 6 5 5 
24 9 8 8 27 5 6 6 
29 5 5 6 30 7 8 7 
33 4 6 6 35 6 4 5 
,. 
34 6 ... 6 6 37 4 5 4 
36 6 6 6 41 8 5 8 
40 5 
' 
5 7 42 5 6 7 
43 5 7 6 45 6 8 7 
44 7 8 8 48 6 7 6 
46 6 6 7 50 8 7 8 
47 6 5 7 53 7 6 5 
49 8 8 6 57 6 8 6 
51 6 6 5 60 6 8 6 , 
54 7 5 6 
56 
~, 
6 6 6 
61 4 5 4 
' 
63 7 7 6 
./ 
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WAIS Digits Backwards 
Group 1 Group 2 
(Placebo-Pi racetam ) ( Pi racetam-P 1 acebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 5 6 6 1 6 7 6 
3 5 5 5 4 5 4 5 
5 5 5 5 6 5 5 6 
1 0 3 6 6 8 5 4 5 
11 8 8 8 9 6 5 6 
12 7 7 7 1 3 3 4 4 
18 4 3 3 14 4 4 4 
20 5 8 7 15 5 4 5 
22 5 5 5 21 5 7 7 
23 4 5 4 25 5 6 6 
24 4 5 5 27 4 5 5 
29 7 7 7 30 4 6 7 
33 3 3 3 35 4 5 5 
34 4 4 5 37 4 4 3 
36 3 3 3 41 5 4 5 
40 5 5 6 42 3 3 3 
43 3 2 3 45 6 5 6 
44 6 4 4 48 3 4 5 
46 5 5 5 50 8 8 8 
47 5 5 4 53 5 4 3 
49 8 7 7 57 6 6 5 
51 3 3 3 60 5 6 6 
54 4 7 7 
56 3 3 3 
61 4 3 3 
63 5 5 4 
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WAIS Similarities Subtest 
Group 1 Group 2 
( Placebo-Piracetam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 14 13 17 1 19 19 19 
3 12 14 13 4 20 21 21 
5 21 20 21 6 15 18 14 
1 0 10 12 12 8 19 20 19 
11 19 19 17 9 13 14 12 
12 18 21 19 1 3 11 14 11 
18 13 11 13 14 16 14 14 
20 19 22 20 15 7 9 11 
22 16 18 18 21 19 20 17 
23 17 18 15 25 20 23 20 
24 19 22 21 27 18 20 19 
29 20 18 20 30 15 18 21 
33 15 14 15 35 15 13 14 
34 9 12 15 37 13 13 15 
36 14 13 15 41 16 1 0 16 
40 19 17 17 42 19 20 19 
43 4 8 5 45 9 15 15 
44 14 17 15 48 13 17 19 
46 18 18 20 50 18 19 18 
47 15 14 13 53 15 13 12 
49 22 22 19 57 15 13 12 
51 17 18 18. 60 20 21 23 
54 21 19 21 
56 15 18 1 7 
61 16 17 19 
63 15 16 15 
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WAIS Object Assembly Subtest 
Group 1 Group 2 
( Placebo-Piracetam) ( Piracetam-Placebo) 
·-
Subject Subject 
Number 1 ·2 3 Number 
1 2 3 
.. 
2 19 19 19 1 11 19 19 
3 15 21 21 4 21 21 22 
5 13 17 18 6 21 21 20 
1 0 6 12 14 8 1 0 12 1 3 
11 17 24 25 9 16 16 15 
12 17 . 19 18 13 1 5 15 12 
18 17 19 17 14 16 20 21 
20 19 21 24 15 17 19 20 
22 13 21 18 21 17 21 23 
23 7 9 12 25 20 19 21 
24 19 21 23 27 12 12 ~ 19 
29 19 19 18 30 13 18 22 
33 10 14 13 35 17 18 18 
' 
34 15 17 19 37 16 17 19 
36 13 16 22 41 20 21 22 
40 12 14 17 42 22 20 24 
43 14 12 15 45 21 23 22 
44 18 19 20 48 11 22 22 
' 
46 17 20 18 50 14 15 19 
47 12 16 17 53 14· 19 19 
49 18 20 20 57 18 19 18 
51 12 22 17 60 17 18 18 
54 17 23 24 
56 19 15 18 
61 14 15 18 
63 13 11 19 
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WAIS Block Design Subtest 
Group 1 Group 2 
(p]acebo-Piracetam ) ( Piracetam-Placebo) 
Subject Subject 
Number 1 2 .3 Number 1 2 3 
2 20 21 21 1 . 23 23 24 
3 18 20 24 4 32 34 35 
5 H 12 1 3 6 33 31 32 
1 0 15 20 21 8 14 16 16 
11 32 29 34 9 19 23 23 
12 16 16 19 1 3 19 19 20 
18 13 19 20 14 25 23 25 
20 33 32 29 15 21 20 20 
22 22 24 24 21 25 32 33 
23 25 25 26 25 29 29 29 
24 24 29 25 27 18 20 25 
29 23 23 23 30 27 23 31 
33 16 15 12 35 23 21 25 
34 17 16 21 37 17 13 17 
36 10 1.6 13 41 32 34 32 
40 22 25 24 42 . 29 30 32 
43 9 16 15 45 32 31 36 
44 19 28 19 48 25 21 26 
46 28 29 27 50 21 26 28 
47 12 10 15 53 19 20 23 
49 28 32 31 57 32 31 32 
51 23 22 20 60 25 19 23 
54 32 37 34 
56 21 24 25 
61 15 19 15 
63 21 22 22 
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WAIS Digit Symbol Substitution Test 
Group 1 Group 2 
( Placebo-Pi racetam ) (Pi racetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 30 34 31 1 37 37 32 
3 30 28 31 . 4 50 50 57 
5 32 36 32 6 42 51 55 
1 0 37 44 51 , 8 33 40 43 
11 50 48 48 9 26 29 29 
12 24 31 30 1 3 22 25 24 
18 21 22 22 14 26 30 31 
20 38 48 45 15 24 23 26 
22 30 47 43 21 45 49 49 
23 41 46 47 25 37 46 44 
24 44 51 51 27 43 43 45 
29 44 41 37 30 38 42 52 
33 28 31 35 35 25 28 32 
34 23 22 25 37 23 23 25 
36 22 28 26 41 20 24 26 
40 42 44 44 42 27 27 34 
43 17 - 20 22 45 30 30 35 
44 37 35 39 48 31 29 38 
46 37 44 31 50 33 34 42 
47 35 36 40 53 38 41 33 
49 53 52 55 57 32 43 41 
51 27 31 29 60 47 46 47 
54 41 46 53 
56 22 32 29 
61 24 25 30 
63 48 47 51 
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WAIS Pro-Rated IQ 
Group 1 Group 2 
( PI acebo-P i racetam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 \ 2 3 Number 1 2 3 
2 106 106 108 1 114 119 119 
98 108 
. 134 140 3 111 4 132 
5 108 113 113 6 112 122 120 
1 0 86 103 105 8 107 113 112 
11 127 137 138 9 97 99 101 
12 109 . 114 113 1 3 90 93 93 
18 90 91 93 14 105 109 116 
20 122 140 139 15 89 93 93 
22 106 124 116 21 11 0 125 127 
23 97 108 108 25 123 128 1 19 
24 11 3 125 124 27 100 108 119 
29 122 114 116 30 109 119 140 
33 87 93 92 35 102 103 109 
.. 
34 93 98 108 37 84 86 es 
36 84 91 99 41 1 1 1 105 115 
40 106 108 117 42 117 118 131 
43 74 84 84 45 107 113 117 
44 100 108 99 48 93 113 120 
46 114 122 120 50 11 0 115 122 
47 100 98 106 53 102 101 96 
49 141 145 134 57 103 11 0 104 
51 1 01 114 102 60 1 16 120 123 
54 113 127 127 
-
56 97 102 102 
61 93 98 100 
63 106 107 1 11 
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MCST - Total cards presented 
Group 1 Group 2 
( Placebo-Piracetam 
' 
(Piracetam-Placebo ) I 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 45 43 39 1 45 43 ' 36 
3 48 48 48 4 36 36 37 
5 48 40 ·41 6 . 36 37 43 
10 48 48 48 8 38 48 39 
11 38 40 42 9 47 48 48 
12 37 . 37 37 ,, 1 3 48 37 47 
18 48 46 48 14 48 I 42 45 
20 36 36 36 15 48 48 46 
22 48 38 42 21 44 48 36 
23 44 43 42 25 47 36 38 
24 38 36 36 27 36 36 45 
29 48 43 48 30 42 48 46 
33 48 48 43 35 . 48 48 48 
34 48 48 48 37 48 48 48 
36 48 48 48 41 37 41 40 
40 47 38 39 42 37 37 36 
43 48 . 48 48 45 39 38 37 
44 44 48 42 48 43 48 38 
46 48 46 41 50 36 43 39 
47 48 48 48 53 42 48 37 
49 36 36 41 57 48 42 Li 1 
51 48 48 42 60 37 42 42 
54 48 48 48 
56 48 48 45 
61 48 48 39 
63 48 48 48 
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MCST - Sets completed 
Group 1 Group 2 
( Placebo-Piracetam) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 6 6 6 1 6 6 6 
3 5 2 3 4 6 6 6 
5 4 6 6 6 6 6 6 
1 0 2 2 1 8 6 5 6 
11 6 6 6 9 6 5 5 
12 6 6 6 13 5 6 6 
18 1 2 2 14 5 6 6 
20 6 6 6 15 6 5 6 
22 4 6 . 6 21' 6 6 6 
23 6 6 6 25 6 6 6 
24 6 6 6 27 6 6 6 
29 5 6 5 30 6 4 6 
33 3 5 6 35 2 2 1 
34 2 1 1 37 1 4 4 
36 1 1 0 41 6 6 6 
40 6 6 6 42 6 6 6 
43 2 2 2 45 6 6 6 
44 6 5 6 48 6 5 6 
46 4 6 6 50 6 6 6 
47 5 5 5 53 6 5 6 
49 6 6 6 57 5 6 6 
51 2 5 6 60 6 6 6 
54 1 0 2 
56 5 4 6 
61 5 5 6 
63 1 5 4 
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MCST - Total Errors 
Group 1 ..., Group 2 
( Placebo-Piracetam ) ( Piracetam-Placebo ' J 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 7 7 2 1 5 3 0 
3 10 27 19 4 0 0 1 
5 14 2 1 6 0 1 4 
1 0 28 25 28 8 2 4 2 
11 1 1 1 9 10 13 10 
12 1 1 1 1 3 6 1 4 
18 28 27 22 14 12 5 5 
20 0 0 0 15 7 6 7 
22 14 1 1 21 6 7 0 
23 5 6 1 25 10 0 2 
24 2 0 0 27 0 0 5 
.29 9 2 6 30 3 12 6 
33 18 15 2 35 35 16 23 
.. 
34 29 27 29 37 42 17 14 
36 27 29 34 41 1 4 2 
40 6 2 1 42 1 1 0 
43 29 23 27 45 3 2 1 
44 7 8 2 48 6 6 2 
46 14 3 2 50 0 2 1 
47 14 10 15 53 5 13 1 
49 0 0 1 57 7 3 4 
51 30 10 4 60 1 2 1 
54 33 39 17 
56 3 18 4 
61 18 13 3 
63 34 1 0 16 ; 
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MCST - Perseverative Errors 
Group 1 Group 2 
( PI acebo-P i race tam ) ( Pi racetam-Placebo) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 0 2 1 1 - - -
3 2 8 3 4 0 0 0 
5 5 0 0 6 0 0 1 
1 0 10 6 4 8 0 0 0 
11 0 0 0 9 5 4 5 
12 1 1 1 1 3 2 0 2 
18 9 6 5 14 5 0 1 
20 0 0 0 15 1 1 2 
22 2 0 0 21 3 2 0 
23 1 0 0 25 5 0 0 
24 0 0 0 27 0 0 1 
29 2· 0 0 30 1 2 1 
33 5 5 0 35 
.• 
21 5 4 
34 7 1 3 37 42 7 1 
36 7 9 13 41 0 1 0 
40 2 0 0 42 0 0 0 
43 7 8 7 45 3 1 0 
44 0 0 1 48 1 1 0 
46 9 1 0 50 0 0 0 
47 5 2 3 53 1 5 0 
49 0 0 .0 57 1 1 1 
51 15 0 0 60 1 0 0 
54 9 7 4 
56 0 2 2 
61. 3 3 1 
63 8 2 4 
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Selective Reminding List Learning (Total Scores) 
Group 1 Group 2 
( Placebo-Piracetam) ( Piracetam-Placebo) 
Subject Subject 
Number 1 2 3 Number 1 2 
'3 
2 39 51 39 1 46 50 51 
3 32 44 35 4 53 55 55 
5 33 29 28 6 46 44 37 
1 0 37 55 39 8 43 43 34 
11 51 48 47 9 43 52 48 
12 34 48 33 1 3 29 26 19 
18 22 35 36 14 36 47 36 
20 54 51 44 15 38 52 35 
22 35 42 42 21 46 50 36 
23 52 47 43 25 51 57 45 
24 42 52 49 27 44 46 35 
29 52 54 39 30 42 50 38 
33 43 43 40 35 39 48 39 .. 
34 36 40 28 37 47 43 28 
36 32 39 30 41 46 49 39 
40 46 41 39 42 31 52 28 
43 33 - 36 28 45 28 37 29 
44 52 46 34 48 38 39 35 
46 54 52 40 50 42 50 37 
47 35 52 45 53 29 31 30 
49 54 53 51 57 42 35 27 
51 40 39 33 60 20 47 30 
54 47 53 32 
56 46 38 38 
61 39 41 31 
63 42 46 39 
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Selective Reminding List Learning (Amount of List Learned) 
Group 1 Group 2 
( Placebo-Piracetam ) ( Piracetam-Placebo) 
Subject Subject 
• 1 2 3 1 2 3 Number Number 
2 9 18 11 1 13 15 16 
3 7 1 3 8 4 18 19 20 
5 5 6 4 6 13 12 9 
1 0 8 18 1 0 8 12 11 8 
11 16 15 14 9 8 19 13 
12 5 . 14 9 1 3 ? 4 1 
18 6 10 9 14 9 14 8 
20 18 17 13 15 . 11 17 10 
22 8 14 12 21 14 17 10 
23 17 15 10 25 18 18 15 
24 11 17 14 27 13 13 8 
29 16 18 12 30 13 13 11 
33 11 12 13 35 8 14 7 
.• 
34 1 0 10 6 37 14 11 6 
36 4 9 6 41 13 15 9 
40 13 1 0 11 42 8 19 6 
43 7 1 0 8 45 8 10 5 
44 17 12 1 0 48 10 5 8 
46 18 . 18 12 50 10 16 8 
47 7 18 17 53 7 7 5 
49 19 19 17 57 12 10 6 
51 10 9 7 60 4 12 5 
54 15 19 8 
56 13 9 13 
61 9 1l 7 
63 12 14 11 
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Restrictive Reminding List Learning (Total Score?) 
Group 1 Group 2 
( P 1 acebo-P i race tam ) ( Pi racetam-P 1 acebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 43 52 41 1 51 57 46 
3 44 37 35 4 50 58 54 
5 33 46 34 6 41 44 44 
1 0 35 49 38 8 36 45 36 
11 52 54 45 9 48 55 38 
12 34 42 29 1 3 21 17 15 
18 34 39 26 14 39 44 32 
20 53 57 50 15 42 44 26 
22 40 43 43 21 51 46 37 
23 47 47 49 25 60 52 43 
24 56 42 46 27 44 47 33 
29 46 54 41 30 43 48 43 
33 40 39 38 35 .- 35 44 39 
34 44 45 32 37 44 48 31 
36 27 37 25 41 51 49 44 
40 43 43 40 42 35 42 38 
43 37 45 31 45 30 35 29 
44 44 47 35 48 51 49 34 
46 51 55 40 50 47 49 46 
47 33 56 30 53 42 33 - 24 
49 54 . 53 55 57 40 37 29 
51 40 41 39 60 31 40 33 
54 53 53 48 
56 42 39 25 
61 42 41 37 
63 44 42 36 
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Restrictive Reminding List Learning (Amount of List Learne.Ql 
Group 1 Group 2 
( Placebo-Piracetam ) ( Pi racetam-P 1 acebo ~ 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 14 18 12 1 17 20 13 
3 13 14 11 4 16 20 16 
5 7 15 10 6 1 0 15 13 
·10 9 17 9 8 13 15 1 0 
11 20 20 15 9 15 19 10 
12 9 14 8 1 3 4 2 3 
18 1 0 12 7 14 12 15 1 0 
20 19 19 17 15 13 15 6 
22 12 14 14 21 17 16 11 
23 17 16 17 25 20 16 13 
24 19 19 15 27 15 16 8 
29 17 19 13 30 14 15 13 
33 14 11 13 35 8 
.• 
15 12 
34 13 15 8 37 13 16 9 
36 6 1 0 6 41 17 16 15 
40 13 15 12 42 9 13 12 
43 1 0 14 9 45 9 9 6 
44 16 16 9 48 18 17 11 
46 19 19 13 50 15 18 15 
47 9 20 1 0 53 13 ·9 5 
49 20 19 19 57 15 12 6 
51 12 12 11 60 7 11 9 
54 18 19 17 
56 14 11 4 
61 15 14 12 
63 13 13 9 
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Serial 3s - Correct Enumerations 
Group 1 Group 2 
( Placebo-Piracetam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 16 14 16 1 25 26 23 
3 5 6 6 4 13 16 17 
. 
5 20 5 13 6 17 20 21 -
10 17 21 21 8 13 15 18 
11 19 20 21 9 11 9 9 
12 9 11 6 1 3 13 17 19 
18 14 . 12 13 14 8 10 10 
20 15 19 22 15 2 8 5 
22 30 29 32 21 20 22 13 
23 13 16 15 25 19 22 20 
24 20 18 19 27 29 27 24 
29 11 16 12 30 23 28 22 
33 18 21 20 35 16 19 18 
.. 
34 8 7 1 3 37 3 7 5 
36 4 4 6 41 9 1 0 9 
40 9 20 18 42 14 12 9 
43 3 4 5 45 15 16 1 7 
44 12 14 15 48 7 4 4 
46 17 16 15 50 22 21 21 
47 4 0 . 12 53 8 7 5 
49 33 33 32 57 1 0 5 2 
51 11 14 11 60 20 17 19 
54 15 18 21 
56 5 11 14 
61 6 7 8 
63 5 3 2 
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Seri a 1 3s - Total ·1 terns Enumerated 
Group 1 Group 2 
( Placebo-Piracetnm ) ( Piracetam-Placebci ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
' 
2 16 15 16 1 25 26 23 
3 7 6 6 4 13 17 17 
.. 
5 21 7 13 6 17 21 21 
1 0 17 23 21 8 14 18 18 
11 19 23 23 9 12 10 9 
12 9 . 12 6 1 3 13 18 19 
18 15 13 13 14 10 1 0 10 
20 15 19 22 15 4 9 6 
22 30 29 32 21 20 24 13 
23 13 17 16 25 19 22 20 
24 21 20 19 27 29 27 25 
29 l1 16 12 30 23 28 22 
33 18 21 20 35 . . 16 21 18 
.. 
34 8 8 13 37 7 8 6 
36 4 5 6 41 10 10 9 
• 
40 1 0 20 18 42 14 12 12 
43 6 5 ' 9 45 15 16 18 
44 13 16 15 48 8 7 6 
46 17 f 6 16 50 22 21 23 
47 5 3 12 53 8 7 8 
49 33 33 32 57 11 7 5 
51 11 14 11 60 20 17 19 
54 16. 18 21 
56 8 11 15 
61 7 7 11 
63 6 4· 2 
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Serial 3s - Error Totals 
Group 1 Group 2 
( Placebo-Piracetam ) ( Piracetam-Placebo ) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 0 1 0 1 0 0 0 
3 2 0 0 4 0 1 0 
5 1 2 0 6 0 1 0 
1 0 0 2 0 8 1 3 0 
11 0 3 2 9 1 1 0 
12 0 1 0 1 3 0 1 0 
18 1 1 0 14 2 0 0 
20 0 0 0 15 2 1 1 
22 0 0 0 21 0 2 0 
23 0 1 1 25 0 0 0 
24 1 2 0 27 0 0 1 
29 0 0 0 30 0 0 0 
33 0 0 0 35 0 2 0 
,. 
34 0 1 0 37 4 1 1 
36 0 1 0 41 1 0 0 
40 1 0 0 42 0 0 3 
43 3 1 4 45 0 0 1 
44 1 2 0 48 1 3 2 
46 0 0 1 50 0 0 2 
47 1 3 0 53 0 0 3 
49 0 0 . 0 57 1 2 3 
51 0 0 0 60 0 0 0 
54 1 0 0 
56 3 0 1 
61 1 0 3 
63 1 1 0 
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lngl is Paired Associate Learning Test 
Group 1 Group 2 
( Placebo-Piracetam) ( Piracetam-Placebo) 
Subject Subject 
Number 1 2 3 Number 1 2 3 
2 4 3 1 t 1 5 8 4 
3 7 4 6 4 4 4 4 
5 14 6 5 6 53 3 3 
1 0 15 4 7 8 32 16 4 
11 3 3 3 9 9 7 7 
12 5 8 13 13 37 4 63 
18 14 11 16 14 10 24 4 
20 3 3 3 15 7 8 15 
22 6 1 0 3 21 10 18 11 
23 8 3 3 25 5 4 5 
24 7 3 3 27 13 6 6 
29 5 3 7 30 26 24 6 
33 7 4 4 35 10 
.. 
8 ·8 
34 15 7 8 37 5 3 5 
36 25 23 11 41 10 11 6 
40 4 4 5 42 10 1 0 5 
43 7 11 9 45 8 7 7 
44 6 3 5 48 39 5 3 
46 4 6 4 50 7 3 3 
47 18 6 5 53 11 10 17 
49 4 7 3 57 13 14 8 
51 11 3 9 60 5 3 3 
54 5 3 3 
56 15 13 '22 
61 7 6 7 
63 12 6 3 
' 
